BioMedLib Search Engine
[ goto HOMEPAGE ]
Save time; Find better answers!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
astrocytoma low grade 2005:2010[pubdate] *count=100
668 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
astrocytoma
' expanded to all its synonyms;
details
'
low grade
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 668
1.
Nakamura M, Ishida E, Shimada K, Nakase H, Sakaki T, Konishi N:
Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas.
Acta Neuropathol
; 2005 Oct;110(4):402-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Frequent HRK inactivation associated with
low
apoptotic index in secondary glioblastomas.
To detect and identify the genetic alterations and methylation status of the HRK gene in human glioblastomas, we analyzed a cohort
of astrocytic
tumors for hypermethylation, loss of heterozygosity on 12q13.1, and gene expression.
Our study examined a series of 36 diffuse
low
-
grade
astrocytomas
, 32 anaplastic
astrocytomas
, 64 primary glioblastomas, and 28 secondary glioblastomas that had evolved from either 24
low
-
grade
diffuse
astrocytomas
or 4 anaplastic
astrocytomas
.
The region around the HRK transcription start site was methylated in 19% of diffuse
astrocytomas
, in 22% of anaplastic
astrocytomas
, in 27% of primary glioblastomas, and in 43% of secondary glioblastomas.
Reverse transcription-PCR analysis also demonstrated a clear agreement between reduced HRK protein levels and
low
or absent HRK transcripts.
Lack of HRK immunoreactivity was significantly correlated with a
low
apoptotic index, whereas a strong association between methylation status and apoptosis was found only in secondary glioblastomas.
Abnormal methylation of HRK was detected in
astrocytic
tumors concurrent with methylation of multiple genes, including p16(INK4a) and p14(ARF).
Our findings suggest that HRK is inactivated mainly by aberrant DNA methylation in
astrocytic
tumors and that reduced HRK expression contributes to the loss of apoptotic control in high-
grade
tumors.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16155764.001).
[ISSN]
0001-6322
[Journal-full-title]
Acta neuropathologica
[ISO-abbreviation]
Acta Neuropathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Apoptosis Regulatory Proteins; 0 / HRK protein, human; 0 / RNA, Messenger
2.
van den Bent MJ:
Anaplastic oligodendroglioma and oligoastrocytoma.
Neurol Clin
; 2007 Nov;25(4):1089-109, ix-x
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The only clinical relevant meaning of this histologic diagnosis was the observation that the prognosis of OD was in general better than that
of astrocytic
tumors of similar
grade
.
Observations have led to the current tendency to consider 1p/19q loss
low
-
grade
and anaplastic oligodendroglioma a separate biologic entity, at least within clinical trials, since they have a much better outcome.
[MeSH-major]
Astrocytoma
/ pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology
Genetic Alliance.
consumer health - Anaplastic Oligoastrocytoma
.
Genetic Alliance.
consumer health - Anaplastic Oligodendroglioma
.
Genetic Alliance.
consumer health - Oligoastrocytoma
.
Genetic Alliance.
consumer health - Oligodendroglioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
The Weizmann Institute of Science GeneCards and MalaCards databases.
gene/protein/disease-specific - MalaCards for oligoastrocytoma
.
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17964027.001).
[ISSN]
0733-8619
[Journal-full-title]
Neurologic clinics
[ISO-abbreviation]
Neurol Clin
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
[Number-of-references]
75
3.
Schramm J, Aliashkevich AF:
Surgery for temporal mediobasal tumors: experience based on a series of 235 patients.
Neurosurgery
; 2007 Feb;60(2):285-94; discussion 294-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: To describe the clinical characteristics, diagnosis, various approaches, and outcomes in a retrospective review
of a
large series of temporomediobasal (TMB) tumors.
METHODS: Charts from 235 patients with TMB tumors were identified from the
glioma
and epilepsy surgery database and from the electronic operations log.
The largest
tumor
groups were
astrocytomas
(38.0%), gangliogliomas (29.8%), dysembryoplastic neuroepithelial
tumor
(11.1%), and glioblastomas (11.1%).
The most frequent
tumor
location was the mesial Type
A tumor
(45.1%), with this type also showing the highest proportion of benign (World Health Organization Grades I and II) histological features (91.3%).
Larger
tumor
size was associated with higher frequency of malignant histopathological findings.
Thirty-eight patients with
low
-
grade
tumors had undergone surgery previously.
CONCLUSION: Small
tumor
size, magnetic resonance imaging, and microsurgery have made resection of mostly benign TMB tumors possible in a large number of patients.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ReprintIn]
Neurosurgery. 2008 Jun;62(6 Suppl 3):1272-82
[
18695547.001
]
(PMID = 17290179.001).
[ISSN]
1524-4040
[Journal-full-title]
Neurosurgery
[ISO-abbreviation]
Neurosurgery
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
Advertisement
4.
Sarkar C, Karak AK, Nath N, Sharma MC, Mahapatra AK, Chattopadhyay P, Sinha S:
Apoptosis and proliferation: correlation with p53 in astrocytic tumours.
J Neurooncol
; 2005 Jun;73(2):93-100
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Apoptosis and proliferation: correlation with p53 in
astrocytic
tumours.
We, as well as several other groups, have earlier demonstrated the association of p53 immunopositivity with increased degree of cell proliferation in
astrocytic
tumours.
Here we have studied the extent of apoptosis in 62 primary human
astrocytic
tumours [25 Diffuse
Astrocytoma
(DA), 9 Anaplastic
Astrocytoma
(AA) and 28 Glioblastoma multiforme (GBM)] in relation to tumour
grade
, proliferative status and p53 protein expression.
However this was not observed in p53 +ve GBM or in
low grade
DA either p53 positive or negative.
Taking p53 negativity in IHC as evidence
of a
functional gene/protein, this extends the link between proliferation and apoptosis, hitherto observed only in cultured cells with functional p53, to a subset of solid tumours.
[MeSH-major]
Astrocytoma
/ metabolism.
Astrocytoma
/ pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioblastoma / metabolism. Glioblastoma / pathology.
Tumor
Suppressor Protein p53 / metabolism
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Bioessays. 2000 Nov;22(11):1007-17
[
11056477.001
]
[Cites]
Nature. 1997 Sep 18;389(6648):300-5
[
9305847.001
]
[Cites]
Cancer Cell. 2002 Jul;2(1):2-4
[
12150817.001
]
[Cites]
J Natl Cancer Inst. 1994 Sep 7;86(17):1286-96
[
8064887.001
]
[Cites]
Am J Pathol. 1995 Jan;146(1):3-15
[
7856735.001
]
[Cites]
Anticancer Res. 2001 Jul-Aug;21(4A):2531-5
[
11724318.001
]
[Cites]
Cancer Gene Ther. 2000 Feb;7(2):224-32
[
10770630.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2026-30
[
8134344.001
]
[Cites]
J Exp Med. 1996 Sep 1;184(3):1155-60
[
9064332.001
]
[Cites]
Cell. 2000 Nov 22;103(5):691-4
[
11114324.001
]
[Cites]
Adv Cancer Res. 2000;77:81-137
[
10549356.001
]
[Cites]
Nature. 1993 Apr 29;362(6423):849-52
[
8479523.001
]
[Cites]
Neurosci Lett. 1995 Aug 4;195(2):81-4
[
7478273.001
]
[Cites]
Nat Med. 1996 May;2(5):574-7
[
8616718.001
]
[Cites]
Virchows Arch. 1995;427(2):175-9
[
7582248.001
]
[Cites]
Gen Diagn Pathol. 1996 May;141(5-6):339-44
[
8780933.001
]
[Cites]
Genes Chromosomes Cancer. 1994 Jun;10(2):143-9
[
7520269.001
]
[Cites]
Acta Neurochir (Wien). 1997;139(9):845-50
[
9351989.001
]
[Cites]
J Clin Oncol. 2003 Jul 1;21(13):2508-18
[
12839017.001
]
[Cites]
Lancet. 1993 May 15;341(8855):1251-4
[
8098400.001
]
[Cites]
Brain Pathol. 1998 Oct;8(4):599-613
[
9804370.001
]
[Cites]
Br J Cancer. 1997;75(9):1269-78
[
9155045.001
]
[Cites]
J Cell Biol. 1999 Jan 25;144(2):281-92
[
9922454.001
]
[Cites]
Cancer Genet Cytogenet. 2003 Jul 15;144(2):156-64
[
12850379.001
]
[Cites]
Brain Tumor Pathol. 1999;16(1):11-6
[
10532418.001
]
[Cites]
Oncol Rep. 2002 Jul-Aug;9(4):703-7
[
12066196.001
]
[Cites]
Mol Carcinog. 1997 Feb;18(2):66-77
[
9049182.001
]
[Cites]
Oncogene. 1994 Jun;9(6):1799-805
[
8183579.001
]
[Cites]
Neuro Oncol. 1999 Apr;1(2):124-37
[
11550308.001
]
[Cites]
Curr Neurol Neurosci Rep. 2002 May;2(3):246-53
[
11937003.001
]
[Cites]
Cell. 1997 Feb 7;88(3):323-31
[
9039259.001
]
[Cites]
Cancer Res. 1995 Mar 1;55(5):999-1001
[
7867012.001
]
[Cites]
Science. 1995 Mar 10;267(5203):1456-62
[
7878464.001
]
[Cites]
Mol Cell Biol. 2001 Feb;21(4):1297-310
[
11158315.001
]
[Cites]
Neuropathol Appl Neurobiol. 1995 Aug;21(4):352-61
[
7494604.001
]
[Cites]
Cell. 1994 Aug 26;78(4):703-11
[
8069917.001
]
[Cites]
Blood. 1993 Jul 1;82(1):15-21
[
8324219.001
]
[Cites]
EMBO J. 2000 Sep 15;19(18):4967-75
[
10990460.001
]
[Cites]
Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4
[
8864278.001
]
[Cites]
J Pathol. 1994 Aug;173(4):333-9
[
7965393.001
]
[Cites]
Nat Genet. 2000 Sep;26(1):37-43
[
10973245.001
]
[Cites]
Genes Dev. 1994 Dec 1;8(23):2817-30
[
7995520.001
]
[Cites]
Cancer Res. 1991 Jun 1;51(11):2979-84
[
2032235.001
]
[Cites]
Science. 1994 Sep 30;265(5181):2091-3
[
8091232.001
]
[Cites]
Acta Neuropathol. 1996;91(1):112-6
[
8773155.001
]
[Cites]
Br J Neurosurg. 2002 Aug;16(4):335-42
[
12389885.001
]
[Cites]
J Neuropathol Exp Neurol. 1998 Aug;57(8):746-57
[
9720490.001
]
[Cites]
J Neurooncol. 2002 Jan;56(1):21-8
[
11949823.001
]
[Cites]
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5006-10
[
2052583.001
]
[Cites]
Cancer Res. 1992 Mar 1;52(5):1342-6
[
1737395.001
]
[Cites]
J Neurooncol. 2000;46(3):215-29
[
10902853.001
]
[Cites]
J Neuropathol Exp Neurol. 1993 Jan;52(1):31-8
[
8381161.001
]
[Cites]
Lab Invest. 1995 Dec;73(6):837-43
[
8558845.001
]
[Cites]
Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11
[
1933891.001
]
[Cites]
Pathology. 2000 May;32(2):84-8
[
10840825.001
]
[Cites]
Genes Dev. 1995 Sep 1;9(17):2170-83
[
7657168.001
]
[Cites]
Cell Death Differ. 2000 Jun;7(6):511-20
[
10822274.001
]
[Cites]
J Neurooncol. 2003 Jun;63(2):129-45
[
12825817.001
]
[Cites]
Clin Cancer Res. 2002 May;8(5):1117-24
[
12006527.001
]
[Cites]
Mutat Res. 2002 Mar;511(1):45-62
[
11906841.001
]
[Cites]
Neoplasma. 2000;47(3):151-5
[
11043837.001
]
[Cites]
J Gastroenterol Hepatol. 2002 Sep;17(9):966-72
[
12167117.001
]
[Cites]
Gene Ther. 2001 Mar;8(6):469-76
[
11313826.001
]
[Cites]
Mol Cell Biol. 1995 Jun;15(6):3032-40
[
7539102.001
]
[Cites]
Cancer. 1997 Jul 15;80(2):242-9
[
9217037.001
]
[Cites]
J Pathol. 1999 Jan;187(1):112-26
[
10341712.001
]
[Cites]
J Neurooncol. 1999;44(3):255-66
[
10720205.001
]
[Cites]
J Neurooncol. 2002 Apr;57(2):105-14
[
12125970.001
]
[Cites]
Arch Pathol Lab Med. 2000 Jan;124(1):108-13
[
10629140.001
]
[Cites]
Oncogene. 2003 Sep 1;22(37):5774-83
[
12947385.001
]
[Cites]
Br J Cancer. 1993 Feb;67(2):205-8
[
8431353.001
]
[Cites]
J Neurooncol. 2002 Jun;58(2):157-65
[
12164688.001
]
[Cites]
Oncology. 2003;64(4):459-67
[
12759546.001
]
[Cites]
Clin Cancer Res. 2002 Jul;8(7):2024-34
[
12114400.001
]
[Cites]
Oncogene. 1997 Aug 14;15(7):871-4
[
9266974.001
]
[Cites]
Cytometry. 2000 Oct 1;41(2):83-8
[
11002262.001
]
[Cites]
Neuro Oncol. 2000 Apr;2(2):96-102
[
11303626.001
]
[Cites]
Clin Neuropathol. 1996 Nov-Dec;15(6):337-41
[
8937780.001
]
[Cites]
Int J Cancer. 1993 Dec 2;55(6):982-7
[
8253536.001
]
[Cites]
J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21
[
8301315.001
]
[Cites]
Brain Pathol. 1993 Jul;3(3):229-35
[
8293182.001
]
(PMID = 15981097.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Tumor Suppressor Protein p53
5.
La Torre D, de Divitiis O, Conti A, Angileri FF, Cardali S, Aguennouz M, Aragona M, Panetta S, d'Avella D, Vita G, La Torre F, Tomasello F:
Expression of telomeric repeat binding factor-1 in astroglial brain tumors.
Neurosurgery
; 2005 Apr;56(4):802-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Twenty flash-frozen surgical specimens obtained from adult patients who underwent craniotomy for microsurgical
tumor
resection, histologically verified as World Health Organization
Grade
II to IV
astrocytomas
, were used.
Expression of TRF1 in
astrocytomas of
different grades was studied by means of both immunohistochemical and Western blotting analysis.
RESULTS: TRF1 was expressed in all
tumor
samples.
The level of its expression was variable, decreasing from
low
-
grade
through high-
grade
astrocytomas
(P = 0.0032).
CONCLUSION: Our findings suggest that the loss of TRF1 expression capability, as a result of down-regulation of TRF1 expression in malignant
gliomas
cells, may play a role in the malignant progression of astroglial brain tumors.
[MeSH-major]
Astrocytoma
/ genetics. Brain Neoplasms / genetics. Telomeric Repeat Binding Protein 1 / genetics
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15792519.001).
[ISSN]
1524-4040
[Journal-full-title]
Neurosurgery
[ISO-abbreviation]
Neurosurgery
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Telomeric Repeat Binding Protein 1
6.
Salmaggi A, Gelati M, Pollo B, Marras C, Silvani A, Balestrini MR, Eoli M, Fariselli L, Broggi G, Boiardi A:
CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients.
J Neurooncol
; 2005 Sep;74(3):287-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CXCL12 expression is predictive
of a
shorter time to
tumor
progression in
low
-
grade
glioma
: a single-institution study in 50 patients.
The clinical course of 50 patients with
low
-
grade
glioma
(31 male, 19 female) undergoing surgery at a single Institution from 1992 to 1996 was analyzed in relationship with known prognostic factors as far as time to
tumor
progression (TTP) and survival time (ST) are concerned.
Histology revealed 11 fibrillary, 6 protoplasmatic, 5 gemistocytic
astrocytoma
, 18 oligoastrocytoma and 10 oligodendroglioma.
Of the remaining 46, twenty-four have shown
disease
progression and 14 have died.
Complete gross
tumor
removal was associated to a longer TTP (P = 0.04 logrank).
Of the investigated immunohistochemical parameters, while MVD was not predictive of subsequent TTP, expression of CXCL12 was associated with a significantly shorter TTP (P = 0.01 logrank): this predictive
value
remained significant (P = 0.02) at multivariate analysis.
The data suggest the possible prognostic
value for
CXCL-12 (an angiogenesis- and
tumor
-growth-related chemokine) on TTP in
low
-
grade
gliomas
.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Brain Neoplasms / metabolism. Chemokines, CXC / biosynthesis.
Glioma
/ metabolism
[MeSH-minor]
Adult. Aged. Chemokine CXCL12. Child. Child, Preschool.
Disease
Progression.
Disease
-Free Survival. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Prognosis. Treatment Outcome
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 2000 Jan;6(1):102-11
[
10656438.001
]
[Cites]
Acta Neurochir (Wien). 1998;140(12):1213-22
[
9932120.001
]
[Cites]
J Neurooncol. 2004 May;67(3):305-17
[
15164986.001
]
[Cites]
Cancer Res. 2003 Apr 15;63(8):1969-74
[
12702590.001
]
[Cites]
Brain Pathol. 2003 Apr;13(2):176-84
[
12744471.001
]
[Cites]
Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3
[
8545771.001
]
[Cites]
J Biol Chem. 2002 Dec 20;277(51):49481-7
[
12388552.001
]
[Cites]
J Neurosurg. 1998 Mar;88(3):513-20
[
9488306.001
]
[Cites]
J Clin Oncol. 2002 Apr 15;20(8):2076-84
[
11956268.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4
[
9276354.001
]
[Cites]
J Neurooncol. 2000 Aug;49(1):71-5
[
11131989.001
]
[Cites]
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
[
9776413.001
]
[Cites]
Neuropathol Appl Neurobiol. 2000 Aug;26(4):319-31
[
10931365.001
]
[Cites]
Br J Neurosurg. 2001 Jun;15(3):247-50
[
11478061.001
]
[Cites]
J Neurooncol. 1997 Feb;31(3):273-8
[
9049856.001
]
[Cites]
Cancer. 1996 Apr 15;77(8):1535-43
[
8608540.001
]
[Cites]
J Neurooncol. 2002 Sep;59(3):231-7
[
12241120.001
]
[Cites]
Oncology. 2000 Feb;58(2):108-16
[
10705237.001
]
[Cites]
J Neurooncol. 1999;45(2):117-25
[
10778727.001
]
[Cites]
Surg Neurol. 2000 Sep;54(3):229-34; discussion 234
[
11118569.001
]
[Cites]
Semin Oncol. 2003 Dec;30(6 Suppl 19):23-8
[
14765381.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24
[
11872276.001
]
[Cites]
J Neuropathol Exp Neurol. 1999 Jan;58(1):46-53
[
10068313.001
]
[Cites]
Ann Neurol. 2002 Dec;52(6):842-5
[
12447941.001
]
[Cites]
Neurosurgery. 1996 May;38(5):872-8; discussion 878-9
[
8727811.001
]
(PMID = 16132525.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC
7.
Weller M, Steinbach JP, Wick W:
Temozolomide: a milestone in the pharmacotherapy of brain tumors.
Future Oncol
; 2005 Dec;1(6):747-54
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Temozolomide (TMZ) is an alkylating agent earlier approved for recurrent anaplastic
astrocytoma
and approved for the treatment of newly diagnosed glioblastoma in the USA and Europe in 2005.
The early preliminary evidence for activity in recurrent malignant
gliomas
further resulted in a broad evaluation of TMZ for other tumors in neuro-
oncology
, mainly
low
-
grade
gliomas
, brain metastases and primary cerebral lymphomas.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16556052.001).
[ISSN]
1479-6694
[Journal-full-title]
Future oncology (London, England)
[ISO-abbreviation]
Future Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
[Number-of-references]
31
8.
Ueda R, Low KL, Zhu X, Fujita M, Sasaki K, Whiteside TL, Butterfield LH, Okada H:
Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.
J Transl Med
; 2007 Dec 19;5:68
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Spontaneous immune responses against
glioma
-associated antigens in a long term survivor with malignant
glioma
.
BACKGROUND: In patients with high
grade
glioma
, little is known regarding existence of naturally occurring adaptive T cell reactivity against
glioma
-associated antigens (GAAs).
In this report, we characterized GAA-specific CD8+ T cells and innate immune cells in a patient who has survived with anaplastic
astrocytoma
(AA) for over 12 years without recurrence.
RESULTS: The patient's
tumor
expressed both EphA2 and IL-13Ralpha2, and in vitro stimulated PBMC demonstrated superior EphA2883-891 and IL-13Ralpha2345-353-specific CTL reactivity compared to PBMC samples from two other patients with progressing malignant
glioma
.
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 1999 Oct 14;401(6754):708-12
[
10537110.001
]
[Cites]
J Clin Oncol. 1999 Nov;17(11):3389-95
[
10550132.001
]
[Cites]
Cancer. 2000 Feb 1;88(3):577-83
[
10649250.001
]
[Cites]
Cancer Res. 2000 Sep 1;60(17):4946-52
[
10987311.001
]
[Cites]
J Cell Biol. 2001 Mar 5;152(5):971-84
[
11238453.001
]
[Cites]
Clin Cancer Res. 2001 Mar;7(3 Suppl):909s-916s
[
11300491.001
]
[Cites]
J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
[
11895036.001
]
[Cites]
Clin Cancer Res. 2002 Sep;8(9):2851-5
[
12231526.001
]
[Cites]
Brain Res Brain Res Rev. 2003 May;42(2):97-122
[
12738053.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8874-9
[
12847287.001
]
[Cites]
J Immunol. 2003 Nov 1;171(9):4927-33
[
14568975.001
]
[Cites]
Clin Cancer Res. 2004 Oct 15;10(20):6946-55
[
15501973.001
]
[Cites]
J Exp Med. 1998 Nov 2;188(9):1641-50
[
9802976.001
]
[Cites]
Nat Med. 1999 Jun;5(6):677-85
[
10371507.001
]
[Cites]
Cancer Res. 1999 Aug 15;59(16):4050-5
[
10463606.001
]
[Cites]
Cancer Res. 2004 Nov 1;64(21):8062-7
[
15520217.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
Int J Cancer. 2005 Jun 20;115(3):450-5
[
15688371.001
]
[Cites]
J Immunol. 2005 Jun 1;174(11):6863-71
[
15905528.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
[
15980149.001
]
[Cites]
Neoplasia. 2005 Aug;7(8):717-22
[
16207473.001
]
[Cites]
Cancer Res. 2006 May 1;66(9):4943-51
[
16651452.001
]
[Cites]
Cancer Res. 2006 Jun 1;66(11):5883-91
[
16740728.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
Science. 2006 Oct 6;314(5796):126-9
[
16946036.001
]
[Cites]
J Invest Dermatol. 2007 Mar;127(3):622-9
[
17039243.001
]
[Cites]
Cancer Res. 2007 Feb 15;67(4):1842-52
[
17293384.001
]
[Cites]
J Clin Invest. 2007 May;117(5):1204-12
[
17476350.001
]
[Cites]
Cancer. 2007 Jul 1;110(1):203-14
[
17541944.001
]
[Cites]
Acta Neuropathol. 2007 Aug;114(2):97-109
[
17618441.001
]
[Cites]
Nat Med. 2007 Sep;13(9):1050-9
[
17704786.001
]
[Cites]
Cancer Immunol Immunother. 2007 Dec;56(12):1931-43
[
17522860.001
]
(PMID = 18093336.001).
[ISSN]
1479-5876
[Journal-full-title]
Journal of translational medicine
[ISO-abbreviation]
J Transl Med
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P01 CA100327; United States / NINDS NIH HHS / NS / P01 NS040923; United States / NINDS NIH HHS / NS / P01 NS40923
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen
[Other-IDs]
NLM/ PMC2244605
9.
Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S:
Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas.
Ann Nucl Med
; 2005 Dec;19(8):677-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Correlation of amino-acid uptake using methionine PET and histological classifications in various
gliomas
.
OBJECTIVE: The uptake of L-methyl-11C-methionine (MET) by
gliomas
is greater than that by intact tissue, making methionine very useful for evaluation
of tumor
extent.
METHODS: We performed this study on 67
glioma
patients between 3 and 69 years of age (36 males and 31 females).
Tumors included diffuse
astrocytoma
, anaplastic
astrocytoma
, glioblastoma, ependymoma, oligodendroglioma, medulloblastoma, dysembryoplastic neuroepithelial
tumor
, choroid plexus papilloma, central neurocytoma, optic
glioma
, gliomatosis cerebri, pleomorphic xanthoastrocytoma, and ganglioglioma.
Tumor
activity and degree of malignancy were evaluated using Ki-67LI (LI: labeling index) and Kaplan-Meier survival curves.
The correlations between methionine uptake and
tumor
proliferation (
tumor
versus contralateral gray matter ratio (T/N) and Ki-67LI) were determined for the group of all subjects.
The existence of significant correlations between T/N and Ki-67LI and between SUV and Ki-67LI was determined
for astrocytic
tumors.
Receiver operating characteristics (ROC) analysis of T/N and standardized uptake
value
(SUV) was performed for the group
of astrocytic
tumors.
RESULTS: For the 67 cases
of glioma
, the degree of accumulation was variable.
Ki-67LI differed significantly between the high-
grade
group and
low
-
grade
group at T/N levels between 1.5 and 1.8 on analysis using
tumor
proliferative potential (p = 0.019-0.031).
The prognosis differed significantly between the high-
grade
and
low
-
grade
groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032).
CONCLUSIONS: When analysis was confined to cases
of astrocytic tumor
, a correlation was noted between methionine accumulation and Ki-67LI.
For the
astrocytic
tumors, T/N ratio seemed to be more useful as a diagnostic indicator than SUV.
The cut-off level of T/N ratio for distinction between high-
grade
and
low
-
grade astrocytoma
appears to lie between 1.5 and 1.6.
[MeSH-major]
Brain Neoplasms / pathology. Brain Neoplasms / radionuclide imaging.
Glioma
/ pathology.
Glioma
/ radionuclide imaging. Methionine / pharmacokinetics. Positron-Emission Tomography / methods
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
Hazardous Substances Data Bank.
(L)-Methionine
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16444993.001).
[ISSN]
0914-7187
[Journal-full-title]
Annals of nuclear medicine
[ISO-abbreviation]
Ann Nucl Med
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Radiopharmaceuticals; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine
10.
Li YZ, Huang ZL, Wei DN, Xie CM, He HQ, Wei YF, Chen L, Wu PH:
[Diffusion tensor imaging of the white matter tracts in preoperative patients with cerebral neoplasm].
Nan Fang Yi Ke Da Xue Xue Bao
; 2006 Nov;26(11):1648-51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Diffusion tensor imaging of the white matter tracts in preoperative patients with cerebral
neoplasm
].
METHODS: Four female and 8 male patients aged from 21 to 62 years with brain malignancies (2 malignant lymphomas, 2
low
-
grade
astrocytomas
, and 8 high-
grade
cerebral
gliomas
) underwent conventional contrast-enhanced MR and DTI examinations before operation.
The DTI patterns in WMT altered by the
tumor
were categorized on the basis of FA1/FA2 ratio as follows: pattern 1, FA1/FA2> or =75% with normal or only slightly decreased FA; pattern 2, 50%< or =FA1/FA2<75% with WMT displacement; pattern 3, 25%< or =FA1/FA2/50% with WMT involvement; pattern 4, FA1/FA2<25% with WMT destruction.
CONCLUSIONS: DTI allows for visualization of WMT and benefits surgical planning for patients with intrinsic brain
tumor
.
There is a positive relationship between the bilateral FA ratio (FA1/FA2) variation and WMT alterations resulting from the
tumor
.
[MeSH-minor]
Adult. Female. Glioblastoma / diagnosis.
Glioma
/ diagnosis. Humans. Male. Middle Aged. Nerve Fibers / radiography. Neural Pathways / radiation effects. Preoperative Care. Reproducibility of Results. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17121724.001).
[ISSN]
1673-4254
[Journal-full-title]
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
[ISO-abbreviation]
Nan Fang Yi Ke Da Xue Xue Bao
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
11.
Salmaggi A, Fariselli L, Milanesi I, Lamperti E, Silvani A, Bizzi A, Maccagnano E, Trevisan E, Laguzzi E, Rudà R, Boiardi A, Soffietti R, Associazione Italiana di Neuro-oncologia:
Natural history and management of brainstem gliomas in adults. A retrospective Italian study.
J Neurol
; 2008 Feb;255(2):171-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Natural history and management of brainstem
gliomas
in adults. A retrospective Italian study.
Brainstem
gliomas
in adults are rare tumors, with heterogeneous clinical course; only a few studies in the MRI era describe the features in consistent groups of patients.
In this retrospective study, we report clinical features at onset, imaging characteristics and subsequent course in a group of 34 adult patients with either histologically proven or clinico-radiologically diagnosed brainstem
gliomas
followed at two centers in Northern Italy.
In 21 of the patients histology was obtained and in 20 it was informative (2 pilocytic
astrocytoma
, 9
low
-
grade astrocytoma
, 8 anaplastic
astrocytoma
and 1 glioblastoma).
Only minor radiological responses were observed after treatments; in a significant proportion of patients (9 out of 15) clinical improvement during therapy occurred in the context of radiologically (MRI) stable
disease
.
Grade
III or IV myelotoxicity was observed in 6 patients.
After a follow-up ranging from 9 to 180 months, all but 2 patients have progressed and 14 have died (12
for disease
progression, 2 for pulmonary embolism).
Investigation of putative prognostically relevant parameters showed that a short time between
disease
onset and diagnosis was related to a shorter survival.
Compared with literature data, our study confirms the clinical and radiological heterogeneity of adult brainstem
gliomas
and underscores the need for multicenter trials in order to assess the efficacy of treatments in these tumors.
[MeSH-major]
Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / therapy.
Glioma
/ pathology.
Glioma
/ therapy
[MeSH-minor]
Adolescent. Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain / pathology.
Disease
Progression. Female. Fluorodeoxyglucose F18. Humans. Image Processing, Computer-Assisted. Italy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Retrospective Studies. Spinal Cord / pathology. Survival Analysis. Treatment Outcome
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurosurg. 2006 Feb;104(2 Suppl):108-14
[
16506498.001
]
[Cites]
Curr Opin Neurol. 2001 Dec;14(6):711-5
[
11723378.001
]
[Cites]
Neurosurg Rev. 2005 Oct;28(4):330-2
[
16001287.001
]
[Cites]
Acta Neurochir Suppl (Wien). 1991;53:148-58
[
1803873.001
]
[Cites]
Brain. 2001 Dec;124(Pt 12):2528-39
[
11701605.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31
[
15850898.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):235-41
[
8420871.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
J Clin Oncol. 2006 Mar 10;24(8):1266-72
[
16525181.001
]
[Cites]
Neurology. 1998 Oct;51(4):1136-9
[
9781543.001
]
[Cites]
Acta Neurochir (Wien). 1986;79(2-4):67-73
[
3962745.001
]
[Cites]
Cancer. 2005 Jan 1;103(1):133-9
[
15565574.001
]
[Cites]
Neurochirurgie. 1989;35(1):41-6
[
2654682.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):757-60
[
2004952.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10 ):987-96
[
15758009.001
]
(PMID = 18293027.001).
[ISSN]
0340-5354
[Journal-full-title]
Journal of neurology
[ISO-abbreviation]
J. Neurol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
12.
Saunders DE, Phipps KP, Wade AM, Hayward RD:
Surveillance imaging strategies following surgery and/or radiotherapy for childhood cerebellar low-grade astrocytoma.
J Neurosurg
; 2005 Mar;102(2 Suppl):172-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Surveillance imaging strategies following surgery and/or radiotherapy for childhood cerebellar
low
-
grade astrocytoma
.
OBJECT: The authors sought to evaluate surveillance strategies for the detection and monitoring of residual and recurrent
disease
in children with cerebellar
low
-
grade
astrocytomas
(CLGAs) treated surgically or with radiotherapy.
(2) those with residual
disease
with no immediate adjuvant therapy; and (3) those who received radiotherapy for residual/recurrent
disease
.
Eighty-four children were followed
for a
mean period of 73 months (range 2-159 months).
Following an incomplete resection, radiologically detected
tumor
progression leading to further treatment was detected at 7, 9, 12, 13, and 20 months, respectively, and an additional six tumors regressed or stablized.
For follow up of residual
tumor
, 6-month interval imaging for at least 3 years, yearly images for another 2 years, and subsequent 2-year imaging is recommended.
[MeSH-major]
Astrocytoma
/ diagnosis. Cerebellar Neoplasms / diagnosis. Magnetic Resonance Imaging.
Neoplasm
, Residual / diagnosis. Tomography, X-Ray Computed
[MeSH-minor]
Adolescent. Cerebellum / pathology. Cerebellum / radiography. Cerebellum / surgery. Child. Child, Preschool.
Disease
Progression. Female. Follow-Up Studies. Humans. Infant. Male.
Neoplasm
Recurrence, Local / epidemiology.
Neoplasm
Staging. Postoperative Care. Remission, Spontaneous. Time Factors
Genetic Alliance.
consumer health - Cerebellar Astrocytoma, Childhood
.
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16156227.001).
[ISSN]
0022-3085
[Journal-full-title]
Journal of neurosurgery
[ISO-abbreviation]
J. Neurosurg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
13.
Gu S, Bao N, Yin MZ:
Combined fontanelle puncture and surgical operation in treatment of desmoplastic infantile astrocytoma: case report and a review of the literature.
J Child Neurol
; 2010 Feb;25(2):216-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Combined fontanelle puncture and surgical operation in treatment of desmoplastic infantile
astrocytoma
: case report and a review of the literature.
Desmoplastic infantile
astrocytoma
is a rare
low
-
grade
malignant brain
tumor
found in infants.
A case of desmoplastic infantile
astrocytoma
, including its clinical manifestations, pathological characteristics, differential diagnosis, treatment, and prognosis, is reported.
[MeSH-major]
Astrocytoma
/ pathology.
Astrocytoma
/ surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Cranial Fontanelles / surgery. Neurosurgical Procedures / methods
Genetic Alliance.
consumer health - Desmoplastic Infantile Astrocytoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
The Weizmann Institute of Science GeneCards and MalaCards databases.
gene/protein/disease-specific - MalaCards for desmoplastic infantile astrocytoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19671888.001).
[ISSN]
1708-8283
[Journal-full-title]
Journal of child neurology
[ISO-abbreviation]
J. Child Neurol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
9
14.
Katsetos CD, Reddy G, Dráberová E, Smejkalová B, Del Valle L, Ashraf Q, Tadevosyan A, Yelin K, Maraziotis T, Mishra OP, Mörk S, Legido A, Nissanov J, Baas PW, de Chadarévian JP, Dráber P:
Altered cellular distribution and subcellular sorting of gamma-tubulin in diffuse astrocytic gliomas and human glioblastoma cell lines.
J Neuropathol Exp Neurol
; 2006 May;65(5):465-77
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Altered cellular distribution and subcellular sorting of gamma-tubulin in diffuse
astrocytic gliomas
and human glioblastoma cell lines.
Centrosome amplification is a pivotal mechanism underlying tumorigenesis but its role in
gliomas
is underinvestigated.
The present study specifically examines the expression and distribution of the centrosome-associated cytoskeletal protein gamma-tubulin in 56 primary diffuse
astrocytic gliomas
(grades II-IV) and in 4 human glioblastoma cell lines (U87MG, U118MG, U138MG, and T98G).
In tumors in adults (n = 46), varying degrees of localization were detected in all
tumor
grades, but immunoreactivity was significantly increased in high-
grade
anaplastic
astrocytomas
and glioblastomas multiforme as compared to
low
-
grade
diffuse
astrocytomas
(p = 0.0001).
A similar trend was noted in diffuse
gliomas
in children but the sample of cases was too small as to be statistically meaningful.
Our results indicate that overexpression and ectopic cellular distribution of gamma-tubulin in
astrocytic gliomas
may be significant in the context of centrosome protein amplification and may be linked to
tumor
progression and anaplastic potential.
[MeSH-minor]
Antigens / metabolism. Blotting, Northern / methods. Cell Line,
Tumor
. Humans. Immunohistochemistry / methods
Genetic Alliance.
consumer health - Glioblastoma
.
COS Scholar Universe.
author profiles
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16772870.001).
[ISSN]
0022-3069
[Journal-full-title]
Journal of neuropathology and experimental neurology
[ISO-abbreviation]
J. Neuropathol. Exp. Neurol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens; 0 / Tubulin; 0 / pericentrin
15.
Schomas DA, Laack NN, Brown PD:
Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic.
Cancer
; 2009 Sep 1;115(17):3969-78
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Low
-
grade
gliomas
in older patients: long-term follow-up from Mayo Clinic.
BACKGROUND:
Low
-
grade
gliomas
(LGGs) are uncommon in older patients, and long-term clinical behavior and prognostic factors are not well defined in this group.
METHODS: The authors retrospectively searched their
tumor
registry for the records of adult patients (> or =18 years) diagnosed as having nonpilocytic LGG between 1960 and 1992 at Mayo Clinic.
Operative pathologic diagnoses comprised
astrocytoma
(n = 22, 69%), mixed oligoastrocytoma (n = 7, 22%), and oligodendroglioma (n = 3, 9%).
Pathologic sampling error failing to recognize higher-
grade
tumors does not seem to account for these poor outcomes.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7
[
9598670.001
]
[Cites]
J Clin Oncol. 1997 Sep;15(9):3129-40
[
9294476.001
]
[Cites]
Cancer. 2005 Mar 15;103(6):1227-33
[
15690327.001
]
[Cites]
J Clin Oncol. 2005 Apr 1;23(10):2372-7
[
15800329.001
]
[Cites]
Lancet. 2005 Sep 17-23;366(9490):985-90
[
16168780.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2707-14
[
16782910.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2715-22
[
16782911.001
]
[Cites]
Neurology. 2007 May 22;68(21):1831-6
[
17515545.001
]
[Cites]
Brain Pathol. 2007 Jul;17(3):308-13
[
17598823.001
]
[Cites]
Acta Neuropathol. 2007 Aug;114(2):97-109
[
17618441.001
]
[Cites]
J Clin Oncol. 2008 Mar 10;26(8):1338-45
[
18323558.001
]
[Cites]
Neurosurgery. 2008 Oct;63(4):700-7; author reply 707-8
[
18981880.001
]
[Cites]
J Neurooncol. 2008 Dec;90(3):341-50
[
18682893.001
]
[Cites]
Neuro Oncol. 2009 Aug;11(4):437-45
[
19018039.001
]
[Cites]
J Clin Oncol. 1999 Nov;17(11):3389-95
[
10550132.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9
[
10571199.001
]
[Cites]
Neurology. 2000 Apr 11;54(7):1442-8
[
10751254.001
]
[Cites]
J Neurosurg. 2000 Jun;92(6):983-90
[
10839259.001
]
[Cites]
Strahlenther Onkol. 2000 Jun;176(6):259-64
[
10897252.001
]
[Cites]
Neurology. 2001 Mar 13;56(5):618-23
[
11245713.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
J Neurosurg. 2001 Nov;95(5):735-45
[
11702861.001
]
[Cites]
J Neurosurg. 2001 Aug;95(2):190-8
[
11780887.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24
[
11872276.001
]
[Cites]
J Clin Oncol. 2002 Apr 15;20(8):2076-84
[
11956268.001
]
[Cites]
J Clin Oncol. 2002 May 1;20(9):2267-76
[
11980997.001
]
[Cites]
J Neurooncol. 2003 Jul;63(3):305-12
[
12892238.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):117-25
[
15093907.001
]
[Cites]
J Clin Oncol. 2004 Aug 1;22(15):3133-8
[
15284265.001
]
[Cites]
Cancer. 1975 Nov;36(5):1681-9
[
172217.001
]
[Cites]
Br J Cancer. 1977 Jan;35(1):1-39
[
831755.001
]
[Cites]
J Neurosurg. 1978 Sep;49(3):333-43
[
355604.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31
[
231022.001
]
[Cites]
Cancer. 1981 Feb 15;47(4):649-52
[
6164465.001
]
[Cites]
Br J Clin Pharmacol. 1982 Sep;14(3):325-31
[
6751362.001
]
[Cites]
J Neurosurg. 1984 Oct;61(4):665-73
[
6470776.001
]
[Cites]
Neurosurgery. 1987 Jun;20(6):975-82
[
3614580.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):837-41
[
3141317.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):663-8
[
2921165.001
]
[Cites]
J Neurosurg. 1989 Jun;70(6):853-61
[
2715812.001
]
[Cites]
Neurosurgery. 1989 May;24(5):686-92
[
2716976.001
]
[Cites]
J Neurosurg. 1989 Oct;71(4):487-93
[
2552044.001
]
[Cites]
Arch Neurol. 1989 Nov;46(11):1238-9
[
2818260.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1351-6
[
2689399.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4
[
2154418.001
]
[Cites]
Ann Neurol. 1992 Apr;31(4):431-6
[
1586143.001
]
[Cites]
Neurosurgery. 1993 Apr;32(4):554-9
[
8474646.001
]
[Cites]
W V Med J. 1993 Mar;89(3):102-5
[
8475621.001
]
[Cites]
J Natl Cancer Inst. 1993 May 5;85(9):704-10
[
8478956.001
]
[Cites]
J Neurosurg. 1993 Jun;78(6):909-14
[
8487073.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1993 May 20;26(2):239-44
[
8387988.001
]
[Cites]
Acta Neurochir (Wien). 1993;123(1-2):1-7
[
8213272.001
]
[Cites]
Cancer. 1994 Apr 1;73(7):1937-45
[
8137221.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112
[
7677836.001
]
[Cites]
J Clin Oncol. 1997 Apr;15(4):1294-301
[
9193320.001
]
[Cites]
J Neurooncol. 1997 Feb;31(3):273-8
[
9049856.001
]
[Cites]
Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3
[
8545771.001
]
[Cites]
J Neurooncol. 1996 Feb;27(2):173-7
[
8699240.001
]
[Cites]
Neurosurgery. 1996 May;38(5):872-8; discussion 878-9
[
8727811.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56
[
8948338.001
]
[Cites]
Neurology. 1999 Mar 10;52(4):867-9
[
10078745.001
]
(PMID = 19536875.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
ENG
[Grant]
United States / NCRR NIH HHS / RR / UL1 RR024150; None / None / / UL1 RR024150-01; United States / NCRR NIH HHS / RR / 1 UL1 RR024150-01; United States / NCRR NIH HHS / RR / UL1 RR024150-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS140676; NLM/ PMC2789453
16.
Di Costanzo A, Pollice S, Trojsi F, Giannatempo GM, Popolizio T, Canalis L, Armillotta M, Maggialetti A, Carriero A, Tedeschi G, Scarabino T:
Role of perfusion-weighted imaging at 3 Tesla in the assessment of malignancy of cerebral gliomas.
Radiol Med
; 2008 Feb;113(1):134-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Role of perfusion-weighted imaging at 3 Tesla in the assessment of malignancy of cerebral
gliomas
.
PURPOSE: This study was performed to clarify the role of perfusion-weighted imaging (PWI) at 3 Tesla in the characterisation of haemodynamic heterogeneity within
gliomas
and surrounding tissues and in the differentiation of high-
grade
from
low
-
grade
gliomas
.
MATERIALS AND METHODS: We examined 36 patients with histologically verified
gliomas
(25 with high-
grade
and 11 with
low
-
grade
gliomas
).
RESULTS: In high-
grade
gliomas
, rCBV were markedly increased in mass [mean+/-standard deviation (SD), 4.3+/-1.2] and margins (4.0+/-1.1) and reduced in necrotic areas (0.3+/-0.3).
In
low
-
grade
gliomas
, mass (2.0+/-1.5) and margin (2.2+/-1.2) rCBV were significantly lower than in high-
grade
gliomas
(p<0.001).
CONCLUSIONS: Three-Tesla PWI helps to distinguish necrosis from tumour mass, infiltrating tumour from oedema and high-
grade
from
low
-
grade
gliomas
.
It enhances the magnetic resonance (MR) assessment of cerebral
gliomas
and provides useful information for planning surgical and radiation treatment.
[MeSH-major]
Brain Neoplasms / diagnosis.
Glioma
/ diagnosis. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods
[MeSH-minor]
Adult. Aged.
Astrocytoma
/ diagnosis. Blood Volume / physiology. Brain Edema / diagnosis. Cerebrovascular Circulation / physiology. Contrast Media. Diagnosis, Differential. Echo-Planar Imaging / methods. Female. Gadolinium DTPA. Ganglioglioma / diagnosis. Glioblastoma / diagnosis. Humans. Image Enhancement / methods. Male. Middle Aged. Necrosis. Oligodendroglioma / diagnosis. Retrospective Studies
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
Hazardous Substances Data Bank.
GADOPENTETATE DIMEGLUMINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21
[
14970020.001
]
[Cites]
Neuroradiology. 2003 Apr;45(4):205-11
[
12687302.001
]
[Cites]
J Magn Reson Imaging. 2006 Oct;24(4):817-24
[
16958061.001
]
[Cites]
Radiology. 2002 Apr;223(1):11-29
[
11930044.001
]
[Cites]
J Magn Reson Imaging. 2001 Apr;13(4):496-520
[
11276094.001
]
[Cites]
Radiol Med. 2003 Mar;105(3):141-9
[
12835637.001
]
[Cites]
AJR Am J Roentgenol. 1998 Dec;171(6):1479-86
[
9843274.001
]
[Cites]
Radiology. 2005 Mar;234(3):869-77
[
15665227.001
]
[Cites]
Magn Reson Imaging Clin N Am. 2006 Feb;14(1):77-88
[
16530636.001
]
[Cites]
Radiol Med. 2002 Jul-Aug;104(1-2):87-91
[
12386559.001
]
[Cites]
Cancer. 2004 Nov 15;101(10):2293-9
[
15476282.001
]
[Cites]
Eur J Radiol. 2003 Dec;48(3):244-51
[
14652141.001
]
[Cites]
Radiology. 2002 Mar;222(3):715-21
[
11867790.001
]
[Cites]
AJNR Am J Neuroradiol. 2005 Oct;26(9):2187-99
[
16219821.001
]
[Cites]
Radiol Med. 2003 Mar;105(3):150-61
[
12835638.001
]
[Cites]
AJNR Am J Neuroradiol. 2004 May;25(5):746-55
[
15140713.001
]
[Cites]
Surg Neurol. 1998 Apr;49(4):436-40
[
9537664.001
]
[Cites]
J Neurosurg. 1995 Oct;83(4):682-9
[
7674019.001
]
[Cites]
Radiology. 1994 Apr;191(1):41-51
[
8134596.001
]
[Cites]
Invest Radiol. 2003 Jul;38(7):385-402
[
12821852.001
]
[Cites]
AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87
[
16551981.001
]
[Cites]
AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32
[
15502131.001
]
[Cites]
Cancer. 1996 Jan 15;77(2):362-72
[
8625246.001
]
[Cites]
Oncologist. 2004;9(5):528-37
[
15477637.001
]
[Cites]
Eur Radiol. 2006 Jan;16(1):180-6
[
16402258.001
]
[Cites]
Neuroradiology. 2004 Aug;46(8):619-27
[
15243726.001
]
[Cites]
AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67
[
16611779.001
]
[Cites]
Clin Radiol. 2003 Jul;58(7):505-13
[
12834633.001
]
[Cites]
Radiology. 1999 Jun;211(3):791-8
[
10352608.001
]
(PMID = 18338133.001).
[ISSN]
0033-8362
[Journal-full-title]
La Radiologia medica
[ISO-abbreviation]
Radiol Med
[Language]
eng; ita
[Publication-type]
Journal Article
[Publication-country]
Italy
[Chemical-registry-number]
0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
17.
Brown PD:
Low-grade gliomas: the debate continues.
Curr Oncol Rep
; 2006 Jan;8(1):71-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Low
-
grade
gliomas
: the debate continues.
Low
-
grade
gliomas
(LGG) are a heterogeneous group of tumors that tend to occur primarily in young adults and children.
Many questions remain in the management of LGGs, including the role of surgical resection (ie, maximal
tumor
resection), the optimal timing of radiation (ie, postoperative vs at the time
of tumor
progression), and the role of chemotherapy (ie, salvage after radiotherapy, primary treatment after surgery, concurrent with radiotherapy).
[MeSH-major]
Astrocytoma
/ pathology.
Astrocytoma
/ therapy. Brain Neoplasms / pathology. Brain Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 2002 Nov 2;360(9343):1361-8
[
12423981.001
]
[Cites]
Ann Oncol. 2003 Dec;14 (12 ):1722-6
[
14630675.001
]
[Cites]
Ann Neurol. 1992 Apr;31(4):431-6
[
1586143.001
]
[Cites]
Neurology. 2005 Jun 28;64(12):2085-9
[
15985578.001
]
[Cites]
J Clin Oncol. 2004 Aug 1;22(15):3133-8
[
15284265.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):527-33
[
8655376.001
]
[Cites]
Brain Pathol. 2003 Apr;13(2):176-84
[
12744471.001
]
[Cites]
J Clin Oncol. 2003 Oct 1;21(19):3710
[
14512412.001
]
[Cites]
Eur Radiol. 2004 Nov;14(11):2061-6
[
15252748.001
]
[Cites]
Semin Oncol. 2004 Oct;31(5):702-13
[
15497124.001
]
[Cites]
J Neurosurg. 1993 Oct;79(4):533-6
[
8410222.001
]
[Cites]
N Engl J Med. 2000 Nov 9;343(19):1350-4
[
11070098.001
]
[Cites]
J Clin Oncol. 2002 May 1;20(9):2267-76
[
11980997.001
]
[Cites]
J Clin Oncol. 2002 Apr 15;20(8):2076-84
[
11956268.001
]
[Cites]
J Clin Oncol. 2003 Jan 15;21(2):251-5
[
12525516.001
]
[Cites]
Clin Radiol. 2005 Apr;60(4):493-502
[
15767107.001
]
[Cites]
J Neurosurg. 1992 Feb;76(2):179-83
[
1730945.001
]
[Cites]
J Neurooncol. 2004 Jul;68(3):263-74
[
15332331.001
]
[Cites]
Neurology. 2001 Mar 13;56(5):618-23
[
11245713.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56
[
8948338.001
]
[Cites]
J Clin Oncol. 2003 Feb 15;21(4):646-51
[
12586801.001
]
[Cites]
Acta Neuropathol. 2004 Jul;108(1):49-56
[
15118874.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):845-51
[
15897509.001
]
[Cites]
Cancer. 2005 Mar 15;103(6):1227-33
[
15690327.001
]
[Cites]
Mayo Clin Proc. 1987 Jun;62(6):450-9
[
3553757.001
]
[Cites]
J Neurooncol. 1997 Feb;31(3):273-8
[
9049856.001
]
[Cites]
Neurology. 2002 Jul 9;59(1):40-8
[
12105305.001
]
[Cites]
J Neurosurg. 1993 Jun;78(6):909-14
[
8487073.001
]
[Cites]
AJR Am J Roentgenol. 1986 Jul;147(1):119-24
[
3487203.001
]
[Cites]
J Neurosurg. 1989 Apr;70(4):568-72
[
2926497.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28
[
7007303.001
]
[Cites]
Ann Oncol. 2003 Dec;14 (12 ):1715-21
[
14630674.001
]
[Cites]
Lancet. 2005 Sep 17-23;366(9490):985-90
[
16168780.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):374-9
[
15667955.001
]
[Cites]
Neuro Oncol. 2003 Jul;5(3):161-7
[
12816722.001
]
[Cites]
Neurology. 2003 Apr 8;60(7):1113-8
[
12682316.001
]
[Cites]
J Neurooncol. 1996 Oct;30(1):61-9
[
8865004.001
]
[Cites]
Radiother Oncol. 1996 Oct;41(1):55-9
[
8961368.001
]
[Cites]
Strahlenther Onkol. 2004 Jul;180(7):408-18
[
15241528.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):117-25
[
15093907.001
]
[Cites]
Neurochirurgia (Stuttg). 1992 Jan;35(1):18-22
[
1570044.001
]
[Cites]
Neurology. 2001 May 22;56(10):1285-90
[
11376174.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24
[
11872276.001
]
[Cites]
Ann Neurol. 1990 Dec;28(6):818-22
[
2178330.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10 ):987-96
[
15758009.001
]
[Cites]
J Clin Oncol. 1994 Oct;12(10):2013-21
[
7931469.001
]
[Cites]
J Neurooncol. 2004 Feb;66(3):333-9
[
15015665.001
]
(PMID = 16566078.001).
[ISSN]
1523-3790
[Journal-full-title]
Current oncology reports
[ISO-abbreviation]
Curr Oncol Rep
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
54
18.
Jacques TS, Eldridge C, Patel A, Saleem NM, Powell M, Kitchen ND, Thom M, Revesz T:
Mixed glioneuronal tumour of the fourth ventricle with prominent rosette formation.
Neuropathol Appl Neurobiol
; 2006 Apr;32(2):217-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Our cases demonstrate the morphological features of the 'rosette-forming glioneuronal tumour of the fourth ventricle', a recently identified tumour characterised by its unique location, neurocytic pseudo-rosette formation and the presence
of a
low grade astrocytoma
component.
However, the clinical data available including the cases presented here, along with the histological features, suggest that these are
low grade
tumours with a good prognosis after surgical resection.
[MeSH-minor]
Adult.
Astrocytoma
/ metabolism.
Astrocytoma
/ pathology.
Astrocytoma
/ physiopathology. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neurocytoma / metabolism. Neurocytoma / pathology. Neurocytoma / physiopathology
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16599951.001).
[ISSN]
0305-1846
[Journal-full-title]
Neuropathology and applied neurobiology
[ISO-abbreviation]
Neuropathol. Appl. Neurobiol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
19.
Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K, Jacobs AH, Heiss WD:
[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors.
J Neurooncol
; 2010 Jan;96(2):231-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Only a few Methyl-[11C]-L-methionine (MET) positron emission tomography (PET) studies have focused on children and young adults with brain
neoplasm
.
The MET
tumor
-uptake relative to a corresponding control region was calculated.
A receiver operating characteristic (ROC) was performed to determine the MET-uptake
value
that best distinguishes tumorous from non-tumorous brain lesions.
A differentiation between high
grade
malignant lesions (mean MET-uptake = 2.00 +/- 0.46) and
low grade
tumors (mean MET-uptake = 1.84 +/- 0.31) was not possible.
There was a significant difference in MET-uptake between the histologically homogeneous subgroups of
astrocytoma
WHO
grade
II and anaplastic
astrocytoma
WHO
grade
III (P = 0.02).
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
(L)-Methionine
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Acta Radiol. 1987 Nov-Dec;28(6):673-81
[
2962599.001
]
[Cites]
J Comput Assist Tomogr. 1983 Dec;7(6):1062-6
[
6415134.001
]
[Cites]
Pediatr Neurol. 1990 May-Jun;6(3):163-70
[
2193641.001
]
[Cites]
J Comput Assist Tomogr. 1992 Sep-Oct;16(5):804-13
[
1522276.001
]
[Cites]
J Comput Assist Tomogr. 1994 Jan-Feb;18(1):110-8
[
8282858.001
]
[Cites]
Clin Neurol Neurosurg. 1995 Nov;97(4):349-53
[
8599907.001
]
[Cites]
J Nucl Med. 1996 Feb;37(2):387-93
[
8667081.001
]
[Cites]
Neurology. 1998 May;50(5):1316-22
[
9595980.001
]
[Cites]
Clin Cancer Res. 2004 Nov 1;10(21):7163-70
[
15534088.001
]
[Cites]
J Neurosurg. 2006 Feb;104(2):238-53
[
16509498.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2006 May;33(5):516-24
[
16450140.001
]
[Cites]
Childs Nerv Syst. 2007 Jul;23(7):739-51
[
17356889.001
]
[Cites]
Neurosurg Rev. 1999 Dec;22(4):210-4
[
10682929.001
]
[Cites]
J Nucl Med. 2000 Jul;41(7):1250-5
[
10914918.001
]
[Cites]
J Nucl Med. 2001 Mar;42(3):432-45
[
11337520.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82
[
11926379.001
]
[Cites]
Cancer. 2002 Sep 15;95(6):1376-86
[
12216107.001
]
[Cites]
Pediatr Neurosurg. 2003 Mar;38(3):146-55
[
12601239.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73
[
12692687.001
]
[Cites]
J Neuroimaging. 2003 Jul;13(3):269-71
[
12889176.001
]
[Cites]
Mol Imaging. 2002 Oct;1(4):309-35
[
12926228.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1389-97
[
12920486.001
]
[Cites]
J Neuroimaging. 2004 Oct;14(4):372-6
[
15358961.001
]
[Cites]
Int J Appl Radiat Isot. 1979 Jul;30(7):393-9
[
478664.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
(PMID = 19575148.001).
[ISSN]
1573-7373
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Carbon Radioisotopes; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester
[Other-IDs]
NLM/ PMC2808525
20.
Raab P, Hattingen E, Franz K, Zanella FE, Lanfermann H:
Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences.
Radiology
; 2010 Mar;254(3):876-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cerebral
gliomas
: diffusional kurtosis imaging analysis of microstructural differences.
PURPOSE: To characterize the non-Gaussian diffusion patterns of cerebral
glioma
microstructure with respect to the different
glioma
grades by using a new method called diffusional kurtosis (DK) imaging.
A Mann-Whitney test was used to compare each histologic
glioma subtype
regarding the diffusion measurements.
Receiver operating characteristic curves were used to test for the parameter with the best sensitivity and specificity
for glioma
grade
discrimination.
RESULTS: In 34 patients with cerebral
gliomas
(five World Health Organization [WHO]
grade
II
astrocytomas
, 13 WHO
grade
III
astrocytomas
, and 16 WHO
grade
IV glioblastomas multiforme), significantly different diffusion patterns were found among the three
glioma
groups.
MK values increased with higher
glioma
malignancy, whereas ADCs tended to decrease with higher malignancy; FA values did not differ significantly among
tumor
groups.
Significant differences between
astrocytoma
grades WHO II and WHO III were demonstrated only by DK values.
Area under the receiver operating characteristic curve was highest for normalized MK (0.972) during testing to discriminate between
low
- and high-
grade
gliomas
.
CONCLUSION: This study demonstrates specific diffusion patterns for
low
- and high-
grade
gliomas
, showing that DK imaging is able to depict microstructural changes within
glioma
tissue and is able to help differentiate among
glioma
grades. (c) RSNA, 2010.
[MeSH-major]
Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods.
Glioma
/ diagnosis
MedlinePlus Health Information.
consumer health - Brain Tumors
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20089718.001).
[ISSN]
1527-1315
[Journal-full-title]
Radiology
[ISO-abbreviation]
Radiology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
21.
Darken RS, Bogitch R, Leonard J, Perry A, McKinstry RC, Gutmann DH, Rubin JB:
Brainstem glioma presenting as pruritus in children with neurofibromatosis-1.
J Pediatr Hematol Oncol
; 2009 Dec;31(12):972-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Brainstem
glioma
presenting as pruritus in children with neurofibromatosis-1.
The most common intracranial tumors are
low
-
grade
astrocytomas
, which most frequently involve the optic pathway, and less often, the brainstem.
In cases of brainstem
glioma
in NF1, treatment decisions are frequently complicated by the paucity of symptoms referable to the
tumor
.
Here, we describe 2 children with NF1 whose initial presentation
of a
growing brainstem
glioma
was localized pruritus.
[MeSH-major]
Brain Stem Neoplasms / diagnosis.
Glioma
/ diagnosis. Neurofibromatosis 1 / diagnosis. Pruritus / diagnosis
Genetic Alliance.
consumer health - Glioma
.
Genetic Alliance.
consumer health - Neurofibromatosis
.
MedlinePlus Health Information.
consumer health - Itching
.
COS Scholar Universe.
author profiles
.
Xenbase.
Xenbase
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19935099.001).
[ISSN]
1536-3678
[Journal-full-title]
Journal of pediatric hematology/oncology
[ISO-abbreviation]
J. Pediatr. Hematol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
22.
Pal D, Hall G, Loughrey C, Shivane A, Chakrabarty A, Chumas P:
Primitive neuroectodermal tumour arising within low grade astrocytoma: transformation, de novo or radiation induced? Report of three cases and review of literature.
Br J Neurosurg
; 2008 Jun;22(3):402-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primitive neuroectodermal tumour arising within
low grade astrocytoma
: transformation,
de
novo or radiation induced? Report of three cases and review of literature.
The transformation from
low grade
to aggressive
astrocytoma
is well known.
However, the development
of a
completely different tumour such as a primitive neuroectodermal tumour (PNET) within a
low grade astrocytoma
(LGA) is rare.
All three patients had histologically proven
low
-
grade astrocytoma
and received radiotherapy following biopsy.
Two patients underwent partial resection for recurrence, one at five and the other ten years later with histological confirmation of
low
-
grade astrocytoma
.
Histology now revealed high
grade
PNET.
Among the six reported cases of PNET arising following prophylactic radiation therapy to
low grade
astrocytomas
, only two occurred within the original tumour.
Whether these cases represent transformation of
low
-
grade astrocytoma
,
de
novo formation of new tumour or radiation induced
neoplasm
is uncertain.
[MeSH-major]
Astrocytoma
/ radiotherapy. Brain Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neuroectodermal Tumors, Primitive / etiology
[MeSH-minor]
Adolescent. Adult. Fatal Outcome. Female. Humans. Male.
Neoplasm
Recurrence, Local / etiology
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18568729.001).
[ISSN]
0268-8697
[Journal-full-title]
British journal of neurosurgery
[ISO-abbreviation]
Br J Neurosurg
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
England
[Number-of-references]
14
23.
Stojic J, Hagemann C, Haas S, Herbold C, Kühnel S, Gerngras S, Roggendorf W, Roosen K, Vince GH:
Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas.
Neurosci Res
; 2008 Jan;60(1):40-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant
gliomas
.
Glioblastomas (GBM) are the most prevalent type of malignant primary brain
tumor
in adults.
They may manifest
de
novo or develop from
low
-
grade
astrocytomas
(LGA) or anaplastic
astrocytomas
.
Tumor
progression is facilitated by an increased activity of proteolytic enzymes such as matrix metalloproteinases (MMPs).
Therefore, MMP-1, MMP-11 and MMP-19 might be of importance for the development of high-
grade
astrocytic
tumors and may be promising targets for therapy.
[MeSH-major]
Brain Neoplasms / diagnosis. Brain Neoplasms / enzymology.
Glioma
/ diagnosis.
Glioma
/ enzymology. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 11 / metabolism. Matrix Metalloproteinases, Secreted / metabolism
[MeSH-minor]
Adolescent. Adult. Aged. Biomarkers,
Tumor
/ analysis. Biomarkers,
Tumor
/ metabolism. Child. Child, Preschool.
Disease
Progression. Female. Gene Expression Regulation, Enzymologic / genetics. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Matrix Metalloproteinase 9 / genetics. Middle Aged.
Neoplasm
Invasiveness / genetics. Predictive
Value of
Tests. Prognosis. RNA, Messenger / analysis. RNA, Messenger / metabolism. World Health Organization
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17980449.001).
[ISSN]
0168-0102
[Journal-full-title]
Neuroscience research
[ISO-abbreviation]
Neurosci. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.- / Matrix Metalloproteinases, Secreted; EC 3.4.24.- / matrix metalloproteinase 19; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
24.
Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J:
Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.
J Neurooncol
; 2005 Feb;71(3):319-23
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Recurrent
low
-
grade
gliomas
: the role of fractionated stereotactic re-irradiation.
PURPOSE: To assess the effectiveness of re-irradiation in recurrent
low
-
grade
gliomas
(LGG).
PATIENTS AND METHODS: Sixty-three patients were treated with fractionated stereotactic re-irradiation in the case of recurrent
gliomas
.
At primary diagnosis of the
tumor
, the histology was
grade
II
astrocytoma
, oligodendroglioma or oligoastrocytoma.
CONCLUSION: Our retrospective data suggest that stereotactically guided fractionated re-irradiation in recurrent
glioma
represents an effective treatment option with good results and few complications.
[MeSH-major]
Brain Neoplasms / radiotherapy. Dose Fractionation.
Glioma
/ radiotherapy.
Neoplasm
Recurrence, Local / radiotherapy. Radiotherapy / methods
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Radiation Therapy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):996-1003
[
14575830.001
]
[Cites]
Cancer. 1993 Jul 1;72 (1):190-5
[
8508405.001
]
[Cites]
Eur J Cancer. 1998 Jan;34(1):98-102
[
9624245.001
]
[Cites]
Cancer. 1994 Sep 15;74(6):1784-91
[
8082081.001
]
[Cites]
Semin Radiat Oncol. 2001 Apr;11(2):145-51
[
11285552.001
]
[Cites]
Arch Neurol. 1989 Nov;46(11):1238-9
[
2818260.001
]
[Cites]
Arch Neurol. 1990 Oct;47(10):1138-40
[
2222248.001
]
[Cites]
Cancer. 1985 Mar 1;55(5):919-27
[
3967199.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7
[
9598670.001
]
[Cites]
Br J Cancer. 2003 Jul 21;89(2):232-8
[
12865907.001
]
[Cites]
J Clin Oncol. 2002 May 1;20(9):2267-76
[
11980997.001
]
[Cites]
J Neurosurg. 1989 Jun;70(6):853-61
[
2715812.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9
[
2542195.001
]
[Cites]
Semin Oncol. 1994 Apr;21(2):236-48
[
8153667.001
]
[Cites]
Can J Surg. 1993 Jun;36(3):271-5
[
8391917.001
]
[Cites]
Radiother Oncol. 2000 Nov;57(2):215-23
[
11054526.001
]
[Cites]
J Clin Oncol. 2003 Jul 1;21(13):2525-8
[
12829671.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8
[
9069312.001
]
[Cites]
J Clin Oncol. 1997 Apr;15(4):1294-301
[
9193320.001
]
[Cites]
Neurology. 2000 Apr 11;54(7):1402-3
[
10751245.001
]
[Cites]
J Clin Oncol. 2003 Feb 15;21(4):646-51
[
12586801.001
]
[Cites]
Radiologe. 1995 Sep;35(9):583-6
[
8588040.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27
[
8040017.001
]
[Cites]
J Neurosurg. 1984 Oct;61(4):665-73
[
6470776.001
]
[Cites]
J Clin Oncol. 2003 Jun 15;21(12 ):2305-11
[
12805331.001
]
[Cites]
Neurosurgery. 1987 Nov;21(5):615-21
[
2827052.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41
[
10613305.001
]
[Cites]
J Neurosurg. 1993 Jun;78(6):909-14
[
8487073.001
]
[Cites]
Cancer. 1997 Jan 15;79(2):370-9
[
9010111.001
]
[Cites]
Oncology. 2000 Feb;58(2):108-16
[
10705237.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):977-82
[
10192343.001
]
[Cites]
Neurology. 1999 Sep 22;53(5):1141-3
[
10496285.001
]
[Cites]
Ann Oncol. 2003 Apr;14 (4):599-602
[
12649108.001
]
[Cites]
Semin Surg Oncol. 2001 Jan-Feb;20(1):13-23
[
11291128.001
]
[Cites]
Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4
[
14765378.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6
[
8795601.001
]
[Cites]
Neurology. 2000 Apr 11;54(7):1442-8
[
10751254.001
]
[Cites]
Clin Neurosurg. 1995;42:488-94
[
8846613.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24
[
11872276.001
]
[Cites]
J Clin Oncol. 1994 Oct;12(10):2013-21
[
7931469.001
]
[Cites]
Neurosurgery. 1996 May;38(5):872-8; discussion 878-9
[
8727811.001
]
[Cites]
Radiology. 1996 Oct;201(1):275-8
[
8816559.001
]
[Cites]
Cancer. 1994 Apr 1;73(7):1937-45
[
8137221.001
]
(PMID = 15735924.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
25.
Payne CA, Maleki S, Messina M, O'Sullivan MG, Stone G, Hall NR, Parkinson JF, Wheeler HR, Cook RJ, Biggs MT, Little NS, Teo C, Robinson BG, McDonald KL:
Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma.
Mol Cancer Ther
; 2008 Oct;7(10):3420-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Loss of prostaglandin D2 synthase: a key molecular event in the transition
of a
low
-
grade astrocytoma
to an anaplastic
astrocytoma
.
Reduction in the mRNA and protein expression of lipocalin-like prostaglandin D(2) (PGD(2)) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression
of astrocytomas
and is predictive of poor survival.
This
finding
has exciting implications for early interventional efforts for the
grade
2 and 3
astrocytomas
.
[MeSH-major]
Astrocytoma
/ enzymology.
Astrocytoma
/ pathology. Intramolecular Oxidoreductases / deficiency
[MeSH-minor]
Cell Line,
Tumor
. Cell Proliferation / drug effects. Cell Survival / drug effects. Cyclooxygenase 2 / metabolism. Cyclooxygenase Inhibitors / pharmacology. DNA Methylation / drug effects. Drug Screening Assays, Antitumor. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Introns / genetics. Lipocalins / genetics. Multivariate Analysis. Proportional Hazards Models. Prostaglandin D2 / pharmacology. Protein Transport / drug effects. Survival Analysis
Genetic Alliance.
consumer health - Anaplastic Astrocytoma
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
SciCrunch.
ArrayExpress: Data: Microarray
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18852145.001).
[ISSN]
1535-7163
[Journal-full-title]
Molecular cancer therapeutics
[ISO-abbreviation]
Mol. Cancer Ther.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cyclooxygenase Inhibitors; 0 / Lipocalins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.2 / prostaglandin R2 D-isomerase; RXY07S6CZ2 / Prostaglandin D2
26.
Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ:
Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Cancer
; 2005 Feb 15;103(4):802-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Successful treatment of
low
-
grade
oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Only limited data are available on the role of chemotherapy in
low
-
grade
OD.
The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 patients with recurrent
low
-
grade
OD.
In the newly diagnosed and responding patients, radiotherapy was withheld until the time
of disease
recurrence.
The median time to
disease
progression in this group was >24 months.
Only one of these patients experienced
disease
progression while receiving chemotherapy.
Several patients showed a signficant clinical improvement despite only a modest improvement of the
tumor
on the MRI scans.
MRI scans were of limited
value for
the assessment of response.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Astrocytoma
/ drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
[MeSH-minor]
Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction. Procarbazine / therapeutic use. Retrospective Studies.
Tumor
Suppressor Protein p53 / genetics. Vincristine / therapeutic use
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2005 American Cancer Society.
(PMID = 15637687.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
27.
Ramírez-Aguilar R, Castillo-Montoya C, Alonso-Vanegas M:
[Complex partial seizures secondary to a low-grade lipoastrocytoma].
Rev Neurol
; 2007 Dec 16-31;45(12):766
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Complex partial seizures secondary to a
low
-
grade
lipoastrocytoma].
[Transliterated title]
Crisis parciales complejas secundarias a un lipoastrocitoma
de bajo grado
.
[MeSH-major]
Astrocytoma
/ complications. Epilepsy, Complex Partial / etiology. Epilepsy, Temporal Lobe / etiology. Lipoma / complications. Supratentorial Neoplasms / complications. Temporal Lobe / pathology
Genetic Alliance.
consumer health - Seizures
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18075993.001).
[ISSN]
0210-0010
[Journal-full-title]
Revista de neurologia
[ISO-abbreviation]
Rev Neurol
[Language]
spa
[Publication-type]
Case Reports; Letter
[Publication-country]
Spain
28.
Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H:
WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?
Acta Neuropathol
; 2007 Aug;114(2):111-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
WHO
grade
associated downregulation of MHC class I antigen-processing machinery components in human
astrocytomas
: does it reflect a potential immune escape mechanism?
We investigated the expression of APM components in
astrocytomas
without detectable defects in HLA class I antigen expression and correlated it with
grade
of malignancy.
Quantitative immunohistochemical analysis
of astrocytomas
revealed reduced expression of the cytosolic proteasome subunit
low
molecular weight protein 2 (LMP2), the endoplasmatic reticulum (ER) transporter associated with antigen processing-1 (TAP1), and the ER chaperone beta2-microglobulin (beta2m) in
astrocytoma
cells when compared to astrocytes from nonpathological brain.
Among human WHO
grade
II-IV
astrocytomas
, downregulation of LMP2, TAP1 and beta2m correlated with
grade
of malignancy.
Furthermore,
astrocytoma
cell lines (n = 12) expressed all APM components analyzed at levels comparable to dendritic cells (DC), which were used for comparative purposes.
However, upregulation of beta2m after stimulation with inflammatory cytokines was significantly lower in
astrocytoma
cell lines than in control cells.
Our results support the hypothesis that coordinated downregulation or impaired upregulation of certain HLA class I APM components may serve as a mechanism for
astrocytoma
cells to evade the host's immune response, even if HLA class I antigen surface expression is not altered.
[MeSH-major]
Antigen Presentation / immunology.
Astrocytoma
/ immunology. Brain Neoplasms / immunology. Histocompatibility Antigens Class I / metabolism.
Tumor
Escape / immunology
[MeSH-minor]
ATP-Binding Cassette Sub-Family B Member 2. ATP-Binding Cassette Transporters / biosynthesis. Adolescent. Adult. Aged. Aged, 80 and over. Cell Line,
Tumor
. Child. Child, Preschool. Cysteine Endopeptidases / biosynthesis. Down-Regulation. Female. Flow Cytometry. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. World Health Organization. beta 2-Microglobulin / biosynthesis
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17541610.001).
[ISSN]
0001-6322
[Journal-full-title]
Acta neuropathologica
[ISO-abbreviation]
Acta Neuropathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / ATP-Binding Cassette Sub-Family B Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Histocompatibility Antigens Class I; 0 / TAP1 protein, human; 0 / beta 2-Microglobulin; 144416-78-4 / LMP-2 protein; EC 3.4.22.- / Cysteine Endopeptidases
29.
Kita D, Yonekawa Y, Weller M, Ohgaki H:
PIK3CA alterations in primary (de novo) and secondary glioblastomas.
Acta Neuropathol
; 2007 Mar;113(3):295-302
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
PIK3CA alterations in primary (
de
novo) and secondary glioblastomas.
We assessed alterations in the EGFR/PTEN/PI3K pathway in 107 primary (
de
novo) glioblastomas and 32 secondary glioblastomas that progressed from
low
-
grade
or anaplastic
astrocytomas
.
Furthermore, this signaling pathway was altered by either PTEN mutations or PIK3CA amplification in 10 of 12 (83%) malignant
glioma
cell lines analyzed.
[MeSH-major]
Gene Expression Regulation, Neoplastic / physiology. Glioblastoma /
classification
. Glioblastoma / metabolism. Phosphatidylinositol 3-Kinases / metabolism
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17235514.001).
[ISSN]
0001-6322
[Journal-full-title]
Acta neuropathologica
[ISO-abbreviation]
Acta Neuropathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
30.
Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P:
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.
J Clin Invest
; 2008 May;118(5):1739-49
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in
low
-
grade
astrocytomas
.
The molecular pathogenesis of pediatric
astrocytomas
is still poorly understood.
To further understand the genetic abnormalities associated with these tumors, we performed a genome-wide analysis of DNA copy number aberrations in pediatric
low
-
grade
astrocytomas
by using array-based comparative genomic hybridization.
Similarly, a marked proportion of
low
-
grade
astrocytomas
from adult patients also had BRAF duplication.
Both the stable silencing of BRAF through shRNA lentiviral transduction and pharmacological inhibition of MEK1/2, the immediate downstream phosphorylation target of BRAF, blocked the proliferation and arrested the growth of cultured
tumor
cells derived from
low
-
grade
gliomas
.
Our findings implicate aberrant activation of the MAPK pathway due to gene duplication or mutation of BRAF as a molecular mechanism of pathogenesis in
low
-
grade
astrocytomas
and suggest inhibition of the MAPK pathway as a potential treatment.
[MeSH-major]
Astrocytoma
/ enzymology.
Astrocytoma
/ genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Gene Duplication. MAP Kinase Signaling System / physiology. Mitogen-Activated Protein Kinases / metabolism. Proto-Oncogene Proteins B-raf / metabolism
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
OMIM: Data: Gene Annotation
.
SciCrunch.
ArrayExpress: Data: Microarray
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mol Cell Biol. 2002 Oct;22(20):7226-41
[
12242299.001
]
[Cites]
Nat Genet. 2006 Mar;38(3):294-6
[
16474404.001
]
[Cites]
J Neuropathol Exp Neurol. 2002 Oct;61(10):896-902
[
12387455.001
]
[Cites]
Cancer Res. 2002 Dec 1;62(23):6997-7000
[
12460918.001
]
[Cites]
Cancer Res. 2003 Mar 15;63(6):1179-82
[
12649172.001
]
[Cites]
Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7
[
12660025.001
]
[Cites]
Cancer Res. 2003 Apr 1;63(7):1454-7
[
12670889.001
]
[Cites]
J Biol Chem. 2003 Jul 18;278(29):26958-69
[
12730209.001
]
[Cites]
Br J Cancer. 2000 Mar;82(6):1218-22
[
10735509.001
]
[Cites]
J Biol Chem. 2000 Oct 13;275(41):31876-82
[
10884385.001
]
[Cites]
Histopathology. 2000 Nov;37(5):437-44
[
11119125.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Mar;33(3):279-84
[
11807985.001
]
[Cites]
Med Pediatr Oncol. 2002 Mar;38(3):173-7
[
11836716.001
]
[Cites]
Nature. 2002 Jun 27;417(6892):949-54
[
12068308.001
]
[Cites]
Nature. 2002 Aug 29;418(6901):934
[
12198537.001
]
[Cites]
Cancer Res. 2003 Aug 1;63(15):4561-7
[
12907632.001
]
[Cites]
Am J Pathol. 2003 Sep;163(3):1033-43
[
12937144.001
]
[Cites]
Nature. 1987 May 28-Jun 3;327(6120):293-7
[
3587348.001
]
[Cites]
Nucleic Acids Res. 1988 Feb 11;16(3):1215
[
3344216.001
]
[Cites]
Hum Genet. 1988 Nov;80(3):224-34
[
3192212.001
]
[Cites]
Cancer Genet Cytogenet. 1989 Jun;39(2):253-79
[
2752377.001
]
[Cites]
Genomics. 1991 Mar;9(3):517-23
[
1840567.001
]
[Cites]
Cancer Res. 1992 Jun 1;52(11):3213-9
[
1317261.001
]
[Cites]
Cancer Genet Cytogenet. 1997 Sep;97(2):125-34
[
9283596.001
]
[Cites]
Genes Chromosomes Cancer. 1997 Dec;20(4):399-407
[
9408757.001
]
[Cites]
Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60
[
9666811.001
]
[Cites]
Clin Cancer Res. 1997 Apr;3(4):523-30
[
9815715.001
]
[Cites]
Cancer Res. 1999 Feb 15;59(4):803-6
[
10029066.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11335-40
[
10500177.001
]
[Cites]
Acta Neuropathol. 2004 Dec;108(6):467-70
[
15517309.001
]
[Cites]
Cancer Res. 2004 Dec 15;64(24):8816-20
[
15604238.001
]
[Cites]
J Clin Invest. 2005 Jan;115(1):94-101
[
15630448.001
]
[Cites]
Science. 2006 Mar 3;311(5765):1287-90
[
16439621.001
]
[Cites]
Nat Med. 2006 Mar;12(3):283-5
[
16520774.001
]
[Cites]
Cell. 2006 Mar 24;124(6):1283-98
[
16564017.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Aug;65(8):794-807
[
16896313.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58
[
17086101.001
]
[Cites]
Cancer Res. 2007 Feb 1;67(3):890-900
[
17283119.001
]
[Cites]
Oncogene. 2007 Feb 15;26(7):1088-97
[
16909113.001
]
[Cites]
J Clin Oncol. 2007 Feb 20;25(6):682-9
[
17308273.001
]
[Cites]
J Mol Med (Berl). 2007 Mar;85(3):227-35
[
17211612.001
]
[Cites]
Ann Neurol. 2007 Mar;61(3):189-98
[
17387725.001
]
[Cites]
Cancer Res. 2007 Apr 15;67(8):3551-4
[
17440063.001
]
[Cites]
J Invest Dermatol. 2007 Jun;127(6):1468-70
[
17301836.001
]
[Cites]
Acta Neuropathol. 2007 Aug;114(2):121-33
[
17588166.001
]
[Cites]
Nat Genet. 2007 Aug;39(8):1013-7
[
17603482.001
]
[Cites]
Nat Genet. 2007 Aug;39(8):1007-12
[
17603483.001
]
[Cites]
Neuropediatrics. 2007 Apr;38(2):61-3
[
17712732.001
]
[Cites]
Brain Pathol. 2008 Jul;18(3):326-37
[
18371186.001
]
[Cites]
Acta Neuropathol. 2005 Feb;109(2):207-10
[
15791479.001
]
[Cites]
Genes Chromosomes Cancer. 2005 Jul;43(3):294-301
[
15834944.001
]
[Cites]
J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
[
15977639.001
]
[Cites]
Neurology. 2005 Oct 25;65(8):1335-6
[
16247081.001
]
[Cites]
J Clin Oncol. 2005 Dec 1;23(34):8853-62
[
16314645.001
]
[Cites]
J Biol Chem. 2006 Feb 17;281(7):3800-9
[
16316983.001
]
[Cites]
Nucleic Acids Res. 2001 May 1;29(9):e45
[
11328886.001
]
(PMID = 18398503.001).
[ISSN]
0021-9738
[Journal-full-title]
The Journal of clinical investigation
[ISO-abbreviation]
J. Clin. Invest.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cyclin D; 0 / Cyclins; 0 / Enzyme Inhibitors; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
[Other-IDs]
NLM/ PMC2289793
31.
Spacca B, Mallucci C, Riordan A, Appleton R, Thorp N, Pizer B:
HSV encephalitis in a child with brain stem glioma: a rare complication of therapy. Case report and review of the neurosurgical literature.
Childs Nerv Syst
; 2007 Nov;23(11):1347-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HSV encephalitis in a child with brain stem
glioma
: a rare complication of therapy. Case report and review of the neurosurgical literature.
CASE REPORT: A 13-year-old boy was diagnosed with an inoperable, biopsy-proven pontine
grade
II
astrocytoma
.
He made slow improvement but died 8 months after diagnosis from
tumor
progression.
A
low
threshold for both investigation with CSF PCR and empirical treatment with intravenous aciclovir is warranted.
[MeSH-major]
Astrocytoma
/ complications. Brain Stem Neoplasms / complications. Encephalitis, Herpes Simplex / etiology. Herpesvirus 1, Human. Radiotherapy / adverse effects
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Radiation Therapy
.
The Weizmann Institute of Science GeneCards and MalaCards databases.
gene/protein/disease-specific - MalaCards for brain stem glioma
.
Hazardous Substances Data Bank.
ACYCLOVIR
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurosurg. 1972 Apr;36(4):499-502
[
4335254.001
]
[Cites]
Hum Pathol. 1998 Mar;29(3):215-22
[
9496822.001
]
[Cites]
Childs Nerv Syst. 1997 Jun;13(6):352-5
[
9272290.001
]
[Cites]
Clin Infect Dis. 2003 May 15;36(10):1335-9
[
12746782.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):239-42
[
10407001.001
]
[Cites]
Herpes. 2004 Jun;11 Suppl 2:48A-56A
[
15319090.001
]
[Cites]
J Clin Microbiol. 1998 Aug;36(8):2229-34
[
9665997.001
]
[Cites]
Antiviral Res. 2006 Sep;71(2-3):141-8
[
16675036.001
]
[Cites]
J Virol. 1999 Dec;73(12):10514-8
[
10559370.001
]
[Cites]
Neuroradiology. 1996 Jan;38(1):73-9
[
8773284.001
]
[Cites]
Pediatr Neurol. 2003 Jul;29(1):69-71
[
13679127.001
]
[Cites]
N Engl J Med. 1986 Jan 16;314(3):144-9
[
3001520.001
]
[Cites]
Neurosurgery. 1999 Mar;44(3):633-5; discussion 635-6
[
10069600.001
]
[Cites]
Herpes. 2004 Jun;11 Suppl 2:57A-64A
[
15319091.001
]
(PMID = 17593375.001).
[ISSN]
0256-7040
[Journal-full-title]
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
[ISO-abbreviation]
Childs Nerv Syst
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antiviral Agents; X4HES1O11F / Acyclovir
[Number-of-references]
14
32.
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A:
Analysis of the IDH1 codon 132 mutation in brain tumors.
Acta Neuropathol
; 2008 Dec;116(6):597-602
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic
astrocytomas
, 12 subependymal giant cell
astrocytomas
, 7 pleomorphic xanthoastrocytomas, 93 diffuse
astrocytomas
, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
A total of 221 somatic IDH1 mutations were detected and the highest frequencies occurred in diffuse
astrocytomas
(68%), oligodendrogliomas (69%), oligoastrocytomas (78%) and secondary glioblastomas (88%).
Primary glioblastomas and other entities were characterized by a
low
frequency or absence of mutations in amino acid position 132 of IDH1.
The very high frequency of IDH1 mutations in WHO
grade
II
astrocytic
and oligodendroglial
gliomas
suggests a role in early
tumor
development.
[MeSH-minor]
Astrocytoma
/ genetics.
Astrocytoma
/ pathology. Base Sequence. DNA Mutational Analysis.
Disease
Progression. Gene Frequency. Glioblastoma / genetics. Glioblastoma / pathology.
Glioma
/ etiology.
Glioma
/ pathology. Humans. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18985363.001).
[ISSN]
1432-0533
[Journal-full-title]
Acta neuropathologica
[ISO-abbreviation]
Acta Neuropathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
EC 1.1.1.41 / Isocitrate Dehydrogenase
33.
Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E:
MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC.
Int J Cancer
; 2009 Sep 15;125(6):1407-13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MicroRNA-10b is overexpressed in malignant
glioma
and associated with
tumor
invasive factors, uPAR and RhoC.
Although the oncogenic and
tumor
suppressive functions of several miRNAs have been characterized, the role of miRNAs in mediating
tumor
invasion and migration remains largely unexplored.
Here, we performed real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays on 43
glioma
samples (17 glioblastoma, 6 anaplastic
astrocytoma
, 10
low
-
grade astrocytoma
, 6 oligodendroglioma and 4 ependymoma) and 6
glioma
cell lines.
We found that miR-10b expression was upregulated in all
glioma
samples compared to non-neoplastic brain tissues.
The expression levels of miR-10b were associated with higher
grade
glioma
.
Finally, multifocal lesions on enhanced MRI of 7 malignant
gliomas
were associated with higher expression levels of miR-10b (p = 0.02).
Our data indicated that miR-10b might play some role in the invasion
of glioma
cells.
[MeSH-major]
Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology.
Glioma
/ genetics. Membrane Glycoproteins / genetics. Receptors, Immunologic / genetics. Receptors, Urokinase Plasminogen Activator / genetics. rho GTP-Binding Proteins / genetics
[MeSH-minor]
Biomarkers,
Tumor
/ genetics. Biomarkers,
Tumor
/ metabolism. Humans. Immunoenzyme Techniques.
Neoplasm
Invasiveness.
Neoplasm
Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction.
Tumor
Cells, Cultured. Up-Regulation
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2009 UICC
(PMID = 19536818.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / LILRB2 protein, human; 0 / Membrane Glycoproteins; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / Receptors, Immunologic; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.6.5.2 / rho GTP-Binding Proteins
34.
Coenen VA, Huber KK, Krings T, Weidemann J, Gilsbach JM, Rohde V:
Diffusion-weighted imaging-guided resection of intracerebral lesions involving the optic radiation.
Neurosurg Rev
; 2005 Jul;28(3):188-95
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
DWI studies were performed together with T1-weighted postcontrast magnetic resonance imaging (MRI) in four patients with lesions in or adjacent to the OR (glioblastoma, oligo-
astrocytoma
, cavernoma, and metastasis; n = 1 each).
Preoperative and postoperative neuroophthalmological testing included, among others, perimetry to define the
value of
diffusion-weighted image guidance during OR lesion resection.
In one case,
low
-
grade
tumor
parts infiltrating the OR were intentionally left.
[MeSH-major]
Affect / physiology. Deep Brain Stimulation. Parkinson
Disease
/ psychology. Parkinson
Disease
/ therapy. Subthalamic Nucleus / physiology
MedlinePlus Health Information.
consumer health - Parkinson's Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Radiology. 1996 Dec;201(3):637-48
[
8939209.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):501-3
[
10727488.001
]
[Cites]
AJNR Am J Neuroradiol. 1996 Aug;17(7):1379-83
[
8871728.001
]
[Cites]
Microsc Res Tech. 2000 Dec 1;51(5):481-92
[
11074619.001
]
[Cites]
Neurosurgery. 2001 Jul;49(1):86-92; discussion 92-3
[
11440464.001
]
[Cites]
Neurosurgery. 2000 Aug;47(2):417-26; discussion 426-7
[
10942015.001
]
[Cites]
Clin Neurosurg. 2002;49:90-102
[
12506550.001
]
[Cites]
Acta Ophthalmol (Copenh). 1976 Dec;54(6):827-41
[
990032.001
]
[Cites]
Epilepsia. 1999 Aug;40(8):1155-8
[
10448831.001
]
[Cites]
Acta Neurochir (Wien). 1988;92(1-4):29-36
[
3407471.001
]
[Cites]
Neuroimage. 1999 Mar;9(3):352-61
[
10075905.001
]
[Cites]
J Neurosurg. 1999 Apr;90(4):791-5
[
10193629.001
]
[Cites]
Acta Neurochir (Wien). 2004 Mar;146(3):265-9; discussion 269-70
[
15015049.001
]
[Cites]
Surg Neurol. 2003 Nov;60(5):381-90; discussion 390
[
14572954.001
]
[Cites]
Neuroimage. 1999 Nov;10(5):489-99
[
10547327.001
]
[Cites]
Neurosurgery. 2000 Nov;47(5):1070-9; discussion 1079-80
[
11063099.001
]
[Cites]
Neurol Clin. 2003 May;21(2):417-43, vi
[
12916486.001
]
[Cites]
Neuroimage. 2003 Oct;20(2):1140-53
[
14568483.001
]
[Cites]
Ann Neurol. 1997 Dec;42(6):951-62
[
9403488.001
]
[Cites]
Surg Neurol. 2002 Nov;58(5):302-7; discussion 308
[
12504288.001
]
(PMID = 15747136.001).
[ISSN]
0344-5607
[Journal-full-title]
Neurosurgical review
[ISO-abbreviation]
Neurosurg Rev
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
35.
Chosdol K, Misra A, Puri S, Srivastava T, Chattopadhyay P, Sarkar C, Mahapatra AK, Sinha S:
Frequent loss of heterozygosity and altered expression of the candidate tumor suppressor gene 'FAT' in human astrocytic tumors.
BMC Cancer
; 2009;9:5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Frequent loss of heterozygosity and altered expression of the candidate
tumor
suppressor gene 'FAT' in human
astrocytic
tumors.
BACKGROUND: We had earlier used the comparison of RAPD (Random Amplification of Polymorphic DNA) DNA fingerprinting profiles
of tumor
and corresponding normal DNA to identify genetic alterations in primary human glial tumors.
METHODS: In this study we used RAPD-PCR to identify novel genomic alterations in the
astrocytic
tumors of WHO
grade
II (
Low Grade
Diffuse
Astrocytoma
) and WHO
Grade
IV (Glioblastoma Multiforme).
RESULTS: Bands consistently altered in the RAPD profile
of tumor
DNA in a significant proportion of tumors were identified.
One such 500 bp band, that was absent in the RAPD profile of 33% (4/12) of the
grade
II
astrocytic
tumors, was selected for further study.
Its sequence corresponded with a region of FAT, a putative
tumor
suppressor gene initially identified in Drosophila.
Fifty percent
of a
set of 40 tumors, both
grade
II and IV, were shown to have Loss of Heterozygosity (LOH) at this locus by microsatellite (intragenic) and by SNP markers.
Semi-quantitative RT-PCR showed
low
FAT mRNA levels in a major subset of tumors.
CONCLUSION: These results point to a role of the FAT in
astrocytic
tumorigenesis and demonstrate the use of RAPD analysis in identifying specific alterations in
astrocytic
tumors.
[MeSH-major]
Astrocytoma
/ genetics. Cadherins / genetics. Central Nervous System Neoplasms / genetics. Genes,
Tumor
Suppressor. Loss of Heterozygosity
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Dev Dyn. 2000 Mar;217(3):233-40
[
10741417.001
]
[Cites]
J Neurooncol. 2000 May;48(1):1-12
[
11026691.001
]
[Cites]
Cancer Genet Cytogenet. 2001 Feb;125(1):41-5
[
11297766.001
]
[Cites]
Mutat Res. 2001 Dec 12;484(1-2):53-9
[
11733071.001
]
[Cites]
Yonsei Med J. 2002 Apr;43(2):145-51
[
11971207.001
]
[Cites]
Int J Cancer. 2002 May 10;99(2):193-200
[
11979433.001
]
[Cites]
Cancer Lett. 2002 Aug 28;182(2):193-202
[
12048165.001
]
[Cites]
Chin Med J (Engl). 2002 Aug;115(8):1201-4
[
12215292.001
]
[Cites]
Histol Histopathol. 2003 Jan;18(1):207-16
[
12507300.001
]
[Cites]
Genes Chromosomes Cancer. 2004 Jan;39(1):93-8
[
14603447.001
]
[Cites]
EMBO J. 2004 Oct 1;23(19):3769-79
[
15343270.001
]
[Cites]
Dev Biol. 1988 Oct;129(2):541-54
[
3417051.001
]
[Cites]
Nucleic Acids Res. 1990 Nov 25;18(22):6531-5
[
1979162.001
]
[Cites]
Cancer Surv. 1990;9(4):631-44
[
1983210.001
]
[Cites]
Biotechniques. 1993 Sep;15(3):388-90
[
8105827.001
]
[Cites]
Brain Pathol. 1993 Jan;3(1):19-26
[
8269081.001
]
[Cites]
Trends Genet. 1995 Jun;11(6):242-6
[
7543710.001
]
[Cites]
Biotechniques. 1995 Jul;19(1):38, 40-2
[
7669294.001
]
[Cites]
Genomics. 1995 Nov 20;30(2):207-23
[
8586420.001
]
[Cites]
Indian J Biochem Biophys. 1996 Dec;33(6):455-7
[
9219429.001
]
[Cites]
Gene. 1998 Jan 5;206(1):45-8
[
9461413.001
]
[Cites]
Mech Dev. 1999 Feb;80(2):207-12
[
10072790.001
]
[Cites]
Arch Neurol. 1999 Apr;56(4):439-41
[
10199332.001
]
[Cites]
Curr Opin Oncol. 2004 Nov;16(6):607-13
[
15627025.001
]
[Cites]
Gene Expr Patterns. 2005 Apr;5(4):483-90
[
15749076.001
]
[Cites]
Cancer. 2005 May 15;103(10):2132-42
[
15830341.001
]
[Cites]
Genes Chromosomes Cancer. 2005 Jul;43(3):260-72
[
15838843.001
]
[Cites]
World J Gastroenterol. 2005 May 28;11(20):3034-9
[
15918185.001
]
[Cites]
J Cell Sci. 2005 Jun 1;118(Pt 11):2347-53
[
15923647.001
]
[Cites]
World J Gastroenterol. 2005 Jul 14;11(26):4102-7
[
15996039.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2220-3
[
16172235.001
]
[Cites]
Int J Cancer. 2005 Nov 20;117(4):683-9
[
15912534.001
]
[Cites]
Clin Chem. 2006 Mar;52(3):370-8
[
16397012.001
]
[Cites]
Nat Genet. 2006 Oct;38(10):1142-50
[
16980976.001
]
[Cites]
Curr Biol. 2006 Nov 7;16(21):2101-10
[
17045801.001
]
[Cites]
Eur J Med Genet. 2007 Jan-Feb;50(1):66-72
[
17081814.001
]
[Cites]
J Neurooncol. 2007 Feb;81(3):249-55
[
17019533.001
]
[Cites]
Acta Neuropathol. 2007 Aug;114(2):97-109
[
17618441.001
]
[Cites]
Oncogene. 2007 Aug 9;26(36):5300-8
[
17325662.001
]
[Cites]
Mol Cell. 2007 Sep 21;27(6):962-75
[
17889669.001
]
[Cites]
Genes Dev. 2007 Nov 1;21(21):2747-61
[
17974916.001
]
[Cites]
BMC Cancer. 2007;7:190
[
17925012.001
]
[Cites]
J Biol Chem. 2008 Feb 29;283(9):5496-509
[
18158288.001
]
[Cites]
Cancer Res. 2008 Apr 15;68(8):2789-94
[
18413746.001
]
(PMID = 19126244.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Cadherins; 0 / DNA Primers; 0 / FAT1 protein, human
[Other-IDs]
NLM/ PMC2631005
36.
Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, Sommer C, Kaina B:
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
Int J Cancer
; 2010 Nov 1;127(9):2106-18
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant
gliomas
: a comparative study on
astrocytoma
and glioblastoma.
The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) is a key player in
tumor
cell resistance.
However, it is unclear whether MGMT promoter methylation correlates with MGMT activity and whether MGMT promoter methylation of the pretreatment
tumor
predicts the MGMT status of recurrences.
To address these questions, we determined MGMT activity promoter methylation and immunoreactivity in pretreatment and recurrent glioblastomas (GB, WHO
Grade
IV), and in
astrocytomas
(WHO
Grade
III).
For astrocytomas
, promoter-methylated samples displayed 0-28 fmol/mg and, nonmethylated samples, 23-107 fmol/mg.
Given a threshold level of 30 fmol/mg of protein, we found a correlation between promoter methylation and no/
low
MGMT activity in 82.4% of the tumors.
Therefore,
classification of
hemimethylated tumors remains questionable.
Although individual exceptions were found, the data show an overall correlation between promoter methylation and lack/
low
MGMT activity in GB and
astrocytomas
.
[MeSH-major]
Astrocytoma
/ enzymology.
Astrocytoma
/ genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Glioblastoma / enzymology. Glioblastoma / genetics. Promoter Regions, Genetic.
Tumor
Suppressor Proteins / genetics.
Tumor
Suppressor Proteins / metabolism
[MeSH-minor]
Cell Line,
Tumor
. Humans. Immunohistochemistry. Recurrence
Genetic Alliance.
consumer health - Glioblastoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20131314.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
37.
Horbinski C, Wang G, Wiley CA:
YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
Int J Clin Exp Pathol
; 2010 Jan 01;3(3):226-37
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
YKL-40 is directly produced by
tumor
cells and is inversely linked to EGFR in glioblastomas.
YKL-40 is a secreted chitinase-like molecule whose expression is associated with
glioma
grade
.
Expression is higher in
astrocytomas
than oligodendrogliomas and has been reported to predict shorter survival and radiation resistance in glioblastomas (GBMs).
Whether YKL-40 is directly produced by
glioma
cells or other admixed nonneo-plastic cells, and whether it correlates with 1p/19q status or other hallmark molecular abnormalities, are unclear.
A rank-order list of YKL-40 expression was determined immunohistochemically in 79 untreated high-
grade
adult glio-mas, including 28 anaplastic oligodendrogliomas (AOs) and 51 GBMs.
Relative YKL-40 expression was compared with
glioma
class, key molecular alterations, and immunohistochemical markers via a series of Spearman rank correlations.
YKL-40 mRNA was abundant in
glioma
cells as well as reactive astrocytes, but was
low
in admixed neurons and macrophages.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Neuro Oncol. 1999 Jan;1(1):44-51
[
11550301.001
]
[Cites]
Oncogene. 2009 Dec 17;28(50):4456-68
[
19767768.001
]
[Cites]
N Engl J Med. 2002 Feb 7;346(6):420-7
[
11832530.001
]
[Cites]
Biochem J. 2002 Jul 1;365(Pt 1):119-26
[
12071845.001
]
[Cites]
Cancer. 2002 Jul 15;95(2):267-74
[
12124825.001
]
[Cites]
Cancer Res. 2002 Aug 1;62(15):4364-8
[
12154041.001
]
[Cites]
Int J Cancer. 2002 Oct 10;101(5):454-60
[
12216074.001
]
[Cites]
J Neurosurg. 2002 Dec;97(6):1397-401
[
12507139.001
]
[Cites]
Clin Cancer Res. 2003 Oct 1;9(12):4423-34
[
14555515.001
]
[Cites]
Biochem J. 2004 Jun 15;380(Pt 3):651-9
[
15015934.001
]
[Cites]
Cancer Res. 1997 Jan 15;57(2):304-9
[
9000573.001
]
[Cites]
Cancer Res. 2005 Mar 1;65(5):1678-86
[
15753362.001
]
[Cites]
Cancer Sci. 2005 Mar;96(3):183-90
[
15771622.001
]
[Cites]
Clin Cancer Res. 2005 Mar 15;11(6):2258-64
[
15788675.001
]
[Cites]
Clin Cancer Res. 2005 May 1;11(9):3326-34
[
15867231.001
]
[Cites]
J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
[
15977639.001
]
[Cites]
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8644-52
[
16361549.001
]
[Cites]
Neurosurg Focus. 2005 Nov;19(5):E2
[
16398466.001
]
[Cites]
Cancer. 2006 Mar 1;106(5):1130-9
[
16456816.001
]
[Cites]
Clin Cancer Res. 2006 Jul 1;12(13):3935-41
[
16818690.001
]
[Cites]
J Biol Chem. 2006 Oct 6;281(40):29583-96
[
16882657.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Dec;65(12):1149-56
[
17146289.001
]
[Cites]
Gynecol Oncol. 2007 Feb;104(2):435-42
[
17023034.001
]
[Cites]
World J Surg Oncol. 2007;5:17
[
17286869.001
]
[Cites]
Clin Cancer Res. 2007 Mar 1;13(5):1429-37
[
17332285.001
]
[Cites]
J Clin Oncol. 2007 Jun 1;25(16):2288-94
[
17538175.001
]
[Cites]
Clin Cancer Res. 2007 Jun 1;13(11):3244-9
[
17545529.001
]
[Cites]
Int J Cancer. 2008 Feb 15;122(4):857-63
[
17957792.001
]
[Cites]
Urol Oncol. 2008 Jan-Feb;26(1):47-52
[
18190830.001
]
[Cites]
Eur J Haematol. 2008 Apr;80(4):310-7
[
18182077.001
]
[Cites]
Int J Cancer. 2008 May 15;122(10):2187-98
[
18092325.001
]
[Cites]
Am J Pathol. 2008 Jul;173(1):130-43
[
18556781.001
]
[Cites]
Adv Ther. 2008 Aug;25(8):801-9
[
18670741.001
]
[Cites]
FEBS Lett. 2008 Sep 22;582(21-22):3193-200
[
18708058.001
]
[Cites]
Oncogene. 2008 Nov 6;27(52):6679-89
[
18724390.001
]
[Cites]
Ann Oncol. 2009 Jan;20(1):71-7
[
18723551.001
]
[Cites]
J Clin Oncol. 2009 Feb 1;27(4):572-8
[
19075264.001
]
[Cites]
BMC Cancer. 2009;9:8
[
19134206.001
]
[Cites]
Brain Pathol. 2009 Jul;19(3):439-48
[
18652591.001
]
[Cites]
Biochem Biophys Res Commun. 2009 Oct 23;388(3):511-6
[
19666003.001
]
[Cites]
Hum Pathol. 2009 Dec;40(12):1790-7
[
19765801.001
]
[Cites]
Clin Cancer Res. 2002 Jan;8(1):196-201
[
11801559.001
]
(PMID = 20224722.001).
[ISSN]
1936-2625
[Journal-full-title]
International journal of clinical and experimental pathology
[ISO-abbreviation]
Int J Clin Exp Pathol
[Language]
ENG
[Grant]
United States / NIMH NIH HHS / MH / K24 MH001717; United States / PHS HHS / / K24 M401717
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
[Other-IDs]
NLM/ PMC2836500
[Keywords]
NOTNLM ; 10q / 1p19q / EGFR / YKL-40 / glioblastoma / oligodendroglioma
38.
Rosenzweig T, Ziv-Av A, Xiang C, Lu W, Cazacu S, Taler D, Miller CG, Reich R, Shoshan Y, Anikster Y, Kazimirsky G, Sarid R, Brodie C:
Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells.
Cancer Res
; 2006 Apr 15;66(8):4139-48
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in
gliomas
and regulates the growth, survival, and invasion
of glioma
cells.
In this study, we examined the expression and functions of related to testes-specific, vespid, and pathogenesis protein 1 (RTVP-1) in
glioma
cells.
RTVP-1 was expressed in high levels in glioblastomas, whereas its expression in
low
-
grade
astrocytomas
and normal brains was very
low
.
Transfection
of glioma
cells with small interfering RNAs targeting RTVP-1 decreased cell proliferation in all the cell lines examined and induced cell apoptosis in some of them.
Overexpression of RTVP-1 increased astrocyte and
glioma
cell proliferation and the anchorage-independent growth of the cells.
In addition, overexpression of RTVP-1 rendered
glioma
cells more resistant to the apoptotic effect
of tumor
necrosis factor-related apoptosis-inducing ligand and serum deprivation.
Finally, we found that RTVP-1 regulated the invasion
of glioma
cells as was evident by their enhanced migration through Matrigel and by their increased invasion in a spheroid confrontation assay.
Our results suggest that the expression of RTVP-1 is correlated with the degree of malignancy
of astrocytic
tumors and that RTVP-1 is involved in the regulation of the growth, survival, and invasion
of glioma
cells.
Collectively, these findings suggest that RTVP-1 is a potential therapeutic target in
gliomas
.
[MeSH-major]
Brain Neoplasms / metabolism. Brain Neoplasms / pathology.
Glioma
/ metabolism.
Glioma
/ pathology.
Neoplasm
Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis
[MeSH-minor]
Amino Acid Sequence. Apoptosis / physiology.
Astrocytoma
/ enzymology.
Astrocytoma
/ metabolism.
Astrocytoma
/ pathology. Cell Growth Processes / physiology. Cell Line,
Tumor
. Cell Survival / physiology. Glioblastoma / enzymology. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Matrix Metalloproteinase 2 / metabolism. Molecular Sequence Data.
Neoplasm
Invasiveness
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16618735.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA-R21-96965
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / GLIPR1 protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2
39.
Komotar RJ, Zacharia BE, Sughrue ME, Mocco J, Carson BS, Tihan T, Otten ML, Burger PC, Garvin JH, Khandji AG, Anderson RC:
Magnetic resonance imaging characteristics of pilomyxoid astrocytoma.
Neurol Res
; 2008 Nov;30(9):945-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Magnetic resonance imaging characteristics of pilomyxoid
astrocytoma
.
OBJECTIVE: Pilomyxoid
astrocytoma
(PMA) is a recently identified pediatric
low
-
grade
neoplasm
that was previously classified as pilocytic
astrocytoma
(PA), yet demonstrates unique histological features and more aggressive behavior.
These tumors have been shown to have significantly shorter progression-free and overall survival probability than classical
low
-
grade
astrocytomas
, as well as a high rate of cerebrospinal fluid (CSF) dissemination.
Radiographic characteristics of the
tumor
were recorded in each case.
CONCLUSION: Pilomyxoid
astrocytoma
is a well-circumscribed pediatric
neoplasm
that commonly originates from the midline of the neuroaxis and lacks peritumoral edema or central necrosis.
It is critical to recognize the predominantly solid and well-circumscribed nature of the
neoplasm
to avoid confusion with an infiltrating
astrocytoma
.
[MeSH-major]
Astrocytoma
/ diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18662499.001).
[ISSN]
0161-6412
[Journal-full-title]
Neurological research
[ISO-abbreviation]
Neurol. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
40.
Aarsen FK, Paquier PF, Reddingius RE, Streng IC, Arts WF, Evera-Preesman M, Catsman-Berrevoets CE:
Functional outcome after low-grade astrocytoma treatment in childhood.
Cancer
; 2006 Jan 15;106(2):396-402
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Functional outcome after
low
-
grade astrocytoma
treatment in childhood.
BACKGROUND: The relatively high survival rate of patients with
low
-
grade astrocytoma
necessitates increasing attention to physical and psychosocial outcomes.
The objective of the current study was to investigate functional outcomes among children who were treated for
low
-
grade
or pilocytic
astrocytoma
in different areas of the brain.
CONCLUSIONS: At long-term follow-up, children who had
low
-
grade
or pilocytic
astrocytomas
were found to have poor functional outcomes, depending on
tumor
site, age, and recurrence.
Therefore, the authors suggest a long-term follow-up of children who are treated for
low
-
grade
or pilocytic
astrocytomas
at a young age to detect and subsequently offer support focused on the medical and cognitive impairments as well as on the behavioral and social consequences of their
disease
.
[MeSH-major]
Astrocytoma
/ therapy. Brain Neoplasms / therapy. Disabled Children. Quality of Life
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16353203.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
41.
Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS:
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas.
J Clin Oncol
; 2008 Mar 10;26(8):1338-45
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Role of extent of resection in the long-term outcome of
low
-
grade
hemispheric
gliomas
.
PURPOSE: The prognostic role of extent of resection (EOR) of
low
-
grade
gliomas
(LGGs) is a major controversy.
Region-of-interest analysis was performed to measure
tumor
volumes based on fluid-attenuated inversion-recovery (FLAIR) imaging.
RESULTS: Median preoperative and postoperative
tumor
volumes and EOR were 36.6 cm(3) (range, 0.7 to 246.1 cm(3)), 3.7 cm(3) (range, 0 to 197.8 cm(3)) and 88.0% (range, 5% to 100%), respectively.
After adjusting each measure
of tumor
burden for age, Karnofsky performance score (KPS),
tumor
location, and
tumor subtype
, OS was predicted by EOR (hazard ratio [HR] = 0.972; 95% CI, 0.960 to 0.983; P < .001), log preoperative
tumor
volume (HR = 4.442; 95% CI, 1.601 to 12.320; P = .004), and postoperative
tumor
volume (HR = 1.010; 95% CI, 1.001 to 1.019; P = .03), progression-free survival was predicted by log preoperative
tumor
volume (HR = 2.711; 95% CI, 1.590 to 4.623; P <or= .001) and postoperative
tumor
volume (HR = 1.007; 95% CI, 1.001 to 1.014; P = .035), and malignant progression-free survival was predicted by EOR (HR = 0.983; 95% CI, 0.972 to 0.995; P = .005) and log preoperative
tumor
volume (HR = 3.826; 95% CI, 1.632 to 8.969; P = .002).
[MeSH-major]
Astrocytoma
/ surgery. Brain Neoplasms / surgery. Oligodendroglioma / surgery
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18323558.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
42.
Akar S, Drappatz J, Hsu L, Blinder RA, Black PM, Kesari S:
Hypertrophic olivary degeneration after resection of a cerebellar tumor.
J Neurooncol
; 2008 May;87(3):341-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hypertrophic olivary degeneration after resection
of a
cerebellar
tumor
.
We report a case of hypertrophic olivary degeneration due to cerebellar surgery
for a
low
-
grade
tumor
.
A 27-year-old female presented with right-sided paresthesias and intermittent leg paresis following a right cerebellar resection
of a tumor
2 weeks prior.
An MRI scan revealed a hypertrophied left anterolateral medulla with increased T2 signal and no diffusion
abnormality
.
Hypertrophic olivary degeneration may be mistaken
for tumor
progression, post-operative vasculopathy or granulation tissue and should be considered in patients undergoing cerebellar surgery.
[MeSH-major]
Astrocytoma
/ surgery. Cerebellar Neoplasms / surgery. Neurosurgical Procedures / adverse effects. Olivary Nucleus / pathology
[MeSH-minor]
Adult. Ataxia / etiology. Diagnosis, Differential. Female. Humans. Hypertrophy. Hypesthesia / etiology. Magnetic Resonance Imaging.
Neoplasm
Recurrence, Local / pathology
Genetic Alliance.
consumer health - Cerebellar Degeneration
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Arq Neuropsiquiatr. 2003 Jun;61(2B):473-7
[
12894288.001
]
[Cites]
J Neurosurg. 2004 Apr;100(4):717
[
15070130.001
]
[Cites]
Mov Disord. 1997 May;12(3):432-7
[
9159743.001
]
[Cites]
Acta Neuropathol. 1981;54(4):275-82
[
7270084.001
]
[Cites]
Brain. 2002 Jun;125(Pt 6):1348-57
[
12023323.001
]
[Cites]
Clin Imaging. 1999 Jul-Aug;23(4):215-7
[
10631896.001
]
[Cites]
Eur J Paediatr Neurol. 2007 Jul;11(4):232-4
[
17400009.001
]
[Cites]
Neuroradiology. 1993;35(5):335-8
[
8327105.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):797-9
[
12754356.001
]
[Cites]
Arq Neuropsiquiatr. 2005 Jun;63(2A):321-3
[
16100982.001
]
[Cites]
Radiology. 1999 Dec;213(3):814-7
[
10580959.001
]
[Cites]
Pediatr Radiol. 1998 Nov;28(11):830-1
[
9799311.001
]
[Cites]
Eur Neurol. 1998;39(2):97-102
[
9520070.001
]
[Cites]
AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1073-7
[
10871017.001
]
[Cites]
AJNR Am J Neuroradiol. 1994 Oct;15(9):1715-9
[
7847219.001
]
[Cites]
Neurology. 1991 Apr;41(4):557-62
[
2011257.001
]
[Cites]
Radiology. 1994 Aug;192(2):539-43
[
8029428.001
]
(PMID = 18217209.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
43.
Rorive S, Maris C, Debeir O, Sandras F, Vidaud M, Bièche I, Salmon I, Decaestecker C:
Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.
J Neuropathol Exp Neurol
; 2006 Aug;65(8):794-807
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Exploring the distinctive biological characteristics of pilocytic and
low
-
grade
diffuse
astrocytomas
using microarray gene expression profiles.
Although World Health Organization (WHO)
grade
I pilocytic
astrocytomas
and
grade
II diffuse
astrocytomas
have been classified for decades as different clinicopathologic entities, few, if any, data are available on the biologic features explaining these differences.
Although more than 50 microarray-related studies have been carried out to characterize the molecular profiles
of astrocytic
tumors, we have identified only 11 that provide sound data on
low
-
grade
astrocytomas
.
We have incorporated these data into a comparative analysis for the purpose of identifying the most relevant molecular markers characterizing
grade
I pilocytic and
grade
II diffuse
astrocytomas
.
Our analysis has identified various interesting genes that are differentially expressed in either
grade
I or
grade
II
astrocytomas
when compared with normal tissue and/or high-
grade
(WHO
grade
III and IV)
astrocytomas
.
Interestingly, a group of 6 genes (TIMP4, C1NH, CHAD, THBS4, IGFBP2, and TLE2) constitute an expression profile characteristic of
grade
I
astrocytomas
as compared with all other categories of tissue (normal brain,
grade
II, and high-
grade
astrocytomas
).
The end products (proteins) of these genes act as antimigratory compounds, a fact that could explain why pilocytic
astrocytomas
behave as compact (well-circumscribed) tumors as opposed to all the other
astrocytic tumor
types that diffusely invade the brain parenchyma.
Having validated these molecular markers by means of real-time reverse transcriptase-polymerase chain reaction, an integrated model was proposed illustrating how and why pilocytic
astrocytomas
constitute a distinct biologic and pathologic entity when compared with diffuse
astrocytomas
.
[MeSH-major]
Astrocytoma
/ genetics. Biomarkers,
Tumor
/ genetics. Brain Neoplasms / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic / genetics. Genetic Predisposition to
Disease
/ genetics
[MeSH-minor]
Adult. Cell Adhesion / genetics. Cell Movement / genetics. Child. Extracellular Matrix Proteins / genetics. Extracellular Matrix Proteins / metabolism. Humans. Models, Neurological.
Neoplasm
Invasiveness / genetics.
Neoplasm
Invasiveness / physiopathology. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16896313.001).
[ISSN]
0022-3069
[Journal-full-title]
Journal of neuropathology and experimental neurology
[ISO-abbreviation]
J. Neuropathol. Exp. Neurol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins
44.
Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K:
Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
J Nucl Med
; 2006 Mar;47(3):393-403
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Analysis of 18F-FET PET for grading of recurrent
gliomas
: is evaluation of uptake kinetics superior to standard methods?
The aim of the present study was to evaluate whether extended analyses
of O
-(2-18F-fluoroethyl)-L-tyrosine (FET) uptake kinetics provide results superior to those of standard
tumor
-to-background ratios in predicting
tumor
grade
in patients with pretreated
gliomas
.
METHODS: Dynamic 18F-FET PET studies (0-40 min after injection of 180 MBq of 18F-FET) were performed on 45
glioma
patients with suspected
tumor
recurrence after multimodal treatment.
For the standard method, tumoral maximal standardized uptake
value
(SUVmax) and the ratio to the background were derived from a summed image 20-40 min after injection.
Results were correlated with the histopathologic findings of MRI/PET-guided stereotactic biopsies and were evaluated with respect to their discriminatory power to separate
low
- from high-
grade
tumors using receiver-operating characteristic (ROC) analyses.
RESULTS: The parameters taking into account the individual time course of 18F-FET uptake were able to differentiate
low
-
grade
from high-
grade
recurrent
astrocytomas
with high diagnostic accuracy, reaching the best differentiation with a sensitivity and specificity of 92% and an area under the ROC curve (AUC) of 0.94.
The
lowest
performance was provided by the standard method (SUVmax: 73% sensitivity, 54% specificity, and 0.60 AUC; SUVmax-to-background ratio: 62% sensitivity, 62% specificity, and 0.59 AUC).
Time-activity curves (5-40 min after injection) slightly and steadily increased in
tumor
-free patients and in
low
-
grade
tumors, whereas high-
grade
tumors showed an early peak around 10-15 min after injection followed by a decrease.
CONCLUSION: This study has shown differences in the dynamics of 18F-FET uptake between recurrent
low
- and high-
grade
gliomas
.
[MeSH-major]
Brain Neoplasms / metabolism. Brain Neoplasms / radionuclide imaging.
Glioma
/ metabolism.
Glioma
/ radionuclide imaging.
Neoplasm
Recurrence, Local / metabolism.
Neoplasm
Recurrence, Local / radionuclide imaging. Tyrosine / analogs & derivatives
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
L-TYROSINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
J Nucl Med. 2006 May;47(5):806
(PMID = 16513607.001).
[ISSN]
0161-5505
[Journal-full-title]
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
[ISO-abbreviation]
J. Nucl. Med.
[Language]
eng
[Publication-type]
Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / O-(2-fluoroethyl)tyrosine; 0 / Radiopharmaceuticals; 42HK56048U / Tyrosine
45.
Passarin MG, Moretto G, Musso AM, Ottaviani S, Masotto B, Ghimenton C, Iuzzolino P, Buffone E, Rudà R, Soffietti R, Vattemi E, Pedersini R:
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
J Neurooncol
; 2010 May;97(3):439-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Intrathecal liposomal cytarabine in combination with temozolomide in
low
-
grade
oligoastrocytoma with leptomeningeal dissemination.
Leptomeningeal dissemination of
low
-
grade
gliomas
is an uncommon event.
A nonenhancing lesion in the right cerebellar peduncle was identified, subtotally resected, and diagnosed as a
grade
II
astrocytoma
.
Complete remission was achieved after 12 months of treatment and the patient is still free from the
disease
after a follow-up of 24 months.
Genetic Alliance.
consumer health - Oligoastrocytoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2004 Aug 1;22(15):3133-8
[
15284265.001
]
[Cites]
Neuro Oncol. 2002 Oct;4(4):253-60
[
12356355.001
]
[Cites]
Clin Cancer Res. 2004 Jun 1;10 (11):3728-36
[
15173079.001
]
[Cites]
J Neurooncol. 2002 May;57(3):231-9
[
12125986.001
]
[Cites]
Ann Pharmacother. 2000 Oct;34(10):1173-8
[
11054987.001
]
[Cites]
J Clin Oncol. 2003 Feb 15;21(4):646-51
[
12586801.001
]
[Cites]
Arch Neurol. 1995 Sep;52(9):912-7
[
7661730.001
]
[Cites]
J Clin Oncol. 2005 May 20;23(15):3605-13
[
15908671.001
]
[Cites]
Ann Oncol. 2003 Dec;14 (12 ):1715-21
[
14630674.001
]
[Cites]
Clin Neurol Neurosurg. 2009 May;111(4):390-4
[
19128871.001
]
[Cites]
Acta Neurochir (Wien). 1994;126(2-4):84-92
[
8042560.001
]
[Cites]
Clin Cancer Res. 1999 Nov;5(11):3394-402
[
10589750.001
]
[Cites]
J Neurooncol. 2007 Jul;83(3):303-6
[
17245619.001
]
[Cites]
Cancer. 1994 Jun 1;73(11):2869-78
[
8194029.001
]
[Cites]
Oncologist. 2006 Jun;11(6):681-93
[
16794247.001
]
(PMID = 19876600.001).
[ISSN]
1573-7373
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Liposomes; 04079A1RDZ / Cytarabine; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
46.
Essig M, Giesel F, Stieltjes B, Weber MA:
[Functional imaging for brain tumors (perfusion, DTI and MR spectroscopy)].
Radiologe
; 2007 Jun;47(6):513-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In cases of brain
tumor
, PWI aids in grading and better differentiation in diagnostics as well as for pre-therapeutic planning.
PWI allows better estimates of biological activity and aggressiveness in
low grade
brain tumors, and in the case of WHO
grade
II
astrocytoma
showing anaplasically transformed
tumor
areas, allows more rapid visu-alization and a better prediction of the course of the
disease
than conventional MRI diagnostics.
Diffusion imaging can be used for describing brain tumors, for evaluating contralateral involvement and the course of the nerve fibers near the
tumor
.
Diagnostic problems such as the differentiation between neoplastic and non-neoplastic lesions, grading cerebral
glioma
and distinguishing between primary brain tumors and metastases can be resolved.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Diffusion Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Radiologe. 2005 Apr;45(4):327-39
[
15800783.001
]
[Cites]
AJNR Am J Neuroradiol. 2000 Oct;21(9):1603-10
[
11039338.001
]
[Cites]
Neuroradiology. 2006 Apr;48 Suppl 1:3-8
[
16699847.001
]
[Cites]
Radiologe. 2004 Jul;44(7):723-32; quiz 733-4
[
15241598.001
]
[Cites]
AJR Am J Roentgenol. 1998 Dec;171(6):1479-86
[
9843274.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82
[
11567824.001
]
[Cites]
Radiology. 1994 Dec;193(3):637-41
[
7972800.001
]
[Cites]
Rofo. 1999 Jul;171(1):38-43
[
10464503.001
]
[Cites]
Radiologe. 2004 Jan;44(1):81-95; quiz 96-7
[
14997867.001
]
[Cites]
Radiologe. 2004 Feb;44(2):164-73
[
14991136.001
]
[Cites]
Neuroimage. 2006 Jun;31(2):531-42
[
16478665.001
]
[Cites]
Radiologe. 2003 Aug;43(8):661-4
[
14504767.001
]
[Cites]
Radiology. 1990 Nov;177(2):401-5
[
2217776.001
]
[Cites]
Radiologe. 2002 Nov;42(11):909-15
[
12458444.001
]
[Cites]
Radiologe. 2005 Jul;45(7):618-32
[
15098092.001
]
[Cites]
Nervenarzt. 2005 Apr;76(4):403-17
[
15349736.001
]
(PMID = 17505814.001).
[ISSN]
0033-832X
[Journal-full-title]
Der Radiologe
[ISO-abbreviation]
Radiologe
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Number-of-references]
21
47.
Kinjo S, Hirato J, Nakazato Y:
Low grade diffuse gliomas: shared cellular composition and morphometric differences.
Neuropathology
; 2008 Oct;28(5):455-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Low grade
diffuse
gliomas
: shared cellular composition and morphometric differences.
Low grade
diffuse
gliomas
arising in the brain are challenging to treat because of their ability to infiltrate adjacent tissue.
We attempted to clarify the cellular composition and histopathological features of
low grade
gliomas
by utilizing morphometric and immunohistochemical analyses.
Seventy-eight cases of
low grade
gliomas
were examined including 21 diffuse
astrocytomas
(DA), 36 oligodendrogliomas (OL), and 21 oligoastrocytomas (OA), based on the WHO
classification
system.
Double immunostaining revealed that expression of Olig2 and GFAP, and Olig2 and nestin was mutually exclusive in most
glioma
cells.
We conclude that each
glioma
include cells expressing GFAP, cells expressing nestin, and cells expressing Olig2 in a characteristic proportion for each
tumor
type.
We suggest that diffuse
gliomas
share cellular compositions in different ratios and that they can be distinguished by morphometrical analysis.
[MeSH-major]
Brain Neoplasms / metabolism. Brain Neoplasms / pathology.
Glioma
/ metabolism.
Glioma
/ pathology
[MeSH-minor]
Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Intermediate Filament Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. Nestin.
Tumor
Suppressor Protein p53 / biosynthesis
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18282166.001).
[ISSN]
1440-1789
[Journal-full-title]
Neuropathology : official journal of the Japanese Society of Neuropathology
[ISO-abbreviation]
Neuropathology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Australia
[Chemical-registry-number]
0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / OLIG2 protein, human; 0 / Tumor Suppressor Protein p53
48.
Burgoyne AM, Palomo JM, Phillips-Mason PJ, Burden-Gulley SM, Major DL, Zaremba A, Robinson S, Sloan AE, Vogelbaum MA, Miller RH, Brady-Kalnay SM:
PTPmu suppresses glioma cell migration and dispersal.
Neuro Oncol
; 2009 Dec;11(6):767-78
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
PTPmu suppresses
glioma
cell migration and dispersal.
Glioblastomas (GBMs) are the highest
grade
of primary brain tumors with
astrocytic
similarity and are characterized by marked dispersal
of tumor
cells.
PTPmu expression was examined in human GBM,
low
-
grade astrocytoma
, and normal brain tissue.
These studies revealed a striking loss of PTPmu protein expression in highly dispersive GBMs compared to less dispersive
low
-
grade
astrocytomas
and normal brain.
The migration of brain
tumor
cells was assessed in vitro using a scratch wound assay.
To assess migration, labeled U-87 MG
glioma
cells were injected into adult rat brain slices, and their movement was followed over time.
Together, these data suggest that loss of PTPmu in human GBMs contributes to
tumor
cell migration and dispersal, implicating loss of PTPmu in
glioma
progression.
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Dev Biol. 2004 Jan 1;265(1):23-32
[
14697350.001
]
[Cites]
Mol Cell Biol. 1994 Jan;14(1):1-9
[
8264577.001
]
[Cites]
Cancer Lett. 2004 Apr 8;206(2):181-91
[
15013523.001
]
[Cites]
Mol Cell Biochem. 1993 Nov;127-128:131-41
[
7935345.001
]
[Cites]
J Biol Chem. 1994 Nov 11;269(45):28472-7
[
7961788.001
]
[Cites]
J Cell Biol. 1995 Oct;131(1):251-60
[
7559782.001
]
[Cites]
J Biol Chem. 1997 Mar 14;272(11):7264-77
[
9054423.001
]
[Cites]
J Cell Biol. 1998 Apr 6;141(1):287-96
[
9531566.001
]
[Cites]
J Virol. 1998 Nov;72(11):8463-71
[
9765382.001
]
[Cites]
J Cell Biol. 1999 Mar 22;144(6):1323-36
[
10087273.001
]
[Cites]
J Neurooncol. 2004 Nov;70(2):217-28
[
15674479.001
]
[Cites]
J Biol Chem. 2005 Nov 11;280(45):37516-25
[
16150730.001
]
[Cites]
J Biol Chem. 2006 Feb 24;281(8):4903-10
[
16380380.001
]
[Cites]
J Neurochem. 2006 Sep;98(5):1497-506
[
16923162.001
]
[Cites]
Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46
[
17057753.001
]
[Cites]
J Neurooncol. 2006 Nov;80(2):133-42
[
16941076.001
]
[Cites]
Mol Biol Cell. 2006 Dec;17(12):5141-52
[
16987961.001
]
[Cites]
Mol Cell Neurosci. 2007 Mar;34(3):453-67
[
17234431.001
]
[Cites]
Mol Cell Neurosci. 2007 Mar;34(3):481-92
[
17276081.001
]
[Cites]
Nat Protoc. 2006;1(3):1165-71
[
17406399.001
]
[Cites]
Cancer Res. 2007 Aug 1;67(15):7203-11
[
17671188.001
]
[Cites]
Genes Dev. 2007 Nov 1;21(21):2683-710
[
17974913.001
]
[Cites]
Annu Rev Pathol. 2006;1:97-117
[
18039109.001
]
[Cites]
Mol Cancer Res. 2008 Jul;6(7):1106-13
[
18644975.001
]
[Cites]
Nat Rev Mol Cell Biol. 2008 Aug;9(8):603-15
[
18648374.001
]
[Cites]
N Engl J Med. 2008 Jul 31;359(5):492-507
[
18669428.001
]
[Cites]
Semin Radiat Oncol. 2001 Apr;11(2):103-12
[
11285548.001
]
[Cites]
J Biol Chem. 2001 May 4;276(18):14896-901
[
11278757.001
]
[Cites]
Cancer Res. 2001 Jun 1;61(11):4612-9
[
11389098.001
]
[Cites]
J Neurosci Res. 2001 Nov 1;66(3):487-96
[
11746367.001
]
[Cites]
Mol Cell Neurosci. 2002 Feb;19(2):292-306
[
11860281.001
]
[Cites]
Neurosurgery. 2003 Jan;52(1):187-96; discussion 196-7
[
12493117.001
]
[Cites]
J Clin Oncol. 2003 Apr 15;21(8):1624-36
[
12697889.001
]
[Cites]
J Neurobiol. 2003 Sep 5;56(3):199-208
[
12884260.001
]
[Cites]
Dev Neurosci. 2003 Mar-Aug;25(2-4):207-16
[
12966218.001
]
[Cites]
Mol Cell Neurosci. 2004 Apr;25(4):558-71
[
15080886.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11
[
15146033.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 May 18;101(20):7618-23
[
15128949.001
]
[Cites]
Expert Opin Ther Targets. 2004 Jun;8(3):211-20
[
15161428.001
]
[Cites]
Dev Biol. 2004 Nov 1;275(1):12-22
[
15464569.001
]
[Cites]
Cancer Res. 1984 Feb;44(2):753-60
[
6318976.001
]
[Cites]
Cytometry. 1992;13(1):48-59
[
1372202.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9
[
1557402.001
]
[Cites]
Cell. 1992 Aug 7;70(3):401-10
[
1643658.001
]
[Cites]
J Biol Chem. 1993 Aug 5;268(22):16101-4
[
8393854.001
]
[Cites]
J Cell Biol. 1993 Aug;122(4):961-72
[
8394372.001
]
[Cites]
Breast Cancer Res Treat. 2004 Mar;84(1):13-9
[
14999150.001
]
(PMID = 19304959.001).
[ISSN]
1523-5866
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
ENG
[Grant]
United States / NINDS NIH HHS / NS / R01 NS051520-04; United States / NEI NIH HHS / EY / P30 EY011373; United States / NINDS NIH HHS / NS / R01 NS051520; United States / NINDS NIH HHS / NS / R01-NS051520; United States / NCI NIH HHS / CA / K08 CA101954; United States / NINDS NIH HHS / NS / NS051520-04; United States / NEI NIH HHS / EY / P30 EY011373-119002; United States / NCI NIH HHS / CA / P20 CA103736; United States / NEI NIH HHS / EY / P30 EY011373-129002; United States / NCI NIH HHS / CA / P30 CA043703; United States / NEI NIH HHS / EY / P30 EY011373-139002; United States / NCI NIH HHS / CA / T32 CA059366; United States / NINDS NIH HHS / NS / NS051520-02; United States / NINDS NIH HHS / NS / NS051520-01A1; United States / NEI NIH HHS / EY / EY011373-139002; United States / NIGMS NIH HHS / GM / T32-GM007250; United States / NEI NIH HHS / EY / P30-EY11373; United States / NEI NIH HHS / EY / EY011373-119002; United States / NINDS NIH HHS / NS / NS051520-03; United States / NINDS NIH HHS / NS / R01 NS051520-02; United States / NINDS NIH HHS / NS / R01 NS051520-01A1; United States / NEI NIH HHS / EY / EY011373-129002; United States / NCI NIH HHS / CA / K08-CA101954; United States / NCI NIH HHS / CA / R01-CA116257; United States / NCI NIH HHS / CA / P30-CA043703; United States / NCI NIH HHS / CA / T32-CA059366; United States / NCI NIH HHS / CA / R01 CA116257; United States / NIGMS NIH HHS / GM / T32 GM007250; United States / NINDS NIH HHS / NS / R01 NS051520-03; United States / NCI NIH HHS / CA / P20-CA103736
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 2
[Other-IDs]
NLM/ PMC2802397
49.
Ess KC, Kamp CA, Tu BP, Gutmann DH:
Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex.
Neurology
; 2005 Apr 26;64(8):1446-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Developmental origin of subependymal giant cell
astrocytoma
in tuberous sclerosis complex.
Children with tuberous sclerosis complex (TSC) harbor developmental brain abnormalities (cortical tubers) and
low
-
grade
tumors (subependymal giant cell
astrocytomas
[SEGAs]).
[MeSH-major]
Astrocytoma
/ genetics.
Astrocytoma
/ metabolism. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Cell Differentiation / genetics. Tuberous Sclerosis / genetics. Tuberous Sclerosis / metabolism
[MeSH-minor]
Adolescent. Animals. Cell Lineage / genetics. Child.
Disease
Models, Animal. Female. Gene Expression Profiling. Gene Expression Regulation, Developmental / genetics. Genetic Markers / genetics. Humans. Infant. Male. Mice. Mice, Knockout. Nerve Tissue Proteins / genetics. Neurons / metabolism. Stem Cells / metabolism.
Tumor
Suppressor Proteins / genetics
Genetic Alliance.
consumer health - Subependymal giant cell astrocytoma
.
Genetic Alliance.
consumer health - Tuberous sclerosis
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
MedlinePlus Health Information.
consumer health - Tuberous Sclerosis
.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15851742.001).
[ISSN]
1526-632X
[Journal-full-title]
Neurology
[ISO-abbreviation]
Neurology
[Language]
eng
[Grant]
United States / NINDS NIH HHS / NS / 5T32-NS07205-21
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Genetic Markers; 0 / Nerve Tissue Proteins; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein
50.
Dixit VD, Weeraratna AT, Yang H, Bertak D, Cooper-Jenkins A, Riggins GJ, Eberhart CG, Taub DD:
Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in astrocytoma motility.
J Biol Chem
; 2006 Jun 16;281(24):16681-90
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in
astrocytoma
motility.
Here, we demonstrate that the human
astrocytoma
cell lines U-118, U-87, CCF-STTG1, and SW1088 express 6-, 11-, 15-, and 29-fold higher levels of GHS-R compared with primary normal human astrocytes.
The ligation of GHS-R by ghrelin on these cells resulted in an increase in intracellular calcium mobilization, protein kinase C activation, actin polymerization, matrix metalloproteinase-2 activity, and
astrocytoma
motility.
In addition, ghrelin led to actin polymerization and membrane ruffling on cells, with the specific co-localization of the small GTPase Rac1 with GHS-R on the leading edge of the
astrocytoma
cells and imparting the
tumor
cells with a motile phenotype.
Disruption of the endogenous ghrelin/GHS-R pathway by RNA interference resulted in diminished motility, matrix metalloproteinase activity, and Rac expression, whereas
tumor
cells stably overexpressing GHS-R exhibited increased cell motility.
The relevance of ghrelin and GHS-R expression was verified in clinically relevant tissues from 20 patients with oligodendrogliomas and
grade
II-IV
astrocytomas
.
Analysis
of a
central nervous system
tumor
tissue microarray revealed that strong GHS-R and ghrelin expression was significantly more common in high
grade
tumors compared with
low grade
ones.
Together, these findings suggest a novel role for the ghrelin/GHS-R axis in
astrocytoma
cell migration and invasiveness of cancers of central nervous system origin.
[MeSH-major]
Astrocytoma
/ metabolism. Peptide Hormones / physiology. Receptors, G-Protein-Coupled / physiology
[MeSH-minor]
Calcium / metabolism. Cell Line,
Tumor
. Cell Movement. Central Nervous System / metabolism. Ghrelin. Humans. Models, Biological. Peptides. RNA Interference. Receptors, Cell Surface / metabolism. Receptors, Ghrelin
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CALCIUM, ELEMENTAL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Endocrinol Metab. 2001 Apr;86(4):1738-45
[
11297611.001
]
[Cites]
Genes Dev. 2001 Jun 1;15(11):1311-33
[
11390353.001
]
[Cites]
Clin Endocrinol (Oxf). 2001 Jun;54(6):759-68
[
11422110.001
]
[Cites]
Nat Rev Neurosci. 2001 Aug;2(8):551-60
[
11483998.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Aug;86(8):3996-9
[
11502844.001
]
[Cites]
Neuro Oncol. 1999 Apr;1(2):109-19
[
11550306.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Oct;86(10):4984-90
[
11600575.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Jan 11;290(1):552-7
[
11779207.001
]
[Cites]
Endocrinology. 2002 Feb;143(2):484-91
[
11796502.001
]
[Cites]
J Biol Chem. 2002 Feb 15;277(7):5667-74
[
11724768.001
]
[Cites]
Oncologist. 2002;7(1):17-33
[
11854544.001
]
[Cites]
J Clin Endocrinol Metab. 2002 Jun;87(6):2988
[
12050285.001
]
[Cites]
Curr Treat Options Oncol. 2000 Dec;1(5):459-68
[
12057153.001
]
[Cites]
Cancer Cell. 2002 Apr;1(3):279-88
[
12086864.001
]
[Cites]
J Pharmacol Exp Ther. 2002 Aug;302(2):822-7
[
12130749.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Dec 20;299(5):739-43
[
12470640.001
]
[Cites]
J Biol Chem. 2002 Dec 20;277(51):49481-7
[
12388552.001
]
[Cites]
J Cell Biol. 2002 Dec 23;159(6):1029-37
[
12486113.001
]
[Cites]
J Biol Chem. 2003 Jan 3;278(1):64-70
[
12414809.001
]
[Cites]
Histol Histopathol. 2003 Jan;18(1):207-16
[
12507300.001
]
[Cites]
Am J Pathol. 2003 Feb;162(2):645-54
[
12547722.001
]
[Cites]
Cell. 2003 Feb 21;112(4):453-65
[
12600310.001
]
[Cites]
Nat Cell Biol. 2003 Mar;5(3):185-7
[
12646870.001
]
[Cites]
Cytokine Growth Factor Rev. 2003 Apr;14(2):113-22
[
12651223.001
]
[Cites]
J Cell Biol. 2003 Apr 28;161(2):417-27
[
12707305.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Jul;88(7):3117-20
[
12843152.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Sep 19;309(2):464-8
[
12951072.001
]
[Cites]
J Biol Chem. 2003 Oct 17;278(42):40601-6
[
12902325.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8
[
14595012.001
]
[Cites]
Science. 2003 Dec 5;302(5651):1690-1
[
14657480.001
]
[Cites]
Horm Metab Res. 2003 Nov-Dec;35(11-12):740-50
[
14710353.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Jan;89(1):400-9
[
14715878.001
]
[Cites]
Eur J Endocrinol. 2004 Feb;150(2):173-84
[
14763915.001
]
[Cites]
Cancer Cell. 2004 Mar;5(3):201-2
[
15050909.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4679-84
[
15070777.001
]
[Cites]
Circulation. 2004 May 11;109(18):2221-6
[
15117840.001
]
[Cites]
J Biol Chem. 2004 May 21;279(21):22118-23
[
15037605.001
]
[Cites]
J Clin Invest. 2004 Jul;114(1):57-66
[
15232612.001
]
[Cites]
BMC Cancer. 2004 Jul 21;4:39
[
15265232.001
]
[Cites]
Nat Rev Cancer. 2004 Aug;4(8):579-91
[
15286738.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Aug;89(8):3739-44
[
15292299.001
]
[Cites]
Clin Cancer Res. 2004 Aug 15;10(16):5622-9
[
15328205.001
]
[Cites]
J Physiol. 2004 Sep 15;559(Pt 3):729-37
[
15272046.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5854-9
[
9159164.001
]
[Cites]
Pathol Oncol Res. 1998;4(3):230-41
[
9761943.001
]
[Cites]
J Clin Endocrinol Metab. 1998 Dec;83(12):4314-20
[
9851770.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):226-31
[
9874800.001
]
[Cites]
EMBO J. 1999 Feb 1;18(3):501-11
[
9927410.001
]
[Cites]
FASEB J. 1999 May;13(8):781-92
[
10224222.001
]
[Cites]
J Neuroendocrinol. 1999 Jul;11(7):491-502
[
10444306.001
]
[Cites]
Circulation. 2004 Dec 14;110(24):3674-9
[
15569841.001
]
[Cites]
Endocrinology. 2005 Jan;146(1):355-64
[
15471959.001
]
[Cites]
Diabetes. 2005 Jan;54(1):259-67
[
15616037.001
]
[Cites]
Am J Physiol Endocrinol Metab. 2005 Mar;288(3):E486-92
[
15507538.001
]
[Cites]
Endocrinology. 2005 Mar;146(3):1514-22
[
15564328.001
]
[Cites]
J Clin Endocrinol Metab. 2005 Mar;90(3):1798-804
[
15585554.001
]
[Cites]
Endocr Rev. 2005 Apr;26(2):203-50
[
15561803.001
]
[Cites]
J Clin Endocrinol Metab. 2005 May;90(5):2920-6
[
15713718.001
]
[Cites]
Gastroenterology. 2005 Jul;129(1):8-25
[
16012930.001
]
[Cites]
Nature. 1999 Dec 9;402(6762):656-60
[
10604470.001
]
[Cites]
J Nutr Health Aging. 1999;3(2):92-101
[
10885804.001
]
[Cites]
J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89
[
10995803.001
]
[Cites]
Science. 2000 Oct 13;290(5490):333-7
[
11030651.001
]
[Cites]
Nature. 2000 Oct 19;407(6806):908-13
[
11057670.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14478-83
[
11121050.001
]
[Cites]
Annu Rev Immunol. 2001;19:397-421
[
11244042.001
]
[Cites]
Clin J Oncol Nurs. 2000 Jul-Aug;4(4):153-8
[
11261094.001
]
(PMID = 16527811.001).
[ISSN]
0021-9258
[Journal-full-title]
The Journal of biological chemistry
[ISO-abbreviation]
J. Biol. Chem.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / / Z01 AG000758-10
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Ghrelin; 0 / Peptide Hormones; 0 / Peptides; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Ghrelin; SY7Q814VUP / Calcium
[Other-IDs]
NLM/ NIHMS41150; NLM/ PMC2271047
51.
Mason WP:
Progress in clinical neurosciences: Advances in the management of low-grade gliomas.
Can J Neurol Sci
; 2005 Feb;32(1):18-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Progress in clinical neurosciences: Advances in the management of
low
-
grade
gliomas
.
The management of
low
-
grade
gliomas
represents one of the most challenging and controversial areas in neuro-
oncology
.
Many aspects of the treatment of
low
-
grade
gliomas
are debated, including the optimal timing of surgery and radiotherapy, the benefit of extensive surgery, and the impact of these variables on the natural history of these indolent and generally incurable tumours.
The recognition that as many as two thirds of
low
-
grade
gliomas
have oligodendroglial features, advances in molecular diagnostics making accurate pathologic diagnosis of oligodendroglial tumours possible, and the established chemosensitivity of malignant oligodendrogliomas, have raised new issues surrounding the potential
value of
chemotherapy for
low
-
grade
gliomas
.
This review will be restricted to
low
-
grade
diffuse
astrocytomas
, oligodendrogliomas, and
low
-
grade
mixed oligoastrocytomas in adults, and provide evidence-based guidelines for the management of these tumours, including the emerging role of chemotherapy as initial treatment.
[MeSH-major]
Brain Neoplasms.
Glioma
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15825542.001).
[ISSN]
0317-1671
[Journal-full-title]
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
[ISO-abbreviation]
Can J Neurol Sci
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Canada
[Number-of-references]
74
52.
Hourani R, Horská A, Albayram S, Brant LJ, Melhem E, Cohen KJ, Burger PC, Weingart JD, Carson B, Wharam MD, Barker PB:
Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children.
J Magn Reson Imaging
; 2006 Feb;23(2):99-107
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PURPOSE: To investigate whether in vivo proton magnetic resonance spectroscopic imaging (MRSI) can differentiate between 1) tumors and nonneoplastic brain lesions, and 2) high- and
low
-
grade
tumors in children.
Nineteen patients had a neuropathologically confirmed brain
tumor
, and 13 patients had a benign lesion.
Ratios
of N
-acetyl aspartate/choline (NAA/Cho), NAA/creatine (Cr), and Cho/Cr were evaluated in the lesion and the contralateral hemisphere.
The best discriminant function to differentiate between high- and
low
-
grade
tumors included the ratios of NAA/Cr and Cho(norm) (Wilks' lambda, P = 0.001; 89.5% of original grouped cases correctly classified).
Cr levels in
low
-
grade
tumors were slightly lower than or comparable to control regions and ranged from 53% to 165% of the control values in high-
grade
tumors.
CONCLUSION: Proton MRSI may have a promising role in differentiating pediatric brain lesions, and an important diagnostic
value
, particularly for inoperable or inaccessible lesions.
[MeSH-major]
Astrocytoma
/ diagnosis. Brain Neoplasms / diagnosis. Germinoma / diagnosis.
Glioma
/ diagnosis. Magnetic Resonance Spectroscopy / methods
[MeSH-minor]
Adolescent. Biopsy, Needle. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male.
Neoplasm
Staging. Retrospective Studies. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Published 2005 Wiley-Liss, Inc.
(PMID = 16374884.001).
[ISSN]
1053-1807
[Journal-full-title]
Journal of magnetic resonance imaging : JMRI
[ISO-abbreviation]
J Magn Reson Imaging
[Language]
eng
[Grant]
United States / NINDS NIH HHS / NS / NS042851; United States / NCRR NIH HHS / RR / P41RR15241
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
53.
Kashyap R, Ryan C, Sharma R, Maloo MK, Safadjou S, Graham M, Tretheway D, Jain A, Orloff M:
Liver grafts from donors with central nervous system tumors: a single-center perspective.
Liver Transpl
; 2009 Oct;15(10):1204-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
However, it has become a common practice to accept organs from donors that have
low
-
grade
tumors or tumors with
low
metastatic potential.
A retrospective review of 1173 liver transplants performed between 1992 and 2006 identified 42 donors diagnosed with a CNS
tumor
.
Twenty (47.6%) of the CNS tumors were glioblastoma multiforme (
astrocytoma grade
IV), 11 (26.2%) were other
astrocytomas
, and 1 (2.4%) was an anaplastic ependymoma.
Twenty (62.5%) neoplasms were
grade
IV tumors, 8 (25%) were
grade
II tumors, and 4 (12.5%) were
grade
III tumors.
In conclusion, in our experience, despite violation of the blood-brain barrier and high-
grade
CNS tumors, recurrence was uncommon.
Grafts from these donors are often an overlooked source of high-quality organs from younger donors and can be appropriately used, particularly in patients who, despite
low
Model for End-Stage Liver
Disease
scores, carry a high risk of mortality.
[MeSH-major]
Central Nervous System Neoplasms / diagnosis. Liver
Diseases
/ therapy. Liver Transplantation / methods. Tissue and Organ Procurement / methods
[MeSH-minor]
Adult. Blood-Brain Barrier. Female. Humans. Male. Middle Aged.
Neoplasm
Metastasis. Retrospective Studies. Time Factors. Tissue Donors. Treatment Outcome
MedlinePlus Health Information.
consumer health - Liver Diseases
.
MedlinePlus Health Information.
consumer health - Liver Transplantation
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 AASLD
[CommentIn]
Liver Transpl. 2010 Jul;16(7):916
[
20583090.001
]
[CommentIn]
Liver Transpl. 2010 Jul;16(7):914-5
[
20583288.001
]
(PMID = 19790151.001).
[ISSN]
1527-6473
[Journal-full-title]
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
[ISO-abbreviation]
Liver Transpl.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
54.
Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ:
Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.
Neurosurgery
; 2006 Jun;58(6):1099-107; discussion 1099-107
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of
low
-
grade
gliomas
.
OBJECTIVE: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically
tumor
progression, in
low
-
grade
gliomas
(LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs.
METHODS: Thirty-five patients with histologically diagnosed LGGs (21
low
-
grade
astrocytomas
and 14
low
-
grade
oligodendrogliomas and
low
-
grade
mixed oligoastrocytomas) were studied with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
Tumor
volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with
tumor
volume progression.
RESULTS: Wilcoxon tests showed patients manifesting an adverse event (either death or progression) had significantly higher rCBV (P = 0.003) than did patients without adverse events (complete response or stable
disease
).
Log-rank tests showed that rCBV exhibited a significant negative association with
disease
-free survival (P = 0.0015), such that
low
rCBV values were associated with longer time to progression.
Lesions with
low
baseline rCBV (< 1.75) demonstrated stable
tumor
volumes when followed up over time, and lesions with high baseline rCBV (> 1.75) demonstrated progressively increasing
tumor
volumes over time.
CONCLUSION: Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging may be used to identify LGGs that are either high-
grade
gliomas
, misdiagnosed because of sampling error at pathological examination or that have undergone angiogenesis in the progression toward malignant transformation.
[MeSH-major]
Astrocytoma
/ therapy. Brain Neoplasms / therapy. Magnetic Resonance Imaging. Oligodendroglioma / therapy
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Blood Volume. Cerebrovascular Circulation. Child. Child, Preschool.
Disease
Progression. Female. Humans. Male. Middle Aged. Predictive
Value of
Tests. Reference Standards. Survival Analysis. Treatment Outcome
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Radiology. 2008 Mar;246(3):989
[
18309030.001
]
(PMID = 16723889.001).
[ISSN]
1524-4040
[Journal-full-title]
Neurosurgery
[ISO-abbreviation]
Neurosurgery
[Language]
eng
[Publication-type]
Duplicate Publication; Journal Article
[Publication-country]
United States
55.
Combs SE, Steck I, Schulz-Ertner D, Welzel T, Kulozik AE, Behnisch W, Huber PE, Debus J:
Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy.
Radiother Oncol
; 2009 Apr;91(1):60-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term outcome of high-precision radiotherapy in patients with brain stem
gliomas
: results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy.
INTRODUCTION: To assess long-term outcome in 85 patients with brain stem
gliomas
treated with fractionated stereotactic radiation therapy (FSRT).
Histopathological examination confirmed a
low
-
grade
glioma
in 57 patients.
Of the group of high-
grade
gliomas
, six were anaplastic
astrocytomas
, and two were classified as glioblastoma.
CONCLUSION: Long-term outcome of FSRT in patients with brain stem
gliomas
is acceptable with
low
rates of side effects.
[MeSH-major]
Brain Stem Neoplasms / radiotherapy.
Glioma
/ radiotherapy
[MeSH-minor]
Adolescent. Adult. Aged. Child, Preschool.
Disease
-Free Survival. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Stereotaxic Techniques. Survival Rate. Treatment Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19285356.001).
[ISSN]
0167-8140
[Journal-full-title]
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
[ISO-abbreviation]
Radiother Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
56.
Jalali R, Dutta D, Kamble R, Gupta T, Munshi A, Sarin R, Dinshaw K:
Prospective assessment of activities of daily living using modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy.
J Neurooncol
; 2008 Dec;90(3):321-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prospective assessment of activities of daily living using modified Barthel's Index in children and young adults with
low
-
grade
gliomas
treated with stereotactic conformal radiotherapy.
PURPOSE: To report prospective evaluations of activities of daily living (ADL) in young patients with
low
-
grade
gliomas
treated with stereotactic conformal radiotherapy (SCRT).
MATERIALS AND METHODS: Between April 2001 and February 2008, 38 children and young adults (age 5-25 years, median 12.5 years) with
low
-
grade
gliomas
with residual/progressive
disease
and treated with SCRT were accrued in a prospective protocol.
RESULT: The patient population consisted of 38 patients (male 29, female 9) with a diagnosis of residual or progressive
low
-
grade
glioma
(pilocytic
astrocytoma
in 27, fibrillary
astrocytoma
in 5, ependymoma in 4, and oligodendroglioma and pleomorphic xanthoastrocytoma in 1 each).
At baseline pre-radiotherapy assessment, patients with impaired visual function and with
low
performance status (Karnofsky performance score, KPS < 70) had significantly lower BI than those with normal vision (P <or= 0.001) and with good performance status (P = 0.001).
On follow-up, maximum improvement in individual BI was seen in the ambulation-related domain in patients with impaired visual function (P = 0.027),
low
KPS (P = 0.015), and age less than 13 years (P = 0.103).
The mean pre-radiotherapy baseline BI of three patients, who eventually developed local recurrence, was only 64 (SD 32.1) as compared with a baseline score of 97.18 seen in patients whose
tumor
remained controlled at follow-up (P <or= 0.001).
CONCLUSIONS: Young patients with
low
-
grade
gliomas
after surgical intervention had a lower than normal BI before starting radiotherapy, suggesting a decrease in ADL possibly due to
tumor
- and surgery-related factors.
Patients who developed
tumor
recurrence at follow-up had a significantly lower BI at baseline than patients with controlled
disease
(P <or= 0.001).
[MeSH-major]
Activities of Daily Living. Brain Neoplasms / psychology. Brain Neoplasms / radiotherapy.
Glioma
/ psychology.
Glioma
/ radiotherapy. Radiotherapy, Conformal / methods. Stereotaxic Techniques. Surveys and Questionnaires
[MeSH-minor]
Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy.
Disease
-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Prospective Studies. Retrospective Studies. Young Adult
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Clin Oncol. 2003 Jun;26(3):273-9
[
12796600.001
]
[Cites]
Clin Oncol (R Coll Radiol). 1995;7(2):82-6
[
7542472.001
]
[Cites]
Clin Oncol (R Coll Radiol). 2000;12(1):36-41
[
10749018.001
]
[Cites]
Ann Oncol. 2003 Dec;14 (12 ):1722-6
[
14630675.001
]
[Cites]
Neurosurg Focus. 2000 May 15;8(5):e3
[
16859281.001
]
[Cites]
Disabil Rehabil. 2004 Feb 18;26(4):235-45
[
15164957.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):507-13
[
10487578.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):747-53
[
2323966.001
]
[Cites]
Radiother Oncol. 2005 Jan;74(1):37-44
[
15683667.001
]
[Cites]
J Clin Oncol. 2004 Aug 1;22(15):3156-62
[
15284268.001
]
[Cites]
Neurosurgery. 2003 Jun;52(6):1348-56; discussion 1356-7
[
12762880.001
]
[Cites]
J Clin Epidemiol. 1989;42(8):703-9
[
2760661.001
]
[Cites]
QJM. 2003 Sep;96(9):643-8
[
12925719.001
]
[Cites]
Clin Oncol (R Coll Radiol). 2003 Oct;15(7):422-8
[
14570092.001
]
[Cites]
J Neurooncol. 1997 Sep;34(2):187-92
[
9210067.001
]
[Cites]
Brain Inj. 1998 Apr;12(4):283-96
[
9562911.001
]
[Cites]
Eur J Cancer Care (Engl). 1995 Jun;4(2):63-8
[
7599873.001
]
[Cites]
J Chronic Dis. 1987;40(6):481-9
[
3597653.001
]
[Cites]
Medicina (Kaunas). 2006;42(2):130-6
[
16528129.001
]
[Cites]
Scand J Caring Sci. 1990;4(3):99-106
[
2120762.001
]
[Cites]
Dev Med Child Neurol. 2003 Dec;45(12):821-8
[
14667074.001
]
(PMID = 18704269.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
57.
Radulović D:
[Natural history of supratentorial low-grade astrocytoma: case report].
Srp Arh Celok Lek
; 2006 Nov-Dec;134(11-12):537-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Natural history of supratentorial
low
-
grade astrocytoma
: case report].
Low
-
grade
astrocytomas
comprise a group of primary brain neoplasms with relatively
low
anaplastic potential, although through time they tend to behave more aggressively.
This report presents a natural history
of a
patient with
low grade astrocytoma
.
Initial computerized tomography and magnetic resonance of brain revealed oval, 4 cm in diameter, lesion in the left parietal region that was considered as
low
-
grade
glioma
.
Repeated computerized tomography showed huge
tumor
in the left frontoparietal region at the site of previous lesion.
Urgent left frontoparietal craniotomy and reduction
of tumor
were performed.
The described patient with
low
-
grade astrocytoma
lived without any oncological treatment eight years and four months from the time when diagnosis was made until intracranial herniation.
The natural history
of disease
in presented patient indicated that rational therapeutic strategy, for
low
-
grade astrocytoma
with epilepsy only, would be deferral of surgery until the time of manifestation of neurological or radiological deterioration.
[MeSH-major]
Astrocytoma
. Brain Neoplasms. Parietal Lobe
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17304770.001).
[ISSN]
0370-8179
[Journal-full-title]
Srpski arhiv za celokupno lekarstvo
[ISO-abbreviation]
Srp Arh Celok Lek
[Language]
srp
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Serbia and Montenegro
58.
Katakowski M, Jiang F, Zheng X, Gutierrez JA, Szalad A, Chopp M:
Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.
Cancer Sci
; 2009 Sep;100(9):1597-604
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
EGFR is a key component of autonomous growth signaling in several tumors, and correlates with the malignancy
grade
of
astrocytoma
.
When implanted in the nude mouse brain, CTX-TNA2 cells induced
low
histological
grade
, benign intraventricular
gliomas
.
In contrast, the same astrocytes with hADAM17 formed large malignant
gliomas
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurosci Res. 2007 Dec;85(16):3523-9
[
17526018.001
]
[Cites]
Expert Opin Ther Targets. 2007 Oct;11(10):1287-98
[
17907959.001
]
[Cites]
Growth Factors. 2007 Aug;25(4):253-63
[
18092233.001
]
[Cites]
World J Gastroenterol. 2008 Apr 28;14(16):2487-93
[
18442194.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6392-7
[
18427106.001
]
[Cites]
J Clin Oncol. 2008 Jun 10;26(17):2821-7
[
18539960.001
]
[Cites]
Mol Cell Biol. 2008 Aug;28(15):4829-42
[
18490439.001
]
[Cites]
Cell Mol Life Sci. 2008 Jul;65(14):2232-43
[
18535782.001
]
[Cites]
Biol Chem. 2008 Aug;389(8):1075-84
[
18979631.001
]
[Cites]
PLoS One. 2008;3(11):e3769
[
19020659.001
]
[Cites]
Cancer Biol Ther. 2009 Jun;8(11):1045-54
[
19395875.001
]
[Cites]
Trends Genet. 2000 Feb;16(2):83-7
[
10652535.001
]
[Cites]
Cancer Res. 2000 Mar 1;60(5):1383-7
[
10728703.001
]
[Cites]
Mol Cell. 2000 Feb;5(2):207-16
[
10882063.001
]
[Cites]
J Cell Mol Med. 2002 Jan-Mar;6(1):1-12
[
12003665.001
]
[Cites]
Cancer Res. 2002 Jun 15;62(12):3335-9
[
12067969.001
]
[Cites]
EMBO J. 2003 Mar 3;22(5):1114-24
[
12606576.001
]
[Cites]
Oncogene. 2003 Mar 6;22(9):1324-32
[
12618757.001
]
[Cites]
EMBO J. 2003 May 15;22(10):2411-21
[
12743035.001
]
[Cites]
Neoplasia. 2003 May-Jun;5(3):198-204
[
12869303.001
]
[Cites]
J Biol Chem. 2003 Oct 3;278(40):38829-39
[
12832423.001
]
[Cites]
J Clin Oncol. 2003 Oct 15;21(20):3798-807
[
12953099.001
]
[Cites]
Oncogene. 2004 Jan 15;23(2):317-29
[
14724562.001
]
[Cites]
Cancer Res. 2004 Mar 15;64(6):1943-50
[
15026328.001
]
[Cites]
N Engl J Med. 2004 May 20;350(21):2129-39
[
15118073.001
]
[Cites]
Science. 2004 Jun 4;304(5676):1497-500
[
15118125.001
]
[Cites]
Cancer Res. 2004 Aug 1;64(15):5283-90
[
15289334.001
]
[Cites]
World J Gastroenterol. 2004 Sep 15;10(18):2735-9
[
15309730.001
]
[Cites]
Am J Pathol. 2004 Nov;165(5):1743-53
[
15509542.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6467-71
[
1378628.001
]
[Cites]
Curr Opin Oncol. 1994 Jan;6(1):77-81
[
8204695.001
]
[Cites]
J Biol Chem. 1996 Nov 8;271(45):28220-8
[
8910439.001
]
[Cites]
EMBO J. 1997 Feb 17;16(4):750-9
[
9049304.001
]
[Cites]
J Neurooncol. 1997 Dec;35(3):303-14
[
9440027.001
]
[Cites]
Int J Biochem Cell Biol. 1999 Jun;31(6):637-43
[
10404636.001
]
[Cites]
Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43
[
15688065.001
]
[Cites]
Exp Cell Res. 2005 Jun 10;306(2):349-56
[
15925591.001
]
[Cites]
J Pathol. 2005 Oct;207(2):156-63
[
16041691.001
]
[Cites]
Cancer Res. 2006 Jan 15;66(2):867-74
[
16424019.001
]
[Cites]
Cancer Res. 2006 Aug 15;66(16):8083-90
[
16912185.001
]
[Cites]
Cancer Res. 2006 Sep 15;66(18):9045-53
[
16982746.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14825-30
[
16990429.001
]
[Cites]
J Clin Invest. 2007 Feb;117(2):337-45
[
17218988.001
]
[Cites]
J Neurosurg. 2007 Mar;106(3):417-27
[
17367064.001
]
[Cites]
Adv Cancer Res. 2007;97:203-24
[
17419947.001
]
[Cites]
Cancer Sci. 2007 May;98(5):674-84
[
17355261.001
]
[Cites]
Biochem Cell Biol. 2007 Feb;85(1):141-9
[
17464354.001
]
[Cites]
Cancer Lett. 2007 Aug 28;254(1):30-41
[
17321672.001
]
[Cites]
Biochem Biophys Res Commun. 2007 Sep 28;361(3):586-92
[
17673180.001
]
[Cites]
J Neurooncol. 2008 Jan;86(1):31-45
[
17611714.001
]
(PMID = 19515085.001).
[ISSN]
1349-7006
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA043892-17; United States / NCI NIH HHS / CA / R01 CA100486-04; United States / NCI NIH HHS / CA / P01 CA043892; United States / NCI NIH HHS / CA / CA100486-04; United States / NCI NIH HHS / CA / R01 CA100486; United States / NCI NIH HHS / CA / P01 CA043892-17
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Angiogenesis Inducing Agents; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
[Other-IDs]
NLM/ NIHMS142282; NLM/ PMC2756136
59.
Leighton C, Fisher B, Macdonald D, Stitt L, Bauman G, Cairncross J:
The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection.
J Neurooncol
; 2007 Apr;82(2):165-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The dose-volume interaction in adult supratentorial
low
-
grade
glioma
: higher radiation dose is beneficial among patients with partial resection.
PURPOSE: To evaluate the hypothesis that adults with partially resected (PR<50% resection) supratentorial
low
-
grade
glioma
(LGG) benefit from higher doses of radiation.
METHODS: Patients receiving post-operative radiation for WHO
grade
I-II LGG at the University of Western Ontario between 1979 and 2001 were studied.
Patient characteristics evaluated included: age, gender, symptom duration>30 days, seizures at presentation, Karnofsky performance status (KPS)<70,
astrocytoma
pathology (AS), and radiation dose.
CONCLUSIONS: The outcome for patients with LGG is dependent on extent
of tumor
resection and radiation dose.
Future trials on therapeutic strategies for LGG should consider stratification of patients by extent
of tumor
resection.
[MeSH-major]
Astrocytoma
/ radiotherapy. Oligodendroglioma / radiotherapy. Supratentorial Neoplasms / radiotherapy
[MeSH-minor]
Adult. Combined Modality Therapy. Female. Humans. Male.
Neoplasm
Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies
Genetic Alliance.
consumer health - Glioma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
J Neurooncol. 2007 Dec;85(3):357
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):996-1001
[
11958894.001
]
[Cites]
Eur J Cancer. 1998 Nov;34(12):1902-9
[
10023313.001
]
[Cites]
Cancer. 1994 Sep 15;74(6):1784-91
[
8082081.001
]
[Cites]
Radiother Oncol. 1993 May;27(2):112-6
[
8356220.001
]
[Cites]
Jpn J Clin Oncol. 2001 Jun;31(6):240-5
[
11463800.001
]
[Cites]
Neurosurgery. 1989 May;24(5):686-92
[
2716976.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9
[
10571199.001
]
[Cites]
J Clin Oncol. 2002 May 1;20(9):2267-76
[
11980997.001
]
[Cites]
J Clin Oncol. 2002 Apr 15;20(8):2076-84
[
11956268.001
]
[Cites]
J Neurooncol. 1996 Feb;27(2):173-7
[
8699240.001
]
[Cites]
J Clin Oncol. 1997 Apr;15(4):1294-301
[
9193320.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56
[
8948338.001
]
[Cites]
Oncology. 2000 Feb;58(2):108-16
[
10705237.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6
[
8795601.001
]
[Cites]
Cancer. 1994 Apr 1;73(7):1937-45
[
8137221.001
]
(PMID = 17357830.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
60.
Molina Saera J, Segura Huerta A, Palomar Abad L, Giménez Ortiz A, Ponce Lorenzo J, Reynés Muntaner G:
[Extra-cranial anaplastic oligoastrocytoma development from a low-grade glioma].
Clin Transl Oncol
; 2005 Apr;7(3):127-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Extra-cranial anaplastic oligoastrocytoma development from a
low
-
grade
glioma
].
[Transliterated title]
Afectación extracraneal
de
oligoastrocitoma anaplásico desarrollado sobre un
glioma de bajo grado
.
This type
of glioma
has a favourable prognosis compared to other brain tumours.
We present a patient who had received treatment previously
for a
lowgrade
glioma
and who subsequently developed an anaplastic oligoastrocytoma in the same zone together with skull and extra-cranial involvement in the
disease
progression.
[MeSH-major]
Astrocytoma
/ pathology. Brain Neoplasms / pathology. Brain Neoplasms / surgery.
Glioma
/ surgery. Neoplasms, Second Primary / pathology. Skull Neoplasms / pathology. Temporal Bone. Temporal Lobe
Genetic Alliance.
consumer health - Glioma
.
Genetic Alliance.
consumer health - Anaplastic Oligoastrocytoma
.
Genetic Alliance.
consumer health - Oligoastrocytoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurosurg. 1992 Mar;76(3):428-34
[
1738022.001
]
[Cites]
Neurosurgery. 1993 Mar;32(3):365-70; discussion 371
[
8455760.001
]
[Cites]
J Clin Oncol. 2001 May 1;19(9):2449-55
[
11331324.001
]
[Cites]
Semin Oncol. 1994 Apr;21(2):236-48
[
8153667.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):839-45
[
11309331.001
]
[Cites]
J Neurooncol. 1999 Jun;43(2):179-85
[
10533731.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):399-403
[
9069313.001
]
[Cites]
Neurology. 2000 Apr 11;54(7):1442-8
[
10751254.001
]
[Cites]
J Neurosurg. 1985 Dec;63(6):881-9
[
4056902.001
]
[Cites]
Cancer. 1994 Apr 1;73(7):1937-45
[
8137221.001
]
(PMID = 15899221.001).
[ISSN]
1699-048X
[Journal-full-title]
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
[ISO-abbreviation]
Clin Transl Oncol
[Language]
spa
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Italy
66.
Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C:
[Histological and molecular classification of gliomas].
Rev Neurol (Paris)
; 2008 Jun-Jul;164(6-7):505-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Histological and molecular
classification of gliomas
].
[Transliterated title]
Classification
histologique et moléculaire des gliomes.
Gliomas
are the most frequent tumors of the central nervous system.
The WHO
classification
, based on the presumed cell origin, distinguishes
astrocytic
, oligodendrocytic and mixed
gliomas
.
The main histological
subtype of
grade
I
gliomas
are pilocytic
astrocytomas
, which are benign.
Diffuse
astrocytomas
, oligodendrogliomas and oligoastrocytomas are
low
-
grade
(II) or high-
grade
(III and IV) tumors.
Glioblastomas correspond to
grade
IV
astrocytomas
. C.
Daumas-Duport et al. have proposed another
classification
based on histology and imaging data, which distinguishes oligodendrogliomas and mixed
gliomas of
grade
A (without endothelial proliferation and/or contrast enhancement), oligodendrogliomas and mixed
gliomas of
grade
B (with endothelial proliferation or contrast enhancement), glioblastomas and glioneuronal malignant tumors.
Many studies have searched
for a
molecular
classification
.
Recurrent abnormalities in
gliomas
have been found.
De
novo glioblastomas, which occur in young patients without
of a
prior history of brain
tumor
and harbor frequent amplification of EGFR, deletion of p16 and mutation of PTEN while mutation of p53 is infrequent.
Secondary glioblastomas occur in the context
of a
preexisting
low
-
grade
glioma
and are characterized by more frequent mutation of p53.
However, histological and molecular classifications do not always correspond as many alterations are shared by high-
grade
tumors, whatever their histological type.
Besides, few molecular alterations have a prognostic
value
.
However, some concerns exist for the method of detection of this
abnormality
.
[MeSH-major]
Brain Neoplasms / pathology.
Glioma
/ pathology
[MeSH-minor]
Animals.
Astrocytoma
/
classification
.
Astrocytoma
/ pathology. Chromosomes / genetics. Humans. Oligodendroglioma /
classification
. Oligodendroglioma / pathology. Signal Transduction / physiology
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18565348.001).
[ISSN]
0035-3787
[Journal-full-title]
Revue neurologique
[ISO-abbreviation]
Rev. Neurol. (Paris)
[Language]
fre
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
France
[Number-of-references]
63
67.
Khan MA, Hashmi S:
Low-grade astrocytoma causing calvarial scalloping.
Pediatr Neurosurg
; 2007;43(2):155-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Low
-
grade astrocytoma
causing calvarial scalloping.
Gliomas
are tumors of the white matter.
Only 1 case of
low
-
grade astrocytoma
causing calvarial erosion has been reported in the literature of the CT era.
We report the first case
of a
low
-
grade astrocytoma
causing calvarial erosion in an adolescent.
[MeSH-major]
Astrocytoma
/ diagnosis.
Astrocytoma
/ surgery. Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Osteolysis / pathology. Osteolysis / surgery. Parietal Lobe / pathology. Parietal Lobe / surgery. Skull / pathology. Skull / surgery
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2007 S. Karger AG, Basel.
(PMID = 17337932.001).
[ISSN]
1016-2291
[Journal-full-title]
Pediatric neurosurgery
[ISO-abbreviation]
Pediatr Neurosurg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Switzerland
68.
Schlierf B, Friedrich RP, Roerig P, Felsberg J, Reifenberger G, Wegner M:
Expression of SoxE and SoxD genes in human gliomas.
Neuropathol Appl Neurobiol
; 2007 Dec;33(6):621-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of SoxE and SoxD genes in human
gliomas
.
Here, we have examined Sox gene expression in 60 human primary
gliomas
.
Transcripts from each of the six group E and group D genes were expressed in
gliomas of
various types and malignancy grades, but with significant differences.
Low
-
grade
astrocytomas
, but not glioblastomas, also showed elevated SOX8 transcript levels.
Taken together, the expression pattern of Sox genes in
gliomas
is heterogeneous and overall compatible with the less differentiated state
of glioma
cells as compared with their normal adult counterparts.
Despite their restricted expression in astrocytes and oligodendrocytes during normal development, none of the Sox genes was selectively expressed in tumours of the oligodendroglial or
astrocytic
lineage.
This is compatible with an origin
of gliomas
from neuroepithelial stem or precursor cells.
[MeSH-major]
Brain Neoplasms / metabolism. Gene Expression.
Glioma
/ metabolism. Sex-Determining Region Y Protein / biosynthesis
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17961134.001).
[ISSN]
0305-1846
[Journal-full-title]
Neuropathology and applied neurobiology
[ISO-abbreviation]
Neuropathol. Appl. Neurobiol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Messenger; 0 / Sex-Determining Region Y Protein
69.
Rushing EJ, Sandberg GD, Horkayne-Szakaly I:
High-grade astrocytomas show increased Nestin and Wilms's tumor gene (WT1) protein expression.
Int J Surg Pathol
; 2010 Aug;18(4):255-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High-
grade
astrocytomas
show increased Nestin and Wilms's
tumor
gene (WT1) protein expression.
Wilms's
tumor
gene (WT1) is overexpressed in a variety of hematologic malignancies and solid tumors.
Recently, WT1 protein has been considered as a molecular target of cancer immunotherapy for several solid tumors and as a tool for monitoring minimal residual
disease
in leukemia patients.
There are only few investigations on WT1 expression in central nervous system neoplasms, which suggest that the WT1 gene may play an important role in tumorigenesis of primary
astrocytic
tumors and that high-
grade
tumors express high levels of WT1 proteins.
We examined 50
low
-
grade
and high-
grade
gliomas
using tissue microarray and immunohistochemical methods to identify WT1 protein, P53, Ki-67, GFAP, NFP, EGFR, nestin, and Neu-N expression.
WT1 and nestin shared overlapping expression in all
gliomas
and were increased in high-
grade
examples, highlighting their potential use as diagnostic and prognostic
tumor
markers.
[MeSH-major]
Astrocytoma
/ metabolism. Brain Neoplasms / metabolism. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism. WT1 Proteins / metabolism
[MeSH-minor]
Adolescent. Adult. Aged. Biomarkers,
Tumor
/ metabolism. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Nestin. Tissue Array Analysis. Young Adult
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19578047.001).
[ISSN]
1940-2465
[Journal-full-title]
International journal of surgical pathology
[ISO-abbreviation]
Int. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / WT1 Proteins
70.
Nagpal J, Jamoona A, Gulati ND, Mohan A, Braun A, Murali R, Jhanwar-Uniyal M:
Revisiting the role of p53 in primary and secondary glioblastomas.
Anticancer Res
; 2006 Nov-Dec;26(6C):4633-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
GBM may develop
de
novo (primary) or through progression from a
low
-
grade
or anaplastic
astrocytoma
(secondary).
Mutational inactivation of the p53 gene and presence of aberrant p53 expression are reported in GBM, suggesting that p53 has a role in
tumor
progression.
This study of seven
de
novo GBM and four secondary GBM patients, indicated that nine out of eleven (82%) had overexpression of p53.
Our histopathological analysis showed that the expression of p53 in three out of four (75%) secondary GBM was confined to the nucleus and the p53 positive cells were randomly distributed throughout the
tumor
.
The expression of p53 in four out of seven (57%)
de
novo GBM was cytoplasmic, diffusive, and confined to the perivascular region of the
tumor
.
In two (29%)
de
novo samples both nuclear as well as cytoplasmic staining that was not confined to the perivascular area was observed.
The results suggest that cytoplasmic p53 may contribute to the formation and maintenance
of de
novo GBM by virtue of its control of the vasculature of tumors.
These results underscore the significance of p53 in the tumorigenesis
of de
novo GBM.
[MeSH-major]
Brain Neoplasms / metabolism. Glioblastoma / metabolism.
Tumor
Suppressor Protein p53 / biosynthesis
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17214319.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
71.
Dickinson PJ, Sturges BK, Higgins RJ, Roberts BN, Leutenegger CM, Bollen AW, LeCouteur RA:
Vascular endothelial growth factor mRNA expression and peritumoral edema in canine primary central nervous system tumors.
Vet Pathol
; 2008 Mar;45(2):131-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Vascular endothelial growth factor (VEGF) is an important regulator
of tumor
angiogenesis and vascular permeability, and has been implicated both in progression of central nervous system (CNS) tumors and development of vasogenic peritumoral edema.
Increased expression of VEGF relative to normal cerebral cortex tissue was seen predominantly in high
grade
astrocytic
(
grade
IV) and oligodendroglial (
grade
III) tumors, with lower expression in
low grade
astrocytomas
(
grade
II) and meningiomas (
grade
I).
Peritumoral edema was present in all
tumor
types; however, a significant association between the extent of peritumoral edema and the level of VEGF expression was not apparent.
[MeSH-major]
Brain Edema / metabolism. Brain Edema / veterinary. Central Nervous System Neoplasms / veterinary. Dog
Diseases
/ metabolism. RNA, Messenger / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
[MeSH-minor]
Animals.
Astrocytoma
/ genetics.
Astrocytoma
/ metabolism.
Astrocytoma
/ pathology.
Astrocytoma
/ veterinary. Dogs. Meningioma / genetics. Meningioma / metabolism. Meningioma / pathology. Meningioma / veterinary. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Oligodendroglioma / veterinary. Polymerase Chain Reaction / veterinary. Protein Isoforms. Retrospective Studies. Statistics, Nonparametric
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18424825.001).
[ISSN]
0300-9858
[Journal-full-title]
Veterinary pathology
[ISO-abbreviation]
Vet. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
72.
Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M:
Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation.
NMR Biomed
; 2005 Oct;18(6):371-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
High-resolution proton magnetic resonance spectroscopy was performed on tissue specimens from 33 patients with
astrocytic
tumors (22
astrocytomas
, 11 glioblastomas) and 13 patients with meningiomas.
Increased anaplasia, with respect to malignant transformation, resulting in a higher malignancy
grade
, was present in 11 recurrences of 22
astrocytoma
patients.
Spectroscopic features
of tumor
types, as determined on samples of the primary occurrences, were in good agreement with previous studies.
Compared with the respective primary
astrocytomas
, characteristic features of glioblastomas were significantly increased concentrations of alanine (Ala) (p = 0.005), increased metabolite ratios of glycine (Gly)/total creatine (tCr) (p = 0.0001) and glutamate (Glu)/glutamine (Gln) (p = 0.004).
Meningiomas showed increased Ala (p = 0.02) and metabolite ratios [Gly, total choline (tCho), Ala] over tCr (p = 0.001) relative to
astrocytomas
, and N-acetylaspartate and myo-inositol were absent.
Metabolic changes of an evolving
tumor
were observed in recurrent
astrocytomas
: owing to their consecutive assessments, more indicators of malignant degeneration were detected in
astrocytoma
recurrences (e.g.
Gly, p = 0.029; tCho, p = 0.034; Glu, p = 0.015; tCho/tCr, p = 0.001) in contrast to the comparison of primary
astrocytomas
with primary glioblastomas.
The present investigation demonstrated a correlation of the tCho-signal with
tumor
progression.
Significantly elevated concentrations of Ala (p = 0.037) and Glu (p = 0.003) and metabolite ratio tCho/tCr (p = 0.005) were even found in recurrent
low
-
grade
astrocytomas
with unchanged histopathological grading (n = 11).
This may be related to an early stage of malignant transformation, not yet detectable morphologically, and emphasizes the high sensitivity of 1H NMR spectroscopy in elucidating characteristics of brain
tumor
metabolism.
[MeSH-major]
Astrocytoma
/ metabolism. Biomarkers,
Tumor
/ metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Magnetic Resonance Spectroscopy / methods. Meningioma / metabolism.
Neoplasm
Recurrence, Local / metabolism
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 John Wiley & Sons, Ltd
(PMID = 15959923.001).
[ISSN]
0952-3480
[Journal-full-title]
NMR in biomedicine
[ISO-abbreviation]
NMR Biomed
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Protons
73.
Schittenhelm J, Mittelbronn M, Nguyen TD, Meyermann R, Beschorner R:
WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes.
Brain Pathol
; 2008 Jul;18(3):344-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
WT1 expression distinguishes
astrocytic tumor
cells from normal and reactive astrocytes.
Particularly in small brain biopsies, it might be difficult to distinguish reactive astrogliosis from
low
-
grade
or infiltration zones of high-
grade
astrocytomas
.
Recently, the over-expression of Wilms'
tumor
gene product WT1 was reported in
astrocytic tumor
cells.
Therefore, we investigated WT1 expression in paraffin-embedded brain sections from 28 controls, 48 cases with astrogliosis of various etiology and 219
astrocytomas
[World Health Organization (WHO) grades I-IV] by immunohistochemistry.
In
astrocytomas
, WT1-positive
tumor
cells were found in pilocytic
astrocytomas
(66.7% of cases), diffuse
astrocytomas
(52.7%) WHO
grade
II (52.7%), anaplastic
astrocytomas
(83.4%) and glioblastomas (98.1%).
Overall, the majority of all
astrocytic
neoplasms (84.5%) expressed WT1.
Establishing a cut-off
value of
0% immunoreactive
tumor
cells served to recognize neoplastic astrocytes with 100% specificity and 68% sensitivity and was associated with positive and negative predictive values of 1 and 0.68, respectively.
[MeSH-major]
Astrocytes / metabolism.
Astrocytoma
/ metabolism. Brain Neoplasms / metabolism. Gliosis / metabolism. WT1 Proteins / biosynthesis
[MeSH-minor]
Adult. Aged. Biomarkers,
Tumor
/ analysis. Endothelial Cells / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18371184.001).
[ISSN]
1015-6305
[Journal-full-title]
Brain pathology (Zurich, Switzerland)
[ISO-abbreviation]
Brain Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / WT1 Proteins
74.
Roodink I, van der Laak J, Kusters B, Wesseling P, Verrijp K, de Waal R, Leenders W:
Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression.
Int J Cancer
; 2006 Nov 1;119(9):2054-62
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Development of the
tumor
vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression.
Tumors arise initially as avascular masses in which central hypoxia induces expression of vascular endothelial growth factor-A (VEGF-A) and subsequently
tumor
vascularization.
We previously reported that in a mouse brain metastasis model of human melanoma, VEGF-A(121) induced a qualitatively different
tumor
vascular phenotype than VEGF-A(165) and VEGF-A(189): in contrast to the latter ones, and VEGF-A(121) did not induce a neovascular bed but rather led to leakage and dilatation of preexistent brain vessels.
Here, we correlate vascular phenotypes with spatial VEGF-A expression profiles in clinical brain tumors (
low grade
gliomas
; n = 6, melanoma metastases; n = 4, adenocarcinoma metastases; n = 4, glioblastoma multiforme; n = 3, sarcoma metastasis; n = 1, renal cell carcinoma metastasis; n = 1).
[MeSH-minor]
Adenocarcinoma / blood supply. Adenocarcinoma / pathology.
Astrocytoma
/ blood supply.
Astrocytoma
/ pathology. Cell Division. Cell Hypoxia. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / pathology. RNA, Messenger / genetics
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16804907.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
75.
Pérez-Gómez JL, Rodríguez-Alvarez CA, Marhx-Bracho A, Rueda-Franco F:
Stereotactic biopsy for brainstem tumors in pediatric patients.
Childs Nerv Syst
; 2010 Jan;26(1):29-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The histopathology was anaplastic
astrocytoma
(30%), followed by fibrillary and pilocytic types (25% each),
low
-
grade astrocytoma
(5%), high-
grade astrocytoma
(5%), and normal tissue (10%).
CONCLUSIONS: Stereotactic biopsy done for clarifiying a diagnostic imaging in brainstem tumors is important in obtaining a definitive diagnosis with a
low
rate of complications.
[MeSH-major]
Astrocytoma
/ pathology. Biopsy / methods. Brain Stem / pathology. Brain Stem Neoplasms / pathology. Stereotaxic Techniques
MedlinePlus Health Information.
consumer health - Biopsy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurosurg. 2006 Feb;104(2 Suppl):108-14
[
16506498.001
]
[Cites]
Acta Neurochir (Wien). 1985;76(1-2):12-7
[
4003123.001
]
[Cites]
Childs Nerv Syst. 2006 Jan;22(1):1-2
[
16311768.001
]
[Cites]
Cancer. 1980 Jun 1;45(11):2787-92
[
7379009.001
]
[Cites]
J Neurosurg. 1989 Sep;71(3):466-7
[
2671296.001
]
[Cites]
Acta Neurochir (Wien). 1998;140(9):899-903
[
9842426.001
]
[Cites]
J Neurooncol. 1988 Dec;6(4):309-17
[
3221258.001
]
[Cites]
Childs Nerv Syst. 2007 Mar;23(3):315-9
[
17058082.001
]
[Cites]
Childs Nerv Syst. 2003 Jun;19(5-6):305-10
[
12732939.001
]
[Cites]
Childs Nerv Syst. 2004 Mar;20(3):143-53
[
14669023.001
]
[Cites]
Acta Neurochir Suppl (Wien). 1989;46:86-9
[
2672719.001
]
[Cites]
Surg Neurol. 1995 Jun;43(6):558-62
[
7482234.001
]
[Cites]
J Neurosurg. 2000 Dec;93(6):951-7
[
11117867.001
]
[Cites]
Neurosurgery. 1983 Mar;12 (3):298-302
[
6302553.001
]
[Cites]
Surg Neurol. 1995 Jun;43(6):563-7; discussion 567-8
[
7482235.001
]
[Cites]
Surg Neurol. 2003 Oct;60(4):311-20; discussion 320
[
14505847.001
]
[Cites]
J Neurosurg. 1986 Jan;64(1):11-5
[
3941334.001
]
[Cites]
Acta Neurochir (Wien). 1992;116(2-4):164-70
[
1502952.001
]
[Cites]
Surg Neurol. 1987 Aug;28(2):100-4
[
3299823.001
]
[Cites]
J Neurosurg. 1989 Feb;70(2):195-200
[
2643686.001
]
[Cites]
Neurosurgery. 1987 Mar;20(3):439-44
[
3574621.001
]
[Cites]
Neurosurgery. 1980 Sep;7(3):243-8
[
7207742.001
]
[Cites]
Arch Dis Child. 1999 Jun;80(6):558-64
[
10332008.001
]
(PMID = 19784659.001).
[ISSN]
1433-0350
[Journal-full-title]
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
[ISO-abbreviation]
Childs Nerv Syst
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
76.
Horger M, Fenchel M, Nägele T, Moehle R, Claussen CD, Beschorner R, Ernemann U:
Water diffusivity: comparison of primary CNS lymphoma and astrocytic tumor infiltrating the corpus callosum.
AJR Am J Roentgenol
; 2009 Nov;193(5):1384-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Water diffusivity: comparison of primary CNS lymphoma and
astrocytic tumor
infiltrating the corpus callosum.
OBJECTIVE: The purpose of this study was to determine whether lymphoma and
astrocytic tumor
infiltrating the corpus callosum can be reliably differentiated with measurement of water diffusivity.
MATERIALS AND METHODS: Echo-planar diffusion-weighted MR images of 27 patients with glioblastoma multiforme, five patients with
low
-
grade astrocytoma
, five patients with gliomatosis cerebri, and nine patients with primary lymphoma infiltrating the corpus callosum were reviewed retrospectively.
Regions of interest were drawn on apparent diffusion coefficient (ADC) maps inside the callosal
tumor
.
ADCs were normalized by calculation of the ratio between the ADC of the
tumor
and the ADC of an uninvolved region of corpus callosum.
RESULTS: The mean ADC of glioblastoma multiforme was 1.13 +/- 0.31 (SD) x 10(-3) mm(2)/s, and the mean
tumor
to corpus callosum ADC ratio was 1.51 +/- 0.46; of
low
-
grade astrocytoma
, 1.14 +/- 0.23 x 10(-3) mm(2)/s and 1.54 +/- 0.28; gliomatosis cerebri, 1.01 +/- 0.20 x 10(-3) mm(2)/s and 1.31 +/- 0.36; and lymphoma, 0.71 +/- 0.13 x 10(-3) mm(2)/s and 0.93 +/- 0.19.
The difference between the mean
tumor
to corpus callosum ADC ratio of lymphoma and that of all grades of
astrocytoma
(1.48 +/- 0.43) was statistically significant (p < 0.001).
The optimal ADC threshold for discriminating
astrocytic tumor
and lymphoma was 0.90 x 10(-3) mm(2)/s (sensitivity, 84%; specificity, 89%).
The optimal threshold
for tumor
to corpus callosum ADC ratio was 1.22 (sensitivity, 73%; specificity, 100%).
CONCLUSION: The water diffusivity and the ADC ratio of the
tumor
to normal-appearing corpus callosum
of astrocytic tumor
differ significantly from those of lymphoma infiltrating the corpus callosum, allowing reliable differentiation of the two types
of tumor
.
[MeSH-major]
Astrocytoma
/ pathology. Brain Neoplasms / pathology. Corpus Callosum / pathology. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / pathology. Lymphoma / pathology. Water / metabolism
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
Hazardous Substances Data Bank.
Water
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19843757.001).
[ISSN]
1546-3141
[Journal-full-title]
AJR. American journal of roentgenology
[ISO-abbreviation]
AJR Am J Roentgenol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
059QF0KO0R / Water
77.
Varghese M, Olstorn H, Sandberg C, Vik-Mo EO, Noordhuis P, Nistér M, Berg-Johnsen J, Moe MC, Langmoen IA:
A comparison between stem cells from the adult human brain and from brain tumors.
Neurosurgery
; 2008 Dec;63(6):1022-33; discussion 1033-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: To directly compare stem cells from the normal adult human brain (adult human neural stem cells [AHNSC]),
Grade
II
astrocytomas
(AC II), and glioblastoma multiforme (GBM), with respect to proliferative and
tumor
-forming capacity and differentiation potential.
METHODS: Cells were isolated from tissue obtained during epilepsy surgery (AHNSCs) or
tumor
surgery (
glioma
stem cells [GSC]).
1) GBM stem cells formed tumors after orthotopic transplantation; AHNSCs showed no sign
of tumor
formation;.
3) both the growth rate and telomerase expression were high in GSCs and correlated with malignancy
grade
(GBM higher than AC II); AHNSCs had
low
telomerase expression;.
7) upon differentiation, AHNSCs produced normal glia and neurons; GSCs produced morphologically aberrant cells often expressing both glial and neuronal antigens; and 8) differentiation of AHNSCs resulted in 2 typical functional phenotypes: neurons (high electrical membrane resistance, ability to generate action potentials) and glial cells (
low
membrane resistance, no action potentials).
CONCLUSION: AHNSCs and stem cells from AC II and GBM differ with respect to proliferation,
tumor
-forming capacity, and rate and pattern of differentiation.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Stem Cells
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19057315.001).
[ISSN]
1524-4040
[Journal-full-title]
Neurosurgery
[ISO-abbreviation]
Neurosurgery
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
78.
Kurian KM, Summers DM, Statham PF, Smith C, Bell JE, Ironside JW:
Third ventricular chordoid glioma: clinicopathological study of two cases with evidence for a poor clinical outcome despite low grade histological features.
Neuropathol Appl Neurobiol
; 2005 Aug;31(4):354-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Third ventricular chordoid
glioma
: clinicopathological study of two cases with evidence
for a
poor clinical outcome despite
low grade
histological features.
Chordoid
glioma of
the third ventricle is a rare glial tumour whose precise histogenesis remains uncertain.
The
neoplasm
tends to occur in women and its clinical presentation is variable, resulting from acute hydrocephalus or impingement upon local structures.
The main differentials for histological diagnosis include chordoid meningiomas, pilocytic
astrocytomas
and ependymomas.
[MeSH-major]
Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / physiopathology.
Glioma
/ pathology.
Glioma
/ physiopathology. Third Ventricle / pathology
Genetic Alliance.
consumer health - Glioma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16008819.001).
[ISSN]
0305-1846
[Journal-full-title]
Neuropathology and applied neurobiology
[ISO-abbreviation]
Neuropathol. Appl. Neurobiol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
79.
Glotsos D, Georgiadis P, Kostopoulos S, Daskalakis A, Kalatzis I, Ravazoula P, Cavouras D:
A pilot study investigating the minimum requirements necessary for grading astrocytomas remotely.
Anal Quant Cytol Histol
; 2009 Oct;31(5):262-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A pilot study investigating the minimum requirements necessary for grading
astrocytomas
remotely.
OBJECTIVE: To investigate the minimum requirements necessary for remote grading
astrocytomas
in terms of selected static images and descriptive histologic characteristics.
STUDY DESIGN: A histopathologist examined 106 formalin-fixed, paraffin-embedded tissue samples of
low
- and high-
grade
astrocytomas
.
Next, the
grade
of each
tumor
was assessed based on the set of 5 images and the World Health Organization (WHO) description of 8 histologic characteristics defined as crucial in grading
astrocytomas
.
CONCLUSION: Our findings suggest that a telepathology system might be valuable for accurate
grade
diagnosis
of astrocytomas
-providing a means for avoiding diagnostic errors-without blocks or slides having to leave the department.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20701092.001).
[ISSN]
0884-6812
[Journal-full-title]
Analytical and quantitative cytology and histology
[ISO-abbreviation]
Anal. Quant. Cytol. Histol.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
United States
80.
El-Gaidi MA, Eissa EM:
Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center.
Pediatr Neurosurg
; 2010;46(4):272-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Infantile intracranial neoplasms: characteristics and surgical outcomes
of a
contemporary series of 21 cases in an Egyptian referral center.
OBJECTIVE: To investigate the demographic, clinical, radiological, pathological and surgical features and outcomes of infantile intracranial neoplasms, the second most common
neoplasm
in infants.
The most common
tumor
was choroid plexus papilloma (23.8%), followed by teratoma (19%) then
astrocytoma
and ependymoma (14.3% each).
The statistically significant predictors of prognosis were the extent of resection and
tumor
grade
.
CONCLUSION: Although the prognosis for infantile intracranial neoplasms is worse than for older children, an overall promising outcome with
low
operative morbidity and mortality was achieved using gross total excision and appropriate adjuvant chemotherapy as part
of a
multidisciplinary approach.
[MeSH-minor]
Adolescent.
Astrocytoma
/ drug therapy.
Astrocytoma
/ mortality.
Astrocytoma
/ surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Egypt / epidemiology. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / surgery. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / surgery. Morbidity. Neurilemmoma / drug therapy. Neurilemmoma / mortality. Neurilemmoma / surgery. Prognosis. Quality of Life. Referral and Consultation / statistics & numerical data. Retrospective Studies. Teratoma / drug therapy. Teratoma / mortality. Teratoma / surgery
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 S. Karger AG, Basel.
(PMID = 21160236.001).
[ISSN]
1423-0305
[Journal-full-title]
Pediatric neurosurgery
[ISO-abbreviation]
Pediatr Neurosurg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
81.
Bobola MS, Silber JR, Ellenbogen RG, Geyer JR, Blank A, Goff RD:
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Clin Cancer Res
; 2005 Apr 1;11(7):2747-55
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain
tumor
cell lines.
Our purpose is (a) to assess the contribution of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) to the resistance of pediatric brain
tumor
cell lines to clinical alkylating agents and (b) to evaluate variables for maximal potentiation of cell killing by the MGMT inhibitor O6-benzylguanine, currently in clinical trials.
Few such data for pediatric
glioma
lines, particularly those from
low
-
grade
tumors, are currently available.
EXPERIMENTAL DESIGN: We used clonogenic assays of proliferative survival to quantitate cytoxicity of the chloroethylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the methylating agent temozolomide in 11
glioma
and five medulloblastoma lines.
Twelve lines are newly established and characterized here, nine of them from
low
-
grade
gliomas
including pilocytic
astrocytomas
.
RESULTS: (a) MGMT is a major determinant of BCNU resistance and the predominant determinant of temozolomide resistance in both our
glioma
and medulloblastoma lines.
[MeSH-major]
Antineoplastic Agents, Alkylating / pharmacology. Dacarbazine / analogs & derivatives. Drug Resistance,
Neoplasm
. Guanine / analogs & derivatives. Guanine / pharmacology. O(6)-Methylguanine-DNA Methyltransferase / metabolism
[MeSH-minor]
Adolescent. Brain / enzymology. Brain / pathology. Carmustine / pharmacology. Cell Survival / drug effects. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Synergism. Enzyme Inhibitors / pharmacology. Female. Humans. Male. Time Factors.
Tumor
Cells, Cultured
COS Scholar Universe.
author profiles
.
Cellosaurus - a cell line knowledge resource.
culture/stock collections - Cell lines described in this publication
.
Hazardous Substances Data Bank.
Carmustine
.
Hazardous Substances Data Bank.
DACARBAZINE
.
Hazardous Substances Data Bank.
GUANINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15814657.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / Enzyme Inhibitors; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
82.
Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, Bartek J:
Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay.
Cell Cycle
; 2008 Aug 15;7(16):2553-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Given the significance
of tumor
microenvironment in general, and the established role of paracrine VEGF signaling in glioblastoma (GBM) biology in particular, we explored the potential autocrine control of human
astrocytoma
behavior by VEGF.
Using a range of cell and molecular biology approaches to study a panel of
astrocytoma
(
grade
III and IV/GBM)-derived cell lines and a series of clinical specimens from
low
- and high-
grade
astrocytomas
, we show that co-expression of VEGF and VEGF receptors (VEGFRs) occurs commonly in
astrocytoma
cells.
Blockade of VEGFR2 by the selective inhibitor (SU1498) abrogated the VEGF-mediated enhancement of
astrocytoma
cell growth and viability under unperturbed culture conditions.
In addition, such interference with VEGF-VEGFR2 signaling potentiated the ionizing radiation-induced
tumor
cell death.
In clinical specimens, both VEGFRs and VEGF were co-expressed in astroglial
tumor
cells, and higher VEGF expression correlated with
tumor
progression, thereby supporting the relevance of functional VEGF-VEGFR signaling in vivo.
Overall, our results are consistent with a potential autocrine role of the VEGF-VEGFR2 (KDR) interplay as a factor contributing to malignant
astrocytoma
growth and radioresistance, thereby supporting the candidacy of this signaling cascade as a therapeutic target, possibly in combination with radiotherapy.
[MeSH-minor]
Autocrine Communication. Cell Cycle. Cell Line,
Tumor
. Humans. Radiation Tolerance. Signal Transduction
Genetic Alliance.
consumer health - Glioblastoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18719373.001).
[ISSN]
1551-4005
[Journal-full-title]
Cell cycle (Georgetown, Tex.)
[ISO-abbreviation]
Cell Cycle
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
83.
Burkhardt K, Heuberger F, Delavelle J:
Pilocytic astrocytoma in the elderly.
Clin Neuropathol
; 2007 Nov-Dec;26(6):306-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pilocytic
astrocytoma
in the elderly.
Pilocytic
astrocytoma
(WHO
Grade
1) is a
low
-
grade
glioma
with a favorable prognosis most commonly diagnosed in patients aged below 20.
It is the most common
glioma
in children, and cases discovered in elderly patients are rare.
We report the highly unusual case of an 85-year-old man whose neurological signs included Parkinsonism, and in whom post mortem examination revealed a pilocytic
astrocytoma
of the brainstem.
[MeSH-major]
Astrocytoma
/ diagnosis. Brain Stem Neoplasms / diagnosis
[MeSH-minor]
Age Factors. Aged, 80 and over. Diagnosis. Diagnosis, Differential. Humans. Male. Parkinson
Disease
/ diagnosis
Genetic Alliance.
consumer health - Pilocytic astrocytoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18232598.001).
[ISSN]
0722-5091
[Journal-full-title]
Clinical neuropathology
[ISO-abbreviation]
Clin. Neuropathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
84.
Nakamura M, Chiba K, Ishii K, Ogawa Y, Takaishi H, Matsumoto M, Toyama Y:
Surgical outcomes of spinal cord astrocytomas.
Spinal Cord
; 2006 Dec;44(12):740-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Surgical outcomes of spinal cord
astrocytomas
.
OBJECTIVES: To analyze prognostic factors for patients with spinal cord
astrocytomas
.
Impacts of the
tumor
histological
grade
, the level of the
tumor
, the types of surgical interventions, and the use of adjuvant radiotherapies on the survival and functional outcomes of 30 patients (18 in
low
-
grade
and 12 high-
grade
malignancy tumors) were analyzed.
RESULTS: The survival rate of the
low
-
grade
malignancy group was significantly higher than that of the high-
grade
group.
The survival rate of the patients with thoracic
astrocytomas
was significantly higher than those with cervical
astrocytomas
.
In both the
low
- and high-
grade
groups, the survival rates in groups P/T were significantly higher than those in group B.
In the
low
-
grade
group, five patients, whose preoperative functional statuses were classified as 'fair' or better, remained 'fair' or better after surgery.
In the high-
grade
group, the postoperative functional statuses were classified as 'no change' or 'aggravated' in all except two patients.
CONCLUSIONS: The
tumor
grade
and the extent
of tumor
resection were significant prognostic factors for survival rate.
In
low
-
grade
malignancy group, good motor function was retained when surgeries were performed before substantial neurological deterioration.
[MeSH-major]
Astrocytoma
/ surgery. Spinal Cord Neoplasms / surgery
[MeSH-minor]
Adolescent. Adult. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged.
Neoplasm
Staging. Prognosis. Statistics, Nonparametric. Survival Rate. Treatment Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16670687.001).
[ISSN]
1362-4393
[Journal-full-title]
Spinal cord
[ISO-abbreviation]
Spinal Cord
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
85.
Keshavarzi S, Meltzer H, Ben-Haim S, Newman CB, Lawson JD, Levy ML, Murphy K:
Initial clinical experience with frameless optically guided stereotactic radiosurgery/radiotherapy in pediatric patients.
Childs Nerv Syst
; 2009 Jul;25(7):837-44
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
MATERIALS AND METHODS: Pediatric patients were selected for treatment after evaluation by a multidisciplinary neuro-
oncology
team including neurosurgery, neurology, pathology,
oncology
, and radiation
oncology
.
Patients were treated for juvenile pilocytic
astrocytoma
(JPA; n = 2), pontine
low
-
grade astrocytoma
(n = 1), pituitary adenoma (n = 3), metastatic medulloblastoma (n = 1), acoustic neuroma (n = 1), and pineocytoma (n = 1).
We followed patients
for a
median of 12 months (range 3-18 months) with no in-field failures and were able to obtain encouraging toxicity profiles.
[MeSH-minor]
Adolescent.
Astrocytoma
/ pathology.
Astrocytoma
/ radiotherapy.
Astrocytoma
/ surgery. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Medulloblastoma / radiotherapy. Medulloblastoma / surgery.
Neoplasm
Metastasis / radiotherapy. Pineal Gland / pathology. Pineal Gland / surgery. Pinealoma / radiotherapy. Pinealoma / surgery. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Prolactinoma / radiotherapy. Prolactinoma / surgery. Tomography, X-Ray Computed. Treatment Outcome
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
MedlinePlus Health Information.
consumer health - Radiation Therapy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Childs Nerv Syst. 2001 May;17(6):341-6; discussion 347
[
11417414.001
]
[Cites]
Pediatr Neurol. 1996 Oct;15(3):193-9
[
8916155.001
]
[Cites]
Med Phys. 2002 Aug;29(8):1729-38
[
12201420.001
]
[Cites]
Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7
[
12493111.001
]
[Cites]
Strahlenther Onkol. 2003 Sep;179(9):585-97
[
14628124.001
]
[Cites]
Neurosurgery. 2004 Jul;55(1):89-98; discussion 98-9
[
15214977.001
]
[Cites]
Neurosurgery. 2004 Oct;55(4):916-24; discussion 924-5
[
15458600.001
]
[Cites]
Br J Neurosurg. 1989;3(3):305-12
[
2506900.001
]
[Cites]
Pediatr Neurosurg. 1990-1991;16(4-5):219-21
[
2135190.001
]
[Cites]
Neurosurg Clin N Am. 1992 Jan;3(1):167-90
[
1633445.001
]
[Cites]
Acta Neurochir Suppl. 1994;62:83-7
[
7717143.001
]
[Cites]
J Neurosurg Anesthesiol. 1995 Apr;7(2):100-8
[
7772962.001
]
[Cites]
Neurosurgery. 1996 Apr;38(4):696-701; discussion 701-2
[
8692387.001
]
[Cites]
Pediatr Neurosurg. 1996;24(3):139-44
[
8870017.001
]
[Cites]
Pediatr Neurosurg. 1996;24(4):193-201
[
8873161.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):875-82
[
9240657.001
]
[Cites]
Anaesth Intensive Care. 1997 Dec;25(6):691-5
[
9452856.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):573-80
[
9806517.001
]
[Cites]
Neurosurg Clin N Am. 1999 Apr;10(2):181-202
[
10099088.001
]
[Cites]
Nature. 1958 Nov 1;182(4644):1222-3
[
13590280.001
]
[Cites]
Childs Nerv Syst. 2005 Apr;21(4):301-7; discussion 308
[
15654635.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1467-72
[
15817352.001
]
[Cites]
Pediatr Blood Cancer. 2005 Sep;45(3):304-10
[
15558704.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):914-21
[
16338096.001
]
[Cites]
NeuroRx. 2006 Apr;3(2):276-91
[
16554265.001
]
[Cites]
Cancer Radiother. 2006 Sep;10(5):283-7
[
16859948.001
]
[Cites]
Semin Oncol Nurs. 2006 Nov;22(4):221-32
[
17095398.001
]
[Cites]
Med Dosim. 2007 Summer;32(2):121-33
[
17472891.001
]
[Cites]
Cancer J. 2007 Mar-Apr;13(2):87-94
[
17476136.001
]
[Cites]
Neurosurgery. 2007 Sep;61(3 Suppl):130-40; discussion 140-1
[
17876243.001
]
[Cites]
Clin Lung Cancer. 2007 Sep;8(8):488-92
[
17922973.001
]
[Cites]
Med Phys. 2007 Oct;34(10):3962-70
[
17985641.001
]
[Cites]
Expert Rev Anticancer Ther. 2007 Nov;7(11):1507-15
[
18020920.001
]
[Cites]
Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S69-77
[
18076312.001
]
[Cites]
J Clin Anesth. 2007 Dec;19(8):616-8
[
18083476.001
]
[Cites]
Neurosurg Focus. 2007;23(6):E4
[
18081481.001
]
[Cites]
Neurosurg Focus. 2007;23(6):E5
[
18081482.001
]
[Cites]
J Neurosurg Pediatr. 2008 Apr;1(4):296-304
[
18377305.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S131-5
[
18406912.001
]
[Cites]
Neurosurgery. 2008 Mar;62(3):647-55; discussion 647-55
[
18425011.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1152-8
[
11704340.001
]
(PMID = 19326128.001).
[ISSN]
1433-0350
[Journal-full-title]
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
[ISO-abbreviation]
Childs Nerv Syst
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Other-IDs]
NLM/ PMC2691523
86.
Hughes MA, Parisi M, Grossman S, Kleinberg L:
Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection.
Int J Radiat Oncol Biol Phys
; 2005 Aug 1;62(5):1423-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary brain tumors treated with steroids and radiotherapy:
low
CD4 counts and risk of infection.
The purpose of this study was to determine the occurrence of
low
CD4 counts and whether monitoring CD4 counts during and after radiotherapy (RT) is warranted.
METHODS AND MATERIALS: CD4 counts were measured during RT in 70 of 76 consecutive patients with newly diagnosed
Grade
III and IV
astrocytoma
and anaplastic oligodendroglioma treated with corticosteroids and seen at the Johns Hopkins Hospital.
Prophylactic trimethoprim-sulfamethoxazole (160 mg/800 mg p.o. every Monday, Wednesday, and Friday) or dapsone (100 mg p.o. daily) in those with sulfa allergy was prescribed only if patients developed a
low
CD4 count.
All patients with
low
CD4 counts were treated with prophylactic antibiotics, and no patient developed Pneumocystis carinii pneumonia.
A prospective study is underway to determine the frequency, depth, and prognostic implications of this
finding
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Steroids
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16029802.001).
[ISSN]
0360-3016
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Adrenal Cortex Hormones
87.
Hunter SB, Varma V, Shehata B, Nolen JD, Cohen C, Olson JJ, Ou CY:
Apolipoprotein D expression in primary brain tumors: analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue.
J Histochem Cytochem
; 2005 Aug;53(8):963-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Apolipoprotein D (apoD) expression has been shown to correlate both with cell cycle arrest and with prognosis in several types of malignancy, including central nervous system
astrocytomas
and medulloblastomas.
Sixteen poorly infiltrating WHO
grade
I glial neoplasms (i.e., pilocytic
astrocytomas
and gangliogliomas) showed an average 20-fold higher apoD expression level compared with the 20 diffusely infiltrating glial neoplasms (i.e., glioblastoma, anaplastic
astrocytoma
, oligodendrogliomas; p=0.00004).
A small number of exceptions (i.e., two high-expressing glioblastomas and three
low
-expressing gangliogliomas) were identified.
Analyzed as individual
tumor
groups, poorly infiltrating
grade
I pilocytic
astrocytomas
and gangliogliomas differed significantly from each
tumor
type within the diffusely infiltrating higher-
grade
category (p<0.05 for each comparison) but not from each other (p>0.05).
Conversely, each individual
tumor
type within the diffusely infiltrating category differed significantly from both pilocytic
astrocytomas
and gangliogliomas (p<0.05) but did not vary from other infiltrating tumors (p>0.05).
Ependymomas, non-infiltrating
grade
II neoplasms, expressed levels of apoD similar to or lower than levels expressed by the diffusely infiltrating
gliomas
.
In addition, apoD expression was 5-fold higher in the slowly proliferating
grade
I glial neoplasms compared with non-proliferating normal brain tissue (p=0.01), suggesting that apoD expression is not simply an inverse measure of proliferation.
ApoD expression measured by quantitative RT-PCR may be useful in the differential diagnosis of primary brain tumors, particularly pilocytic
astrocytomas
and gangliogliomas.
[MeSH-major]
Apolipoproteins / biosynthesis. Brain Neoplasms / metabolism.
Glioma
/ metabolism
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FORMALDEHYDE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16055749.001).
[ISSN]
0022-1554
[Journal-full-title]
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
[ISO-abbreviation]
J. Histochem. Cytochem.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Apolipoproteins; 0 / Apolipoproteins D; 0 / Fixatives; 0 / Ki-67 Antigen; 1HG84L3525 / Formaldehyde; 8002-74-2 / Paraffin
88.
Morales H, Kwock L, Castillo M:
Magnetic resonance imaging and spectroscopy of pilomyxoid astrocytomas: case reports and comparison with pilocytic astrocytomas.
J Comput Assist Tomogr
; 2007 Sep-Oct;31(5):682-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Magnetic resonance imaging and spectroscopy of pilomyxoid
astrocytomas
: case reports and comparison with pilocytic
astrocytomas
.
BACKGROUND AND PURPOSE: Pilomyxoid
astrocytomas
(PMAs) have been described only recently.
They appear as
low
-
grade
tumors sharing imaging features similar to pilocytic
astrocytomas
(PAs).
However, pilomyxoid
astrocytomas
have different histological features and behave more aggressively than PAs.
Short echo time MRS obtained in 2 PMAs showed
low
myoinositol/Cr ratios in tumoral regions in comparison with PA.
The third PMA was different to those previously reported in the literature because it was hemispheric rather than hypothalamic in location in addition to having
low
intratumoral ratios of Cho/Cr.
[MeSH-major]
Astrocytoma
/ metabolism.
Astrocytoma
/ pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Myxoma / metabolism. Myxoma / pathology
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
Hazardous Substances Data Bank.
CREATINE
.
Hazardous Substances Data Bank.
CHOLINE CHLORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17895777.001).
[ISSN]
0363-8715
[Journal-full-title]
Journal of computer assisted tomography
[ISO-abbreviation]
J Comput Assist Tomogr
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
4L6452S749 / Inositol; MU72812GK0 / Creatine; N91BDP6H0X / Choline
89.
Ohnishi M, Matsumoto T, Nagashio R, Kageyama T, Utsuki S, Oka H, Okayasu I, Sato Y:
Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein.
Pathol Int
; 2009 Nov;59(11):797-803
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Proteomics
of tumor
-specific proteins in cerebrospinal fluid of patients with
astrocytoma
: usefulness of gelsolin protein.
Changes in cerebrospinal fluid (CSF) composition have been shown to accurately reflect pathological processes in the CNS, and are potential indicators of abnormal CNS states, such as
tumor
growth.
To detect biomarkers in high-
grade
astrocytomas
, the differential expression of proteins in the cerebrospinal fluid was analyzed from two cases each of diffuse
astrocytoma
(
grade
II), and glioblastoma (
grade
IV) using agarose 2-D gel electrophoresis (2-
DE
).
It was found that the expression of gelsolin protein decreased with histological
grade
.
To examine whether gelsolin is a useful indicator
of tumor
aggressiveness or patient outcome, its expression was further studied on immunohistochemistry in 41 formalin-fixed and paraffin-embedded
astrocytomas
.
The positive cell rate of gelsolin in tumors was 59.4% in
grade
II, 30.0% in
grade
III and 29.4% in
grade
IV, respectively.
Gelsolin expression was significantly lower in high-
grade
astrocytomas
(
grade
III or IV) than in
low
-
grade
astrocytomas
(
grade
II; P < 0.05).
Moreover, in
astrocytomas
the overall survival of patients in the
low
-expression group was significantly poorer than in the high expression group (P < 0.05).
These data suggest that gelsolin is a prognostic factor in
astrocytoma
.
[MeSH-major]
Astrocytoma
/ cerebrospinal fluid. Biomarkers,
Tumor
/ cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Gelsolin / cerebrospinal fluid
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19883430.001).
[ISSN]
1440-1827
[Journal-full-title]
Pathology international
[ISO-abbreviation]
Pathol. Int.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Australia
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Gelsolin
90.
Juhász C, Chugani DC, Muzik O, Wu D, Sloan AE, Barger G, Watson C, Shah AK, Sood S, Ergun EL, Mangner TJ, Chakraborty PK, Kupsky WJ, Chugani HT:
In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors.
J Cereb Blood Flow Metab
; 2006 Mar;26(3):345-57
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Abnormal metabolism of tryptophan has been implicated in modulation
of tumor
cell proliferation and immunoresistance. alpha-[(11)C]Methyl-L-tryptophan (AMT) is a PET tracer to measure cerebral tryptophan metabolism in vivo.
In the present study, we have measured
tumor
tryptophan uptake in 40 patients with primary brain tumors using AMT PET and standard uptake values (SUV).
All
grade
II to IV
gliomas
and glioneuronal tumors showed increased AMT SUV, including all recurrent/residual tumors.
Low
-
grade
astrocytic gliomas
showed increased tryptophan metabolism, as measured by k(3)'.
In
astrocytic
tumors,
low grade
was associated with high k(3)' and lower VD', while high-
grade
tumors showed the reverse pattern.
The findings show high AMT uptake in primary and residual/recurrent
gliomas
and glioneuronal tumors.
Increased AMT uptake can be due to increased metabolism of tryptophan and/or high volume of distribution, depending on
tumor
type and
grade
.
High tryptophan metabolic rates in
low
-
grade
tumors may indicate activation of the kynurenine pathway, a mechanism regulating
tumor
cell growth.
AMT PET might be a useful molecular imaging method to guide therapeutic approaches aimed at controlling
tumor
cell proliferation by acting on tryptophan metabolism.
[MeSH-minor]
Adolescent. Adult. Aged. Carbon Radioisotopes. Child. Child, Preschool. Electroencephalography / methods. Electroencephalography / standards. Female. Gadolinium. Glucose / metabolism. Humans. Infant. Magnetic Resonance Imaging / methods. Magnetic Resonance Imaging / standards. Male. Middle Aged.
Neoplasm
Staging. Positron-Emission Tomography / methods. Positron-Emission Tomography / standards. Seizures / metabolism. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
GLUCOSE
.
Hazardous Substances Data Bank.
(L)-Tryptophan
.
Hazardous Substances Data Bank.
GADOLINIUM, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16079785.001).
[ISSN]
0271-678X
[Journal-full-title]
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
[ISO-abbreviation]
J. Cereb. Blood Flow Metab.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Carbon Radioisotopes; 13510-08-2 / alpha-methyltryptophan; 8DUH1N11BX / Tryptophan; AU0V1LM3JT / Gadolinium; IY9XDZ35W2 / Glucose
91.
Spena G, Garbossa D, Barletta L, Prevost C, Versari P:
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-.
Neurol Med Chir (Tokyo)
; 2010;50(5):410-3
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Preoperative chemotherapy for infiltrative
low
-
grade
oligoastrocytoma: a useful strategy to maximize surgical resection -case report-.
A 38-year-old woman presented with a large infiltrative left frontal
low
-
grade
glioma
manifesting as partial seizures of the left arm and lower limb.
The residual
tumor
was stable, and the frequency of seizures had lessened dramatically at the last follow-up examination at 18 months.
[MeSH-major]
Antineoplastic Agents, Alkylating / therapeutic use.
Astrocytoma
/ drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoadjuvant Therapy / methods. Preoperative Period
Genetic Alliance.
consumer health - Oligoastrocytoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20505301.001).
[ISSN]
1349-8029
[Journal-full-title]
Neurologia medico-chirurgica
[ISO-abbreviation]
Neurol. Med. Chir. (Tokyo)
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
92.
Gasinska A, Skolyszewski J, Glinski B, Niemiec J, Adamczyk A, Krzyszkowski T, Zabek M:
Age and bromodeoxyuridine labelling index as prognostic factors in high-grade gliomas treated with surgery and radiotherapy.
Clin Oncol (R Coll Radiol)
; 2006 Aug;18(6):459-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Age and bromodeoxyuridine labelling index as prognostic factors in high-
grade
gliomas
treated with surgery and radiotherapy.
AIMS: To determine the prognostic
value of
proliferative potential and DNA ploidy in 72 brain tumours (36
grade
III and 36
grade
IV
astrocytomas
) using bromodeoxyuridine (BrdUrd) incorporation and flow cytometry.
No difference was observed in mean BrdUrd LI between
grade
III and
grade
IV sub-groups.
A significantly higher percentage of DNA aneuploidy was observed in
grade
III
gliomas
(69.4%) than in
grade
IV
gliomas
(52.8%).
Univariate analysis showed that younger patients (< or = 51 years) (P = 0.021) with
grade
III
gliomas
(P = 0.030) and
low
tumour proliferation rate (BrdUrd LI < or = 2.7%, P = 0.028) had significantly higher 5-year survival rates.
CONCLUSION: In this study, independent prognostic factors for patients with high-
grade
gliomas
treated with surgery and post-operative radiotherapy are age and tumour proliferation rate assessed according to the BrdUrd LI.
[MeSH-major]
Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Bromodeoxyuridine.
Glioma
/ radiotherapy.
Glioma
/ surgery
[MeSH-minor]
Adult. Age Factors. Aged. Cell Proliferation / drug effects. Combined Modality Therapy. DNA,
Neoplasm
/ analysis. DNA,
Neoplasm
/ drug effects.
Disease
Progression. Female. Flow Cytometry. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis.
Neoplasm
Staging. Oxygen / pharmacology. Ploidies. Prognosis. Sensitivity and Specificity. Staining and Labeling. Survival Rate. Treatment Outcome.
Tumor
Cells, Cultured
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
BROMODEOXYURIDINE
.
Hazardous Substances Data Bank.
OXYGEN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16909969.001).
[ISSN]
0936-6555
[Journal-full-title]
Clinical oncology (Royal College of Radiologists (Great Britain))
[ISO-abbreviation]
Clin Oncol (R Coll Radiol)
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Neoplasm; G34N38R2N1 / Bromodeoxyuridine; S88TT14065 / Oxygen
93.
Ohgaki H:
Genetic pathways to glioblastomas.
Neuropathology
; 2005 Mar;25(1):1-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Glioblastomas, the most frequent and malignant human brain tumors, may develop
de
novo (primary glioblastoma) or by progression from
low
-
grade
or anaplastic
astrocytoma
(secondary glioblastoma).
These glioblastoma subtypes constitute distinct
disease
entities that affect patients of different ages and develop through different genetic pathways.
There is evidence that G:C-->A:T transition mutations at CpG sites in the TP53 gene are significantly more frequent in
low
-
grade
astrocytomas
with promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene than in those without methylation.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15822813.001).
[ISSN]
0919-6544
[Journal-full-title]
Neuropathology : official journal of the Japanese Society of Neuropathology
[ISO-abbreviation]
Neuropathology
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Australia
[Number-of-references]
63
94.
Fisher PG, Tihan T, Goldthwaite PT, Wharam MD, Carson BS, Weingart JD, Repka MX, Cohen KJ, Burger PC:
Outcome analysis of childhood low-grade astrocytomas.
Pediatr Blood Cancer
; 2008 Aug;51(2):245-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcome analysis of childhood
low
-
grade
astrocytomas
.
BACKGROUND: We aimed to determine the long-term natural history of
low
-
grade
astrocytomas
(LGA) in children, with respect to pathology, and to evaluate influence of treatment on survival.
RESULTS: Two hundred seventy-eight children (160 males; mean age 9.1 years;
tumor
location: 77 cerebrum, 62 cerebellum, 51 hypothalamic, 30 thalamus, 9 ventricle, 40 brainstem, and 9 spine) were assessed.
Among 246 specimens reviewed, diagnoses were 135 pilocytic
astrocytoma
(PA), 27 diffuse
astrocytoma
(DA), 75 unclassifiable well-differentiated
astrocytoma
(
NOS
), and 9 subependymal giant cell
astrocytoma
.
Reviewed diagnoses were highly associated with OS (P < 0.0001), with 5-year OS for PA 96%, DA 48%, and
NOS
86%; these differences remained significant when stratified by location or extent of resection.
Among patients with residual
tumor
after surgery, 5-year PFS was 48% with observation alone (n = 114), no different (P = 0.32) from that achieved with immediate irradiation (n = 86).
While
tumor
location and resection extent affect outcome, pathologic diagnosis when carefully interpreted significantly influences long-term survival.
[MeSH-major]
Astrocytoma
/ mortality. Brain Neoplasms / mortality
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18386785.001).
[ISSN]
1545-5017
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
95.
Chamberlain MC:
Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Cancer
; 2008 Sep 1;113(5):1019-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Temozolomide for recurrent
low
-
grade
spinal cord
gliomas
in adults.
BACKGROUND: There is no standard therapy for surgery- and radiotherapy-resistant, recurrent,
low
-
grade
spinal cord
gliomas
.
Therefore, a retrospective study of temozolomide (TMZ) in adults with recurrent
low
-
grade
spinal cord
gliomas
with a primary objective of determining progression-free survival (PFS) was performed.
METHODS: Twenty-two patients (11 men and 11 women) aged 20 years to 55 years (median, 35 years) with recurrent spinal cord
gliomas
(World Health Organization
grade
2
astrocytoma
in 19 patients and oligoastrocytoma in 3 patients) were treated.
TMZ-related toxicity included constipation (9 patients, 1 with
grade
3), lymphopenia (9 patients, 1 with
grade
3), fatigue (7 patients, 1 with
grade
3), neutropenia (6 patients, 2 with
grade
3), and thrombocytopenia (6 patients, 2 with
grade
3).
Four (18%) patients demonstrated a partial radiographic response, 12 (55%) demonstrated stable
disease
, and 6 (27%) had progressive
disease
after 2 cycles of TMZ.
Time to
tumor
progression ranged from 2 months to 28 months (median, 14.5 months).
CONCLUSIONS: TMZ demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent
low
-
grade
spinal cord
gliomas
.
[MeSH-major]
Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives.
Glioma
/ drug therapy. Spinal Cord Neoplasms / drug therapy
[MeSH-minor]
Adult.
Disease
-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged.
Neoplasm
Recurrence, Local / drug therapy. Retrospective Studies
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 American Cancer Society.
(PMID = 18615600.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
96.
Caseiras GB, Thornton JS, Yousry T, Benton C, Rees J, Waldman AD, Jäger HR:
Inclusion or exclusion of intratumoral vessels in relative cerebral blood volume characterization in low-grade gliomas: does it make a difference?
AJNR Am J Neuroradiol
; 2008 Jun;29(6):1140-1
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Inclusion or exclusion of intratumoral vessels in relative cerebral blood volume characterization in
low
-
grade
gliomas
: does it make a difference?
We assessed the influence of inclusion (method 1) and exclusion (method 2) of intratumoral vessels when determining maximum relative cerebral blood volume (rCBVmax) in 3 types of
low
-
grade
gliomas
(LGGs):
astrocytomas
, oligoastrocytomas, and oligodendrogliomas.
However, only method 2 demonstrated a significant (P = .026) association between rCBVmax and membership
of a
differently ranked histologic category.
[MeSH-major]
Blood Volume. Brain Neoplasms / blood supply. Brain Neoplasms / pathology.
Glioma
/ blood supply.
Glioma
/ pathology. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Neovascularization, Pathologic / pathology
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18388221.001).
[ISSN]
1936-959X
[Journal-full-title]
AJNR. American journal of neuroradiology
[ISO-abbreviation]
AJNR Am J Neuroradiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
97.
Zscharnack K, Kessler R, Bleichert F, Warnke JP, Eschrich K:
The PFKFB3 splice variant UBI2K4 is downregulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
Neuropathol Appl Neurobiol
; 2009 Dec;35(6):566-78
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The PFKFB3 splice variant UBI2K4 is downregulated in high-
grade
astrocytomas
and impedes the growth of U87 glioblastoma cells.
Here, we studied the role of the PFKFB3 splice variants in human
astrocytic gliomas
.
METHODS: We analysed the PFKFB3 splice variants in 48
astrocytic gliomas
by RT-PCR and real-time PCR.
RESULTS: UBI2K5 and UBI2K6 are the predominant splice variants in rapidly proliferating high-
grade
astrocytomas
while the expression of UBI2K3 and UBI2K4 is mainly restricted to
low
-
grade
astrocytomas
and nonneoplastic brain tissue.
The UBI2K4 mRNA level is downregulated in
astrocytic gliomas
with increasing malignancy
grade
.
CONCLUSIONS: Our results demonstrate that the splice variant UBI2K4 impedes the tumour cell growth and might serve as a tumour suppressor in
astrocytic
tumours.
[MeSH-major]
Astrocytoma
/ metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Phosphofructokinase-2 / metabolism
[MeSH-minor]
Brain / metabolism. Cell Count. Cell Line,
Tumor
. Cell Proliferation. Cell Survival. Down-Regulation. Humans.
Neoplasm
Staging. Polymerase Chain Reaction. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Transfection
Genetic Alliance.
consumer health - Glioblastoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19490427.001).
[ISSN]
1365-2990
[Journal-full-title]
Neuropathology and applied neurobiology
[ISO-abbreviation]
Neuropathol. Appl. Neurobiol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Protein Isoforms; 0 / RNA, Messenger; EC 2.7.1.105 / PFKFB3 protein, human; EC 2.7.1.105 / Phosphofructokinase-2
98.
Huber J, Sovinz P, Lackner H, Mokry M, Eder H, Urban C:
Diencephalic syndrome: a frequently delayed diagnosis in failure to thrive.
Klin Padiatr
; 2007 Mar-Apr;219(2):91-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We describe the clinical course of two children suffering from diencephalic syndrome due to unresectable hypothalamic
gliomas
and emphasize the importance of chemotherapy as a first-line treatment.
Imaging of the brain showed a suprasellar mass, identified histologically as
low grade
pilocytic
astrocytoma
.
Both patients were treated with chemotherapy which induced
tumor
regression and stable
disease
.
CONCLUSIONS: Diencephalic syndrome caused by a hypothalamic/chiasmatic
astrocytoma
is a rare cause of failure to thrive in children so that diagnosis is frequently delayed.
[MeSH-major]
Astrocytoma
/ diagnosis. Failure to Thrive / etiology. Hypothalamic
Diseases
/ diagnosis. Hypothalamic Neoplasms / diagnosis. Optic Chiasm. Optic Nerve Neoplasms / diagnosis
[MeSH-minor]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Hydrocephalus / etiology. Infant.
Neoplasm
, Residual / drug therapy
Genetic Alliance.
consumer health - Diencephalic Syndrome
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17405074.001).
[ISSN]
0300-8630
[Journal-full-title]
Klinische Pädiatrie
[ISO-abbreviation]
Klin Padiatr
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
99.
Jahraus CD, Tarbell NJ:
Optic pathway gliomas.
Pediatr Blood Cancer
; 2006 May 1;46(5):586-96
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Optic pathway
gliomas
.
Optic pathway
gliomas
represent approximately 5% of all pediatric intracranial tumors.
While these tumors are most frequently
low grade
astrocytomas
, they follow a highly variable clinical course, and accordingly, there is much debate regarding their optimal management.
An overall favorable prognosis for this
tumor
emphasizes the need for careful selection of therapy.
Herein, we review the major features of optic pathway
glioma
, including epidemiology, pathology, therapeutic interventions, outcome, and treatment sequelae.
[MeSH-major]
Cranial Nerve Neoplasms. Optic Nerve
Glioma
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16411210.001).
[ISSN]
1545-5009
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
110
100.
Gumprecht H, Grosu AL, Souvatsoglou M, Dzewas B, Weber WA, Lumenta CB:
11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas.
Zentralbl Neurochir
; 2007 Feb;68(1):19-23
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
11C-Methionine positron emission tomography for preoperative evaluation of suggestive
low
-
grade
gliomas
.
OBJECTIVE: The treatment regimen for cerebral
gliomas
is different, depending on the histological
grade
of the lesion.
The therapeutic strategy for anaplastic
gliomas
and glioblastomas is more aggressive, including microsurgical removal, radiation and chemotherapy.
The management for
low
-
grade
gliomas
is still under discussion, operation or "wait and see" tactics are possible options.
Although most of the
low
-
grade
gliomas
appear as hypointense lesions without contrast medium (CM) enhancement on magnetic resonance images, in some cases lesions without CM enhancement can be anaplastic tumours as well.
11C-Methionine positron emission tomography (MET-PET) was performed for preoperative evaluation of non or
low
CM enhancing intracerebral lesions, so-called suggestive
low
-
grade
gliomas
.
METHOD: 20 patients harbouring suggestive
low
-
grade
gliomas
were included.
Histologically the 2 patients with sparse CM enhancement and MET uptake were glioblastoma multiforme, 10/14 patients with MET uptake and without CM enhancement had an anaplastic
astrocytoma
WHO III, 3/14 with MET uptake and no CM enhancement had an anaplastic oligoastrocytoma WHO III, and 1/14 had an oligoastrocytoma
grade
II.
The lesions of the 4 patients without MET uptake and without CM enhancement were classified as
astrocytoma grade
II in 2 cases, as
astrocytoma grade
I in 1 case and as
astrocytoma
III in one case.
CONCLUSION: According to the results of this study, we find MET-PET to be a helpful tool for pretreatment evaluation of non-CM enhancing, suggestive
low
-
grade
intracerebral lesions.
[MeSH-major]
Brain Neoplasms / radionuclide imaging.
Glioma
/ radionuclide imaging. Methionine. Radiopharmaceuticals
[MeSH-minor]
Astrocytoma
/ radionuclide imaging.
Astrocytoma
/ surgery. Glioblastoma / radionuclide imaging. Glioblastoma / surgery. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neurosurgical Procedures. Positron-Emission Tomography
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.